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Abstract 
 Chronic liver disease is the 12th leading cause of death in the United States and 
consists of a continuum of pathologies. Following initial injury, a patient develops 
steatosis, or excess fat accumulation. While the liver has the remarkable ability to repair 
itself, if injury persists, the wound healing process becomes deregulated and excess 
extracellular matrix (ECM) can accumulate resulting in fibrosis. If the etiologic agent is 
not removed, a patient can progress to cirrhosis and hepatocellular carcinoma. Despite 
decades of research, there are currently no effective treatments for advanced liver 
disease and a liver transplantation is the only treatment option for patients.  There are 
two main approaches of developing novel therapeutics to cure liver disease. First, 
understanding mechanisms of liver injury can lead to potential pharmacologic targets. 
Second, because the liver has the remarkable capacity to heal itself, understanding the 
mechanisms that allow this to happen may reveal potential places that can be targeted 
to enhance this recovery process. This is an appealing approach because wound 
healing consists of mostly identical steps regardless of the injury-provoking incident and 
therefore could apply to liver injury of varied etiologies, and maybe even wound repair in 
extra-hepatic organs.  Therefore, I chose to focus my dissertation research on exploring 
hepatic wound healing after acute and chronic liver injury.   
 Hyaluronan (HA) is a ubiquitous, anionic glycosaminoglycan in the ECM that can 
hold 1,000 times its weight in water. HA, HA binding proteins, and HA receptors (the HA 
network) are implicated in aspects of the wound healing process in the skin, intestine, 
and lung. The HA network plays roles in injury, inflammation, and fibrogenesis; all 
primary aspects of wound healing. In fact, high basal HA levels and sustained HA 
induction in fetal skin are associated with the scarless wound healing that occurs after 
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injury. Adult dermal tissue, which heals with a scar, has lower basal HA levels and a 
transient HA induction following injury. HA is elevated in the plasma of patients with liver 
disease and correlates with disease severity. Despite HA’s connection to wound healing 
and its use as a biomarker for liver disease, little work has been done to investigate if 
HA is involved in liver wound repair. We hypothesize that the HA network contributes to 
hepatic wound healing.  
 Our first focus was on a role for HA itself in hepatic wound healing. HA is 
synthesized by one of three enzymes (HAS1, 2, or 3) and previous studies show that 
Has3-/- mice have decreased dextran sodium sulfate (DSS)-induced colitis and 
ventilator induced lung injury. We therefore, hypothesized that Has3-/- mice would be 
protected from liver injury and fibrosis. Using mice deficient in HAS3, wild-type mice, 
and carbon tetrachloride (CCl4) we induced both acute and chronic liver injury. We 
found that Has3-/- mice have increased injury, but also increased wound healing, 
including inflammation, regeneration, and matrix remodeling compared to wild-type mice 
after acute CCl4 exposure. This increased wound healing was associated with an 
increase in hepatic HA deposition and expression of the HA receptor HA mediated 
motility receptor (HMMR). After chronic CCl4, Has3-/- mice had increased pro-fibrotic 
transcripts, but no increase in fibrosis. This disconnect was attributed to increased 
matrix metabolism and was again associated with increased HMMR expression 
compared to wild-type mice.  
 This led us to investigate a role for HMMR in hepatic wound healing. HMMR can 
be both intracellular and extracellular and plays a role in cell cycle progression and cell 
migration, important aspects of wound healing. We hypothesized that Hmmr-/- mice 
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would have delayed wound healing following acute and chronic liver injury due to 
impaired hepatocyte proliferation and impaired macrophage-mediated matrix 
metabolism. Using CCl4, we induced both acute and chronic liver injury in Hmmr-/- and 
wild-type mice. Hmmr-/- mice had decreased inflammation, regeneration, and matrix 
remodeling despite no difference in liver injury compared to wild-type mice after acute 
liver injury. This was associated with decreased hepatic HA deposition. After chronic 
liver injury, Hmmr-/- mice had decreased pro-fibrotic transcripts but no difference in 
fibrosis. Similar to Has3-/- mice, this disconnect can be attributed to differences in 
matrix remodeling, with Hmmr-/- mice having less matrix metabolism compared to wild-
type mice.  
 My work is the first to demonstrate that HA and HMMR are involved in hepatic 
wound healing. The culmination of this work led to the development of a working model 
connecting HA and HMMR with hepatic wound healing. Following liver injury, 
hepatocytes and resident liver macrophages synthesize pro-inflammatory cytokines and 
chemokines. These cytokines then stimulate hepatic stellate cells (HSC) to synthesize 
and deposit HA in the injured areas of the liver, while the chemokines recruit circulating 
macrophages to the liver. Then, we propose two feed forward loops, the first being 
where the HA can increase water retention thereby increasing HSC activation by 
increasing mechanical stress and further increasing HA deposition. Second, we also 
propose a feed forward loop between HA and inflammation, where the HA contributes to 
inflammation and increased inflammation further increases HA synthesis by HSC. 
Additionally, we propose that macrophages that are being recruited to the liver express 
HMMR and can use the HA:HMMR interaction to localize to the necrotic area and clear 
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tissue debris. In the case of chronic liver injury, this HA:HMMR interaction can localize 
scar associated macrophages to the fibrotic septae and increase matrix degradation 
and facilitate fibrosis resolution. Finally, the increased inflammatory microenvironment 
of the healing liver, and perhaps intracellular HMMR, promotes hepatocyte proliferation. 
Together, HA and HMMR contributes to inflammation, regeneration, and matrix 
remodeling to aid in the hepatic wound healing process.  
 Taken together, our data demonstrate that the HA network, in particular HA and 
HMMR, is involved in both acute and chronic liver injury and wound healing. Further 
work should be completed to evaluate other aspects of the HA network, including other 
receptors and HA binding proteins. Additionally, exploring what role the HA:HMMR 
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Liver disease 
 Liver disease describes a broad range of pathological conditions caused by a 
number of etiologic agents, including drugs, alcohol or other toxins, viruses, obesity, 
cholestasis, genetic disorders, and ischemia/reperfusion (Bataller and Brenner, 2005; 
Abu-Wasel et al., 2013; Leise et al., 2014; Roberts et al., 2014; Thannickal et al., 2014; 
Woolbright and Jaeschke, 2015). Regardless of the causative agent, patients diagnosed 
with liver disease follow a similar progression (outlined in Figure 1-1). Patients are 
initially diagnosed with steatosis, or fatty liver disease, characterized by an excess 
accumulation of triglycerides in hepatocytes (Charlton, 2004; Postic and Girard, 2008). 
It is also possible for these patients to develop an acute inflammatory response called 
steatohepatitis (Yilmaz, 2012; Rosso et al., 2014). A sub-set of patients progress from 
steatosis to fibrosis, which is characterized by an excess accumulation of extracellular 
matrix (ECM) in the liver. This ECM can affect the normal structure and function of the 
liver, however until fibrosis becomes advanced the liver is able to heal itself by 
degrading this ECM (Bataller and Brenner, 2005; Pellicoro et al., 2014). Some patients 
progress further to advanced fibrosis and eventually develop cirrhosis, which can lead 
to hepatocellular carcinoma (HCC) (Pellicoro et al., 2014; Tsochatzis et al., 2014; Zhou 
et al., 2014). In fact, 80-90% of HCC cases have cirrhosis as an underlying risk factor 
(Simonetti et al., 1991; Llovet et al., 2003). Once a patient develops advanced cirrhosis 
or HCC, liver disease is no longer reversible and a liver transplant is the only treatment 
option available (Rai, 2013). This presents a problem not only because a liver transplant 
is invasive and costly, but there are a limited number of healthy livers available for  
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Figure 1-1: Liver disease progression.  
 
Following initial injury, a patient is diagnosed with steatosis or excess accumulation of 
triglyceride. With further injury, some patients progress to fibrosis, characterized by 
excess extracellular matrix (ECM), and even further to cirrhosis, where the excess ECM 
forms nodules of regeneration hepatocytes. The ECM also becomes crosslinked in 
cirrhosis making regression more difficult, which is possible even in early cirrhosis. At 
any point in this continuum, steatohepatitis can occur. This is a result of extensive cell 
death and inflammation. Hepatocellular carcinoma can occur in patients who progress 
past cirrhosis, and cirrhosis underlies 80-90% of HCC cases in the clinics. If advanced 
cirrhosis or HCC develops, a liver transplant is required for survival. 
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transplant, partially due to the obesity epidemic (Bilbao et al., 2003; Saidi et al., 2012; 
Parikh et al., 2015).  
 According to the Center for Disease Control (CDC), chronic liver disease and 
cirrhosis was the 12th leading cause of death in the United States in 2014. The total 
number of deaths increased significantly from 2013 to 2014, following an increasing 
trend over the past 15 years (Kochanek et al., 2016). For some patients, simply 
removing the etiologic agent, whether that be drugs, alcohol, over nutrition, or reducing 
the viral load, is enough to allow the liver to heal itself, however, the patients that do 
progress to advanced liver disease and require a transplant are left without other 
therapeutic options (Pellicoro et al., 2014; Tsochatzis et al., 2014). There is a need for 
basic science and translational research to shed light on new mechanisms associated 
with liver disease pathobiology. It was the goal of my dissertation research to advance 
our understanding of liver disease by focusing specifically on identifying novel 
mechanisms of wound repair after acute and chronic liver injury.  Identifying ways to halt 
the progression of liver disease and/or accelerate its reversal would reduce the need for 
a transplant to cure advanced liver disease.  
 
Hepatic wound healing 
 Hepatic wound healing is analogous to skin wound healing and includes periods 
of inflammation, regeneration, and matrix remodeling (Pellicoro et al., 2014; Balaji et al., 
2015). Each of these stages in wound healing is discussed in detail below (and outlined 
in Figure 1-2); with specific focus on hepatic wound healing following toxin-induced liver 





Figure 1-2: Acute wound healing progression. 
Following acute injury, the liver goes through the wound healing process. Initially 
coagulation and complement factors are activated and inflammatory chemokines and 
cytokines are released locally. These factors recruit circulating monocytes and prime 
the healthy hepatocytes to enter the cell cycle. This is followed by the regeneration and 
replacement of hepatocytes and the remaining hepatic cells (hepatic stellate cells, 
cholangiocytes, and endothelial cells). During this regenerative phase, activated hepatic 
stellate cells are synthesizing a provisional matrix, including laminin and fibronectin, and 
collagen proteins. These matrices then must be remodeled by matrix 
metalloproteinases (MMPs) and their inhibitors (TIMPs) in order to restore normal liver 







Figure 1-3: Chronic wound healing progression. 
 
Following chronic injury, inflammation is induced and remains elevated becoming 
chronic and unremitting. Similarly, hepatocytes continue regenerating eventually being 
surrounded by ECM and forming nodules that can later become cancerous. Matrix 
synthesis by activated hepatic stellate cells outweighs matrix degradation by matrix 
metalloproteinases (MMPs) and a scar forms that can eventually disrupt normal hepatic 
structure and function leading to the need for a liver transplant.  
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incomplete wound repair (outlines in Figure 1-3). The result of the incomplete wound 
repair is an accumulation of ECM that disrupts the normal structure and function of the 
liver (Guo and Friedman, 2007; Pellicoro et al., 2014).  
 
Initial injury 
 Acute liver injury can occur in a number of ways, including viral hepatitis, 
ischemia/reperfusion, cholestasis, or toxins (Penny, 2013; Leise et al., 2014; Woolbright 
and Jaeschke, 2015). A portion of liver disease in developed countries, like the United 
States, is attributed to toxins, specifically acetaminophen (APAP) toxicity due to 
overdose, and alcohol abuse (Penny, 2013; Jaeschke, 2015). Both APAP toxicity and 
alcohol abuse cause centrilobular injury, meaning the hepatocytes around the central 
vein are affected by the toxin (Gujral et al., 2002; Szabo and Mandrekar, 2010; Penny, 
2013; Wang et al., 2016a). This is partly due to the increased cytochrome P40 (CYP) 
enzymes located around the central veins; specifically CYP2E1, one of many enzymes 
involved in both APAP and ethanol metabolism (Lee et al., 1996; Lu et al., 2008; 
Abdelmegeed et al., 2010). The reactive/biologically active metabolites produced attack 
hepatocytes and cause cell death (Gujral et al., 2002; Szabo and Mandrekar, 2010).  
 Although the focus of the remaining dissertation is on toxin induced liver injury, 
there are several other ways the liver can be injured. During ischemia/reperfusion, there 
are periods of hypoxia and subsequently a return of oxygenated blood (Kupiec-
Weglinski and Busuttil, 2005; Li et al., 2015). This leads to a shortage of energy 
sources, production of reactive oxygen species (ROS), and a build-up of toxic 
metabolites, all of which can cause hepatic cell death (Jaeschke, 2003; Kupiec-
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Weglinski and Busuttil, 2005; Li et al., 2015). Cholestasis, whether intrahepatic or 
extrahepatic, leads to a build-up of toxic bile acids in hepatocytes and results in cell 
death (Hofmann, 1999; Wagner et al., 2009; Woolbright et al., 2015). In the case of 
ethanol, the metabolites that cause the liver damage also cause gut leakiness, which 
leads to increased circulating lipopolysaccharide (LPS) and subsequent LPS-mediated 
hepatic inflammation (Schaffert, 2009). In all cases, the extent of cellular injury dictates 




 Necrotic hepatocytes release danger associated molecular patterns (DAMPs) 
including HMGB1 and mtDNA (Rock and Kono, 2008; McDonald and Kubes, 2016). 
These DAMPs, along with chemokines like CXCL2, promote neutrophil recruitment and 
infiltration into the liver, which occurs very early after initial injury (McDonald et al., 
2010; Moles et al., 2014; McDonald and Kubes, 2016). These neutrophils migrate to the 
area of necrosis using a chemoattractant gradient produced by the necrotic tissue 
(Foxman et al., 1997; Heit et al., 2002). Neutrophils play a role in the removal of cellular 
debris, but they can also exacerbate hepatic tissue injury (Ramaiah and Jaeschke, 
2007; Huang et al., 2015).  
 DAMPs and LPS activate Kupffer cells, resident liver macrophages, leading to 
the synthesis of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNFα) and 
interleukin 6 (IL6) as well as ROS (Marangoni et al., 2006; Rock and Kono, 2008; 
Martin-Murphy et al., 2010; Aziz-Seible et al., 2011; Dixon et al., 2013; Woolbright and 
9	
Jaeschke, 2015). The dying hepatocytes and activated hepatic stellate cells (HSC) also 
release pro-inflammatory chemokines (Dambach et al., 2002; Chang et al., 2015b). 
These cytokines and chemokines, of which CCL2 (also known as monoctye 
chemoattractant protein 1  (MCP1)) is particularly important, recruit bone marrow 
derived monocytes to the liver where they differentiate into macrophages and continue 
to promote the inflammatory microenvironment (Dambach et al., 2002; Baeck et al., 
2012). Similar to neutrophils, recruited macrophages can both exacerbate tissue injury 
and aid in tissue repair (Duffield et al., 2005; Possamai, 2010). For example, the pro-
inflammatory microenvironment created by recruited macrophages can lead to 
increased tissue damage via ROS production (Marangoni et al., 2006). However, 
recruited macrophages aid in repair during the later stages of wound healing, by 
removing necrotic debris and making room for the regenerating hepatic cells to expand 
(Duffield et al., 2005; Mochizuki et al., 2014). The recruited macrophages are also a 
source of matrix metalloproteinases (MMPs), which are important in matrix degradation 
as discussed below (Fallowfield et al., 2007a). 
 
Regeneration 
 The liver performs many vital functions in the body including filtering and 
detoxifying the blood, absorbing nutrients delivered to the liver from the intestinal tract, 
producing bile acids to aid in digestion, and by producing complement proteins 
important for innate immunity, and proteins involved in coagulation  (Wagner et al., 
2009; Pluta et al., 2010; Dixon et al., 2013). Because these functions are required for 
organism survival, the liver acquired the remarkable ability to regenerate during 
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evolution (Michalopoulos and DeFrances, 1997; Cienfuegos et al., 2014; Mao et al., 
2014). Historically, this is likely because of the high chances that mammals, including 
our ancestors, ingested toxins that damaged the liver and required regeneration for 
organism survival; regeneration-competent survivors then passed their genes on to the 
next generation who then had a critical survival advantage over those less able to 
withstand toxin-mediated liver injury (Michalopoulos and DeFrances, 1997; Mao et al., 
2014).  This same regenerative process still occurs following any liver injury sustained 
in mammals today (Michalopoulos and DeFrances, 1997; Mao et al., 2014).  
 Uninjured hepatocytes are primed by DAMPs and pro-inflammatory mediators, 
including TNFα and complement factors C3a and C5a, to enter the cell cycle, a process 
that occurs soon after hepatic injury (Grisham, 1962; Webber et al., 1998; Strey et al., 
2003; Rock and Kono, 2008; Bohm et al., 2010; Cienfuegos et al., 2014). Growth 
factors, including hepatocyte growth factor (HGF) and epidermal growth factor (EGF), 
promote progression through the cell cycle (Huh et al., 2004; Natarajan et al., 2007; 
Cienfuegos et al., 2014). Once the liver regains lost mass and resumes normal function, 
regeneration is halted (Michalopoulos and DeFrances, 1997; Mao et al., 2014). While 
many mechanisms for initiation of regeneration are known, the mechanisms for 
termination of regeneration are more controversial (Rychtrmoc et al., 2012; Mao et al., 
2014). Transforming growth factor β (TGFβ), chromatin remodeling proteins, 
peroxisome proliferator-activated receptor (PPAR) signaling, miRNAs, integrin linked 
kinase (ILK) and the restoration of normal function may each or all contribute to halting 
liver regeneration (Apte et al., 2009; Yuan et al., 2011; Rychtrmoc et al., 2012; Jin et al., 
2015). 
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 Hepatocytes are not the only cells damaged after toxin-mediated liver injury and 
a patient requires all cell types, including Kupffer cells, HSC, cholangiocytes and liver 
sinusoidal endothelial cells (LSECs), to regenerate or be replaced to regain normal liver 
function (Cienfuegos et al., 2014). After initial hepatic injury, Kupffer cells within the 
necrotic area can also sustain damage and die, and therefore must be replaced, but 
there is some controversy on whether the remaining Kupffer cells are able to proliferate 
or if they must be replaced with bone marrow derived macrophages that differentiate 
into Kupffer cells (Yamamoto et al., 1996; Scott et al., 2016). HSC store the majority of 
the body’s vitamin A in lipid droplets, and activate (discussed below) or die following 
liver injury (Friedman, 2008a). The remaining HSC proliferate to restore hepatic 
function, primarily in response to fibroblast growth factors (FGFs) (Schumacher and 
Guo, 2016). Similar to the above cell types, cholangiocytes, which line the bile ducts, 
are damaged during liver injury and also must be replaced (Michalopoulos and 
DeFrances, 1997). In some instances, it is possible for healthy hepatocytes to 
transdifferentiate into cholangiocytes, aiding in biliary tree repair (Limaye et al., 2010). 
LSECs, are normally fenestrated to allow nutrients to pass from the blood to the space 
of Disse and reach the hepatocytes as well as allow proteins produced in the liver to 
enter systemic circulation (Herrnberger et al., 2014; Poisson et al., 2017). Following 
injury, LSECs fuse and lose their fenestration (Poisson et al., 2017).  LSEC within the 
necrotic area will die and must be replaced with proliferating LSEC in the healthy tissue 
or sinusoidal progenitor cells (DeLeve, 2013; Hu et al., 2014; Poisson et al., 2017). The 
hepatic regenerative process is tightly controlled with hepatocytes regenerating shortly 
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after injury, followed by Kupffer cells, HSC, and cholangiocytes, and lastly LSEC 
(Grisham, 1962; Taub, 2004; Cienfuegos et al., 2014). 
 
Matrix remodeling 
 Matrix remodeling happens throughout the wound healing process and includes 
both matrix deposition and matrix metabolism. Following injury, HSC lose their vitamin A 
depot and activate in response to a number of cytokines and growth factors including, 
platelet derived growth factor (PDGF) released by inflammatory cells and TGFβ acting 
in an autocrine fashion (Friedman, 2000; Friedman, 2008a; Liu et al., 2009; Wells and 
Schwabe, 2015). The engulfment of dying hepatocytes and changes in the ECM also 
promote HSC activation (Friedman, 2000; Dechene et al., 2010). Activated HSC 
express smooth muscle actin (αSMA) and synthesize ECM proteins like type 1 collagen 
(Friedman, 2000; Perepelyuk et al., 2013). The liver also contains a population of portal 
fibroblasts surrounding the biliary tree that can also synthesize ECM components, 
particularly around the portal tract. However, HSC are likely the main contributor to 
excess ECM deposition during liver wound healing and fibrosis, even in cholestasis-
induced liver fibrosis (Mederacke et al., 2013; Perepelyuk et al., 2013; Wells and 
Schwabe, 2015). 
 In order to prevent ECM accumulation, the activated HSC must quit synthesizing 
ECM components. There is some controversy over how this process is stopped with 
evidence of HSC returning to a quiescent state, undergoing apoptosis, or becoming 
senescent all being reported (Issa et al., 2001; Oakley et al., 2005; El Taghdouini et al., 
2015; Jin et al., 2016). Matrix degradation occurs throughout the wound healing process 
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and once HSC stop making ECM, the provisional matrix, including collagen, laminin, 
and fibronectin, must be removed to restore normal liver architecture and vasculature 
(Jonker et al., 1992; Alwayn et al., 2008; Duarte et al., 2015; Poole and Arteel, 2016). 
This is done by the increased production, release, and activation of MMPs (Hemmann 
et al., 2007; Alwayn et al., 2008; Duarte et al., 2015). MMPs are primarily produced by 
the macrophages that infiltrated the liver in response to liver injury (Duffield et al., 2005; 
Fallowfield et al., 2007a). Activated HSC are the major source of tissue inhibitor of 
MMPs (TIMPs), which inhibit MMP activity and prevent overzealous matrix degradation 
(Hemmann et al., 2007; Osawa et al., 2013). Once all hepatic cells have regenerated or 
been repopulated and the matrix has been properly remodeled, the liver has healed 
completely and hepatic function is successfully restored. 
   
Chronic Liver Injury and Fibrosis 
 If a patient sustains chronic liver injury through chronic hepatitis, chronic alcohol 
exposure, or obesity, the above outlined wound healing process continues and 
becomes deregulated (Pellicoro et al., 2014). Continuing cycles of hepatocyte cell death 
result in chronic inflammation, a hallmark of chronic liver disease (Czaja, 2014; Seki and 
Schwabe, 2015).  This sustained inflammation results in chronically activated HSC 
(Friedman, 2000; Imamura et al., 2005; Czaja, 2014). In fact, persistently high levels of 
TNFα promote HSC survival (Osawa et al., 2013; Yang and Seki, 2015). The increased 
stiffness of the ECM also promotes HSC activation resulting in unrelenting pro-fibrotic 
signals, which maintain and exacerbate HSC activation (Dechene et al., 2010). Loss of 
LSEC fenestration results in capillarization of the sinusoids, which also promotes HSC 
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activation (DeLeve, 2015; Poisson et al., 2017). These hyper-activated HSC continue to 
synthesize collagen and other ECM proteins overwhelming macrophage MMP 
production and MMP-mediated ECM degradation (Gressner and Bachem, 1990; 
Bataller and Brenner, 2005; Hemmann et al., 2007; Friedman, 2008b; Perepelyuk et al., 
2013). This imbalance results in a build-up of ECM, which then disrupts the normal 
architecture of the liver (Friedman, 2008b; Pellicoro et al., 2014). The excess collagen 
that accumulates is cross-linked by lysyl oxidase (LOX) enzymes, particularly LOXL2, 
which promotes collagen stabilization and suppresses the reversal of fibrosis (Ikenaga 
et al., 2017).  
 As the progression of liver disease continues, ECM accumulates around nodules 
of regenerating hepatocytes (Gogel et al., 2000). These nodules disrupt liver function 
and can lead to decreased blood flow through the liver and portal hypertension, which is 
a clinical symptom of cirrhosis (Tsochatzis et al., 2014; Garbuzenko, 2015). Cirrhosis is 
a major risk factor for HCC, with approximately 80-90% of HCC cases occurring in 
patients with cirrhosis (Gogel et al., 2000; Llovet et al., 2003). For some patients, simply 
removing the etiologic agent can halt progression of fibrosis to cirrhosis or even reverse 
fibrosis, unfortunately this is not the case for all patients (Bataller and Brenner, 2005). 
Parallel to ECM remodeling after acute liver injury, fibrosis can be resolved by 
increasing MMP activity through macrophage recruitment and by halting collagen 
synthesis by HSC (Issa et al., 2001; Fallowfield et al., 2007b; Adhyatmika et al., 2015; 
El Taghdouini et al., 2015). Despite numerous ongoing clinical trials for novel anti-
fibrotic drugs based on promising preclinical observations, no treatments have been 
approved by the FDA (Cohen-Naftaly and Friedman, 2011; Mehal and To, 2016). 
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Therefore, although fibrosis and early cirrhosis are reversible, once patients progress to 
advanced cirrhosis or HCC, the only treatment option remains a liver transplant. 
 
Carbon tetrachloride (CCl4) as a model of liver disease 
 
History of CCl4 
 Rodent models, including mouse models, have long been used in laboratories to 
understand the mechanisms driving disease pathogenesis and progression and to test 
treatment options for those diseases. While dosing mice with APAP and ethanol can be 
used to study acute toxicity, there are many difficulties in studying the chronic liver injury 
that patients experience (Schaffert, 2009; McGill et al., 2012). We therefore chose to 
utilize the hepatotoxicant carbon tetrachloride (CCl4), which can be used to induce both 
acute liver injury and, when administered chronically, liver fibrosis (Weber et al., 2003; 
Constandinou et al., 2005). In the early 20th century, CCl4 was used as a fire retardant 
(it was put in glass balls to be thrown at the base of fires), and later it was used as 
solvent for dry cleaners and machinists (Joron et al., 1957; Faroon et al., 2003). 
Eventually it was learned that CCl4 was toxic and could cause liver, lung, and kidney 
damage and its use as a fire retardant and solvent was largely discontinued (Joron et 
al., 1957; Faroon et al., 2003).  
 
Modeling Acute Liver Injury 
 A single intraperitoneal injection of CCl4 causes significant liver damage in a 
mouse and can therefore be used as a model of acute liver injury. CCl4 is bioactivated 
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by CYP2E1, predominantly in zone 3 hepatocytes, to the trichloromethyl radical (McCay 
et al., 1984; Wong et al., 1998; Weber et al., 2003). This radical is metabolized further 
to more reactive metabolites that then attack the lipids in hepatocyte membranes 
causing lipid peroxidation (McCay et al., 1984; Weber et al., 2003; Knockaert et al., 
2012). As the membranes become disrupted and the intrinsic protective response 
becomes overwhelmed, the cells undergo necrotic cell death (Wang et al., 2013; Xie et 
al., 2015). Similar to ethanol and APAP, CCl4 causes centrilobular necrosis, and the 
liver undergoes the above outlined wound healing process (Taniguchi et al., 2004; Xie 
et al., 2015). While it is a different mechanism of toxicity, studying the wound healing 
process following CCl4 exposure can provide insight into not only toxin induced liver 
injury, but also other clinically relevant acute liver diseases such as viral hepatitis 
infections.  
 
Modeling Chronic Liver Injury 
 While modeling acute liver injury with APAP and ethanol exposure closely mimics 
the human liver injury seen in the clinic, modeling chronic liver disease has proven more 
difficult. Exposing mice to CCl4 at least twice a week for an extended period of time can 
induce fibrosis, similar to that seen in the clinic (Constandinou et al., 2005). Depending 
on the exposure time, it is possible to induce fibrosis, early cirrhosis, or advanced 
cirrhosis (Constandinou et al., 2005; Zhang et al., 2011). This is unique to CCl4, as 
chronic ethanol exposure will not lead to fibrosis in mouse models (Bertola et al., 2013; 
Crespo Yanguas et al., 2016). Once fibrosis or cirrhosis is established in the mouse, it is 
then possible to study the resolution of the fibrosis over time after cessation of further 
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toxin-mediated injury, which can help provide insight into mechanisms responsible for 
fibrosis regression in patients (Jiao et al., 2012; Ramachandran et al., 2012). 
 
Sub-Strain Differences in Mouse Models of Liver Injury 
 The mouse is a valuable and universal tool in laboratories all over the world, and 
different strains of mice exhibit genotypic and phenotypic differences, which can greatly 
impact experimental outcomes (Reynolds, 2011; Walkin et al., 2013). Recently, mice of 
the same strain but different sub-strains were evaluated for possible differences in 
several experimental models of human disease. Sub-strains are defined as branches of 
an inbred strain that are either known or suspected to be genetically different from the 
original inbred strain (Mekada et al., 2009). The commonly used C57BL/6 strain has two 
distinct sub-strains that were established after a breeding pair moved from The Jackson 
Laboratory (Jackson) to the National Institute of Health (NIH) in the 1950s (Mekada et 
al., 2009; Zurita et al., 2011). These sub-strains are called C57BL/6J (6J, Jackson) and 
C57BL/6N (6N, NIH). After separation, the 6J mice developed a spontaneous mutation 
in the nicotinamide nucleotide transhydrogenase (Nnt) gene (Huang et al., 2006; Ronchi 
et al., 2013). This mutation results in a deletion of exons 7-11 of the Nnt gene and leads 
to a non-functional protein (Huang et al., 2006). The NNT enzyme is partially 
responsible for antioxidant defense within the mitochondria. It is located on the inner 
mitochondrial membrane and converts NADP+ to NADPH using the proton gradient and 
NADH (Hoek and Rydstrom, 1988; Ronchi et al., 2013). The NADPH produced acts as 
a cofactor for glutathione reductase to convert oxidized glutathione (GSSG) to reduced 
glutathione (GSH) (Vogel et al., 1999; Dalton et al., 2004).  
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 Possible differences in hepatotoxicity came to light when two separate groups 
reported conflicting results in JNK2 deficient mice following acute APAP toxicity 
(Gunawan et al., 2006; Bourdi et al., 2008). While Gunawan, et al. reported Jnk2-/- mice 
were partially protected following APAP exposure when compared to wild-type controls, 
Bourdi, et al. reported Jnk2-/- mice had exacerbated injury following the same dose of 
APAP (Gunawan et al., 2006; Bourdi et al., 2008). The different outcomes reported in 
these two studies were explained by the fact that each group used a different C57BL/6 
sub-strain control mouse to which the Jnk2-/- mice were being compared. It was later 
discovered 6N mice are more susceptible to liver injury compared to 6J mice at the 
same APAP dose (Bourdi et al., 2011). This was not due to differences in CYP2E1 
activity or glutathione depletion, an important antioxidant defense system in APAP 
toxicity (Duan et al., 2016). Due to the similarities in toxicity between APAP and CCl4, it 
is also important to identify any potential differences in CCl4-mediated hepatotoxicity 
and in the wound healing response between B6 sub-strains. Any potential differences 
would then become important to consider when using wild-type mice as controls for 
genetically modified mice. It is imperative to ensure wild-type and transgenic mice are 
on the same background sub-strain to allow for appropriate data interpretation as was 






 In 1934, Karl Meyer and John Palmer isolated a high molecular weight substance 
from the vitreous humor of cow eyes (Meyer and Palmer, 1934). They described the 
molecule as containing uronic acid, an amino sugar, and possibly a pentose and named 
it hyaluronic acid, later called hyaluronan (HA), from hyaloid (vitreous) and uronic acid 
(Meyer and Palmer, 1934; Balazs et al., 1986). In the 1950’s, Meyer reported the 
chemical structure as a repeating disaccharide of glucuronic acid and n-
acetylglucosamine (Figure 1.3) (Meyer, 1958). The monosaccharides are linked 
together through repeating β-1,4 and β-1,3 glycosidic bonds (Figure 1-4) (Necas et al., 
2008; Jiang et al., 2011). It is now known that HA is a ubiquitous, highly anionic, 
glycosaminoglycan found in high levels in the eye, lung, skin, and joints (Fraser et al., 
1997; Manasa et al., 2012; Anderegg et al., 2014; Temple-Wong et al., 2016).  
 
HA Synthesis 
 Endogenous HA is a polydisperse high molecular weight (HMW) molecule and 
can reach up to 107 Da (Manasa et al., 2012). Unlike other glycosaminoglycans that are 
synthesized in the Golgi apparatus and exported to the extracellular space, HA is 
synthesized and extruded simultaneously at the plasma membrane forming a glycocalyx 
around cells (Necas et al., 2008). HA is also incorporated into the ECM and performs 
such functions as space filling, lubrication, and stabilization (Laurent and Fraser, 1992; 
Anderegg et al., 2014; Temple-Wong et al., 2016). Additionally, HA has no core protein, 
and because of its unique structure, and anionic properties, HA can hold 1000 times its 
weight in water (Laurent and Fraser, 1992; Wang et al., 2011; Manasa et al., 2012). 






Figure 1-4: Structure of hyaluronan. 
The structure of hyaluronic acid is a repeating disaccharide consisting of D-glucuronic 
acid and N-acetylglucosamine. The monosaccharides are linked through repeated β-1,4 




 Three enzymes are responsible for making mammalian HA, hyaluronan synthase 
(HAS) 1, 2, and 3 (Spicer and McDonald, 1998). Each of the three HAS enzymes is 
located on different chromosomes suggesting an early gene duplication and divergence 
(Spicer and McDonald, 1998; Jiang et al., 2011). HAS enzymes differ in the size and 
amount of HA produced and are described in detail below (and in Figure 1-5) (Spicer 
and McDonald, 1998; Itano et al., 1999). The HAS enzymes are usually co-expressed, 
and their expression patterns depend on cell type, developmental stage, and the cellular 
response to injury (Spicer and McDonald, 1998; Jacobson et al., 2000; Jiang et al., 
2011). The expression pattern and activity can also depend on hetero- and homo-
dimerization of the HAS enzymes (Bart et al., 2015). The primary postnatal HA-
synthesizing cell types are fibroblasts and endothelial cells, and in the liver, activated 
HSC are the primary source of HA (Spicer and McDonald, 1998; Jiang et al., 2011; Xu 
et al., 2013; Neuman et al., 2016).  
 
 HAS1 
 HAS1 is the least active HA synthesis enzyme, shown by the smallest pericellular 
coat/glycocalyx visualized using a particle exclusion assay and Cos-1 cells transfected 
with mouse Has1 (Spicer and McDonald, 1998; Itano et al., 1999). Cos-1 cells were 
used for this study because they are known to have little endogenous HAS activity 
(Spicer and McDonald, 1998; Itano et al., 1999). Using human HAS genes for 
transfection, HAS1 requires higher sugar substrate concentration, as found in 
hyperglycemic conditions, to synthesize the same amount of HA as HAS2 and HAS3 in 
euglycemic conditions (Rilla et al., 2013). Therefore, HAS1 may play a role in diabetes 
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Figure 1-5: The synthetic capacity of the three mammalian hyaluronan synthases 
(HAS). 
 
HAS1 synthesizes HA at an average of 2 X 105 Da to 2 X 106 and has the lowest 
synthetic capacity of the three enzymes. HAS2 makes more and larger HA, with an 
average molecular mass of >2 X 106 Da. HAS3 makes slightly smaller HA at an average 
of 1 X 105 to 1 X 106 HA and also has a higher synthetic capacity than HAS1. All HA is 




pathologies, where increased glucose levels are correlated with increased HA levels in 
serum and in the kidney (Mine et al., 2006; Rugheimer et al., 2008). In fact, 
inflammation and increased glucose, both of which are present in diabetes, can induce 
Has1 expression (Bastard et al., 2006; Rilla et al., 2013; Zhuang and Yin, 2013; 
Siiskonen et al., 2015). When HAS1 is given unlimited substrate, it produces a 
polydisperse HA population and averages 2 X 105 to 2 X 106 Da (Spicer and McDonald, 
1998; Itano et al., 1999).  
 
 HAS2 
 When Cos-1 cells over expressing mouse Has2 were provided with unlimited 
substrate, the cells synthesized HA that had broad polydispersity but averaged >2 X 106 
Da, slightly larger than the HA produced by mouse HAS1 (Itano et al., 1999). HAS2 
plays a vital role in embroyonic development of the heart. In fact, Has2-/- mice die at 
E9.5 due to cardiac and vascular abnormalities. Explanted atrioventricular canals from 
hearts of Has2-/- mice are rescued back to wild-type phenotype by providing exogenous 
HA or after transfection with Has2 cDNA suggesting a critical role for HA synthesized by 
HAS2 in heart development (Camenisch et al., 2000). Like HAS1, HAS2 expression can 
be induced. For example, osteopontin induces HAS2 expression in human mammary 
epithelial cells and prostaglandins induce HAS2 expression in human vascular 
endothelial cells (Meyer-Kirchrath et al., 2004; Cook et al., 2006). In rat keratinocytes, 
EGF up-regulates Has2 expression while TGFβ down-regulates Has2 expression 




 HAS3 is unique in terms of the size of HA that it produces. When Cos-1 cells 
were transfected with mouse Has3, the HA produced was slightly smaller than the other 
two synthases averaging 1 X 105 to 1 X 106 Da (Itano et al., 1999). Unlike HAS1, human 
HAS3 synthesizes HA even at low substrate concentrations and its activity is unaffected 
by additional substrate (Rilla et al., 2013). It is important to note that although HAS3 
produces smaller HA compared to HAS1 and HAS2, all endogenously produced HA is 
considered HMW-HA and pro-homeostatic (Fraser et al., 1997; Cowman et al., 2015). In 
rat keratinocytes EGF upregulates Has3 expression and TGFβ downregulates Has3 
expression (Pasonen-Seppanen et al., 2003). Despite the fact that cells usually express 
all three enzymes, they can be differentially regulated by various external stimuli and 
this regulation depends on the cell type being examined (Jacobson et al., 2000). 
 
 HAS deficient mice 
 The creation of animals deficient in HAS enzymes has been a great aid in 
helping to elucidate roles for HA in health and disease. In Has1-/- mice, exon five is 
interrupted with a neomycin cassette that makes it catalytically dead (Kobayashi et al., 
2010). HAS3 in Has3-/- mice is also catalytically dead due to deletion of a portion of 
exon 4 (Bai et al., 2005). Has2-/- whole body knockouts are embryonic lethal but viable, 
conditional knockout mice were created by inserting loxP sites around exon 2, which 
contains the start codon (Camenisch et al., 2000; Matsumoto et al., 2009). These 
conditional knockouts allow for exploration into HAS2’s role in tissue homeostasis and 
injury in postnatal life (Matsumoto et al., 2009).  
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HA turnover and homeostatic degradation 
 HA is turned over in the body every 2-3 days (Fraser et al., 1997). During normal 
turnover, HA is degraded by hyaluronidases (Jiang et al., 2011). There are six known 
vertebrate hyaluronidases that degrade HA into smaller, yet variable sized fragments 
(Csoka et al., 2001; Jiang et al., 2011). Hyaluronidase (HYAL) 1 and HYAL2 are the 
most abundant and functionally important in the body (Fraser et al., 1997; Csoka et al., 
1999; Csoka et al., 2001). HYAL1 is expressed in high levels in the liver, kidney, heart 
and spleen, is pH-dependent, and located primarily in lysosomes within the cell (Csoka 
et al., 1999; McAtee et al., 2015). HYAL2 is ubiquitously expressed (Csoka et al., 1999). 
It can be membrane bound and act in conjunction with CD44 to bring HMW-HA close to 
the cell surface for cleavage into low molecular weight (LMW-HA) fragments (Csoka et 
al., 2001; Rai et al., 2001; Albeiroti et al., 2015). HA that is cleaved initially by HYAL2 
can be internalized and further degraded by HYAL1 and glycosidases intracellularly 
(Csoka et al., 2001; Stern, 2003; de la Motte, 2011). However, in some tissue, HYAL2 is 
intracellular with no extracellular or membrane localization, suggesting that there are 
tissue specific localizations for HYAL enzymes (Chow et al., 2006). Platelets are unique 
in that they have HYAL2 activity but no HYAL1 activity leaving HA degraded by platelets 
in the extracellular environment and able to act as a potent, pro-inflammatory signaling 
molecule (discussed below) (Albeiroti et al., 2015). In tissues such as the skin and 
joints, HA turnover and recycling is done locally, but once HA reaches the blood stream 
a majority of it (85-90%) is taken up by LSEC, primarily via HA receptor for endocytosis 
(HARE), and the individual sugar molecules are reused (Fraser et al., 1997; Harris et 
26	
al., 2007; Gushulak et al., 2012). As more research into HA and HA turnover is being 
done, new HA degrading enzymes are being discovered including KIAA1199 and 
TMEM (Yoshida et al., 2013; Yamamoto et al., 2017). 
 
HMW-HA signaling 
 As stated above, HA is synthesized and released into the extracellular space as 
a HMW (defined as ≥500kDa unless otherwise stated) polymer and promotes 
homeostasis (Noble, 2002; Ruppert et al., 2014). For example, U937 cells treated with 
LPS release pro-inflammatory cytokines like TNFα, IL1β, and IL6, and co-treatment with 
HMW-HA (800kDa, 2700kDa) reduces the release of each of these cytokines in a 
concentration-dependent manner (Yasuda, 2007). HMW-HA has similar effects in vivo. 
In a model of T-cell mediated liver disease, HMW-HA (780, 900, 1200kDa) limits liver 
injury in a size and concentration dependent manner (Nakamura et al., 2004). HMW-HA 
promotes this homeostatic environment through interactions with HA receptors and HA 
binding proteins (referred to as the HA network), which are discussed below (and 
outlined in Figure 1-6 and 1-7) (Manasa et al., 2012; Yang et al., 2012).  
 Cluster of differentiation 44 (CD44) is a transmembrane adhesion molecule and 
the most well understood and widely expressed HA receptor (Aruffo et al., 1990; Teder 
et al., 2002). HMW-HA binds CD44 and links several CD44 receptors together, 
promoting an anti-inflammatory, homeostatic environment. However, the exact 
mechanism by which HMW-HA promotes tissue homeostasis is not well established 
(Bollyky et al., 2009; Yang et al., 2012; Ruppert et al., 2014). CD44 also helps to  
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Figure 1-6: The balance of high molecular weight HA (HMW-HA) and low 
molecular weight HA (LMW-HA) influences HA signaling. 
HMW-HA, characterized in this dissertation as HA greater than or equal to 500kDa, 
clusters the receptor CD44 and sends tissue integrity and homeostasis signals 
intracellularly. LMW-HA, characterized in this dissertation as less than or equal to 






Figure 1-7 The HA network 
 
The HA network consists of HA, Hyaluronan synthase (HAS) enzymes, and associated 
cell surface HA receptors and HA binding proteins. HAS enzymes synthesize HA at the 
cell surface and simultaneously extrude HA into the extracellular space. There it can 
bind proteins such as aggrecan and versican to form a stable space filling matrix that 
can aid in joint lubrication and shock absorption. The stable matrix also aids in hydration 
and maintaining barrier functions in the skin. HA can also bind cell surface receptors 
such as CD44 which aids in cell coat stability, migration, and HA internalization. HA 
bound to toll like receptor (TLR) 2 and TLR4 promotes pro-inflammatory gene 
expression, and HA bout to HA mediated motility receptor (HMMR) promotes migration 
of macrophages and fibroblasts.  
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maintain cell-coat stability (Knudson et al., 1996). HMW-HA can also maintain 
homeostasis by binding other HA binding proteins like aggrecan and versican to form a 
stable space filling matrix important in joint lubrication and skin elasticity, respectively 
(Hasegawa et al., 2007; Seror et al., 2012). 
 
LMW-HA signaling 
 During tissue injury HMW-HA is degraded to LMW-HA fragments (defined as 
≤300kDa unless otherwise stated) by HYALs as well as ROS (Moseley et al., 1997; 
Csoka et al., 2001). Following this degradation, LMW-HA fragments interact with 
several receptors including CD44 and toll like receptor 2 and 4 (TLR2 and TLR4) (Aruffo 
et al., 1990; Hardwick et al., 1992; Jiang et al., 2005). These HA receptors are found on 
many cell types, including macrophages, fibroblasts, and epithelial cells (Teder et al., 
2002; Jiang et al., 2005; Ruffell et al., 2011; Tolg et al., 2012). The signaling that occurs 
during LMW-HA-receptor interaction is specific to the cell type responding to HA and the 
particular receptor(s) ligated; this is discussed in more detail below (and outlined in 
Figures 1-6 and 1-7). 
 The CD44-LMW-HA interaction is implicated in several cellular processes 
including cell migration and invasion, and glycocalyx stability (Knudson et al., 1996; 
Marhaba and Zoller, 2004). CD44 also plays a role in the internalization of HA 
fragments.  For example, Cd44-/- mice exhibit decreased survival and unremitting 
inflammation following bleomycin induced lung injury due to persistence of pro-
inflammatory HA fragments in the injured lung (Knudson et al., 2002; Teder et al., 
2002).  
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 TLR2 and TLR4 are part of the innate immune system and are pattern 
recognition receptors with well-established ligands, Gram-positive and Gram-negative 
bacterial components, respectively (Mencin et al., 2009). In addition to the bacterial 
components they recognize, both TLR2 and TLR4 recognize LMW-HA. This is thought 
to be due to the similar repeating nature of bacterial cell-wall components and the HA 
molecule (Takeuchi et al., 1999; Jiang et al., 2005; Jiang et al., 2011). During bleomycin 
induced lung injury, LMW-HA (135kDa) requires TLR2, TLR4, and the adapter protein 
MYD88 to elicit an innate immune response both in vitro and in vivo (Jiang et al., 2005). 
Primary human macrophages stimulated with LMW-HA (200kDa) polarize into M1 pro-
inflammatory macrophages primarily through HA interaction with TLR2, TLR4, which 
again requires the adaptor protein MYD88 (Jiang et al., 2011; Sokolowska et al., 2014).  
 
HA and HA mediated motility receptor (HMMR) signaling 
 While much is known about the size-dependent interactions of HA with CD44 and 
TLR2 and 4, much less is known about HA mediated motility receptor (HMMR) or any 
size-dependent reactions with HA it may have. HMMR (also known as receptor for HA 
mediated motility or RHAMM) was originally isolated from chick fibroblast cultures 
(Turley, 1982). It was subsequently cloned by Eva Turley’s group and was aptly named 
for its role in tumor cell migration (Hardwick et al., 1992). Basal HMMR levels are low, 
but it is rapidly induced following injury (Lovvorn et al., 1998; Bagli et al., 1999; Zaman 
et al., 2005). Unlike CD44 and the TLRs, HMMR is not a transmembrane protein, 
however, as the name suggests, HMMR plays a role in migration and motility not only of 
tumor cells as was first described but also of both macrophages and fibroblasts 
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(Hardwick et al., 1992; Tolg et al., 2006; Tolg et al., 2012). In fact, a HMMR mimetic that 
inhibits the interaction between HA and HMMR limits wound closure in a model of 
excisional skin repair by limiting macrophage and fibroblast migration into the injured 
tissue (Tolg et al., 2012). Similarly, Hmmr-/- fibroblasts are unable to migrate in a 3D 
collagen gel assay when stimulated with HA (Tolg et al., 2006). HMMR is unique in that 
it is also found intracellularly and aids in cell cycle progression (Assmann et al., 1999; 
Chen et al., 2014). Specifically, HMMR aids in mitotic spindle integrity during cell 
division and Hmmr-/- embryonic fibroblasts exhibit multi-pole spindles and incomplete 
cytokinesis (Tolg et al., 2010). Together, these receptors allow the simple HA molecule 
to have a wide range of signaling capabilities.  
 
Clinical Uses of HA 
 
 HA as a biomarker 
 Blood levels of HA are much lower than other tissues and in healthy individuals 
are between 10 and 100ng/mL (Laurent and Fraser, 1992; Cowman et al., 2015). 
Patients with advanced liver disease have increased HA blood levels, which have a 
positive correlation to disease severity (Lee et al., 2010; Lee et al., 2013; Rostami and 
Parsian, 2013). This is mainly thought to be due to the injured and dysfunctional LSECs, 
which are the main cell type responsible for systemic HA clearance (Fraser et al., 1997; 
van den Broek et al., 2013). Similarly, increased HA synthesis is associated with several 
types of cancer, and HA is currently being investigated as a biomarker for cancer 
progression (Kuwabara et al., 2003; Auvinen et al., 2013; Peng et al., 2016). For 
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example, in the case of metastatic breast cancer, plasma HA levels correlate with poor 
prognosis in patients (Peng et al., 2016).  
 HA levels from other fluids are also being investigated as potential non-invasive 
markers of disease. HA levels are increased in lung tissue from human patients with 
cancer and this is mirrored in sputum samples from the same patients, suggesting 
sputum HA levels could be used as a biomarker for lung cancer (Rangel et al., 2015). 
Additionally, urinary HA levels are increased in patients with bladder cancer (Lokeshwar 
et al., 2000; Shariat et al., 2008). While HA is not the only biomarker used for the 
diagnosis of any disease, it is becoming increasingly helpful for physicians looking to 
avoid invasive and costly medical procedures.  
 
 HA as treatment for skin aging 
 As mentioned above, the skin contains a large portion of the total HA in the body, 
but the amount of HA in human skin varies depending on age, with young skin 
containing more HA (Reed et al., 1988; Fraser et al., 1997). There is approximately 200-
500µg HA/g skin tissue, with a large percentage of that HA in the dermis (Tammi et al., 
1994; Fraser et al., 1997). HA’s association with extracellular HA binding proteins, such 
as aggrecan and versican, as well as CD44, help provide a strong and stable ECM in 
the skin (Hardingham and Fosang, 1992; LeBaron et al., 1992; Pasonen-Seppanen et 
al., 2012). Because of its importance in skin homeostasis and hydration, there is great 
interest in the use of HA as a topical or injectable treatment to renew a youthful 
appearance in the skin (Anderegg et al., 2014; Paliwal et al., 2014). In fact, in patients 
with UV damaged skin, injection of a stabilized HA filler increases collagen synthesis 
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and the study’s authors suggest that it is due to the mechanical stretching and activation 
of the dermal fibroblasts (Wang et al., 2007). 
 
 HA as treatment for arthritis 
 HA is also a major component of synovial fluid, which contains between 2-4mg 
HA/mL of fluid (Fraser et al., 1997; Cowman et al., 2015; Temple-Wong et al., 2016). Its 
ability to hold large amounts of water helps it to aid in the lubrication of the joint and act 
as a shock absorber (Fraser et al., 1997; Cowman et al., 2015). As we age, the 
concentration and molecular weight distribution of articular HA changes; the 
concentration of HA decreases, as does the average molecular weight, resulting in 
decreased lubrication leading to osteoarthritis and joint pain (Band et al., 2015; 
Kosinska et al., 2015; Temple-Wong et al., 2016). Currently, intra-articular injection of 
HA, primarily HMW-HA, is an effective treatment for osteoarthritis by increasing joint 
lubrication and is associated with decreased IL6 production (Guidolin and Franceschi, 
2014; Kusayama et al., 2014; Park et al., 2014). Inflammation, another important 
component of arthritis, is decreased following HMW-HA injection in a rodent model of 
collagen induced arthritis primarily due to a decrease in TLR2 and TLR4 and their 
subsequent downstream signaling pathways (Campo et al., 2011). The increase in joint 
lubrication and viscosity combined with a decrease in inflammation makes HA, 
specifically HMW-HA, a viable option for the treatment of joint degeneration and 
alleviating patients’ painful symptoms (Campo et al., 2011; Guidolin and Franceschi, 
2014).   
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 HA to treat abdominal adhesions 
 Post-operative adhesions are a common complication following abdominal 
surgery and can cause abdominal pain, small bowel obstruction, or infertility in females 
(Ward and Panitch, 2011). In recent years, a HA-carboxymethyl cellulose (HA-CMC) 
barrier has been implanted in the abdomen of patients after surgery to aid in abdominal 
adhesion prevention (Ward and Panitch, 2011; Picaud et al., 2014). This barrier turns to 
gel 1 day after implantation and is fully absorbed by the body within 1 week (Ward and 
Panitch, 2011). HA-CMC barriers are used to prevent adhesions after a number of 
abdominal procedures including both laproscopic and open abdominal surgeries 
(Stawicki et al., 2014; Ha et al., 2016). Use of the barriers is beneficial by limiting the 
number and severity of adhesions while having no adverse effects. However a powder 
version of the same HA-CMC formula shows an increase in adverse outcomes (ten 
Broek et al., 2014).  
 
 Targeted drug delivery using HA 
 In addition to HA itself being used to treat aging, arthritis, and intra-abdominal 
adhesions, HA is being tested for use as a vehicle for drug delivery. CD44, a receptor 
involved in HA endocytosis, is overexpressed in several cancers and contributes to 
metastasis (Auvinen et al., 2013; Kim and Kumar, 2014; Gao et al., 2015). By taking 
advantage of this fact, targeted drug delivery is being explored using HA coated anti-
cancer drugs (Liu et al., 2015; Wang et al., 2016b). In vitro, HA coated nanoparticles 
containing 5-flourouracil induce apoptosis in colon cancer cells above that of non-HA 
coated nanoparticles (Liu et al., 2015). Similar results were found in HeLa cells treated 
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with HA coated nanoparticles containing doxorubicin (Wang et al., 2016b). In an in vivo 
mouse model of breast cancer, mice treated with HA-conjugated liposomes containing 
gemcitabine had slower drug clearance compared to free gemcitabine and liposome 
encapsulated gemcitabine, and this correlated with a greater reduction in tumor volume 
(Han et al., 2016). While these studies are still in the early stages, HA appears to be a 
promising drug delivery system for cancer treatment.  
 
Goals of the studies within this dissertation 
 
 As stated at the beginning of this dissertation, chronic liver disease is an 
abundant and expensive burden on the United States population (Kochanek et al., 
2016). There are few treatments and no cures for advanced liver disease, except for a 
liver transplant, which comes with a host of problems. These include invasive surgery, 
the life-long immuno-suppression associated with anti-rejection drugs, cost, and the 
limited supply of healthy liver donors available (Rai, 2013; Parikh et al., 2015). For these 
reasons, the objective of my dissertation research was to identify new pathways of liver 
wound healing with the goal of identifying novel therapeutic targets to improve liver 
repair after acute and chronic liver injury.  To reach this objective, we used mouse 
models of liver injury to study mechanisms of hepatic wound healing after acute and 
chronic liver injury induced by CCl4. 
 The HA network, including HA, HA binding proteins, and receptors, plays a role 
in wound healing in the intestine, lung, and skin (both fetal and adult) (West et al., 1997; 
de la Motte, 2011; Jiang et al., 2011). The progression of wound healing has been well 
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defined in the skin, but also occurs in solid organ healing and includes steps of 
inflammation, regeneration, and matrix remodeling (Gurtner et al., 2008). In fetal skin, 
the wound healing process that occurs after an injury is referred to as regenerative 
healing; the result is minimal to no scar formation and this is associated with 
consistently high levels of HMW-HA, limiting inflammation (Leung et al., 2012). 
Conversely, in adult skin, wound healing after injury results in scar tissue formation and 
is associated with a transient increase in HA (West et al., 1997; Bayat et al., 2003). 
Acute hepatic wound healing can be considered analogous to fetal wound healing 
where there is no scar formation while chronic wound healing results in a scar, similar to 
adult skin healing (Pellicoro et al., 2014). However, the role that HA plays in repair after 
acute and chronic liver injury is unknown. 
 It has been known for over 30 years that plasma HA levels are elevated in 
patients with liver disease. However we are the first to explore if the HA network is 
involved in liver injury or repair (Engstrom-Laurent et al., 1985). As outlined above, liver 
disease, particularly fibrosis, is described as deregulated cycles of wound healing 
following chronic injury (Pellicoro et al., 2014). Because HA has been implicated in 
wound healing responses in other organs and HA is increased in the plasma of patients 
with liver disease, we hypothesize that the HA network is vital to hepatic wound healing 
after acute and chronic liver injury.   
 HA is increased after tissue damage in the lung, skin, and intestine (Bai et al., 
2005; Mack et al., 2012; Kessler et al., 2015). If this increase is prevented, as is the 
case in mice deficient in HAS enzymes, the wound healing process is perturbed. 
Specifically, Has3-/- mice are protected from both dextran sodium sulfate (DSS) 
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induced colitis and ventilator induced lung injury as evident by decreased tissue 
damage (Bai et al., 2005; Kessler et al., 2015). In DSS-induced colitis, this decreased 
tissue damage is associated with decreased HA deposition in the colon of these mice 
(Kessler et al., 2015). In ventilator induced lung injury, the decreased injury is 
associated with decreased LMW-HA fragments (Bai et al., 2005). We therefore 
hypothesized that Has3-/- mice would be protected from CCl4 induced liver injury and 
inflammation.  
 HMMR is unique in that it can be both extracellular and intracellular and plays 
roles in cell migration and proliferation, respectively (Tolg et al., 2006; Chen et al., 
2014). Specifically, preventing the HA:HMMR interaction following dermal wound injury 
prevents macrophage and fibroblast migration and leads to defective wound repair (Tolg 
et al., 2006; Tolg et al., 2012). Additionally, Hmmr knockdown in HeLa cells results in 
mitotic spindle defects and aberrant proliferation (Chen et al., 2014). Both cell migration 
and hepatocyte proliferation are vital parts of the regenerative wound repair process, 
therefore we hypothesized that Hmmr-/- mice would have decreased or delayed wound 
healing following acute CCl4 exposure.  
 Unlike the regenerative wound healing observed after acute liver injury, chronic 
liver injury results in excess ECM accumulation and a fibrotic scar (Pellicoro et al., 
2014). Because we hypothesized Has3-/- mice would have decreased injury after acute 
CCl4 exposure, we subsequently hypothesized that Has3-/- mice would have less 
fibrosis compared to wild-type mice after chronic CCl4 exposure. Chronic liver injury and 
fibrosis are associated with persistent inflammation and deregulated wound healing. We 
hypothesized that Hmmr-/- mice would have decreased wound healing after acute CCl4 
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exposure, so we in turn hypothesized that Hmmr-/- mice would have decreased fibrosis 
after chronic CCl4 exposure compared to wild-type mice.   
 One final goal of this study, which came to light after discovering the genetically 
deficient mice described above were on different backgrounds, was to identify 
differences in liver injury, wound healing, and fibrosis between C57BL/6 sub-strains. 
Specifically, we evaluated acute hepatotoxicity and wound healing following a single 
injection of CCl4 in both the 6J and 6N sub-strains of mice. Differences in toxicity occur 
following APAP induced liver injury, and we hypothesized that these differences will 
occur following CCl4 injury as well, with 6N mice having increased injury (Bourdi et al., 
2011; Duan et al., 2016). We also hypothesized that this increased injury may contribute 
to a difference in the wound healing response following acute CCl4; i.e. 6N mice will 
have increased wound healing.  We also investigated any potential differences in frank 
fibrosis between 6J and 6N mice, and hypothesized that 6N mice would have increased 
fibrosis following chronic CCl4 exposure compared to 6J mice due to increased liver 
injury and subsequently more robust repair.  















Portions of this chapter are adapted from 1) McCracken, JM et al. “Differential effects of 
hyaluronan synthase 3 deficiency after acute vs chronic liver injury in mice” 
Fibrogenesis and Tissue Repair 2016; Licensed under Creative Commons Attribution 
4.0 International License and 2) McCracken, JM et al. “C57BL/6 substrains exhibit 
different responses to acute carbon tetrachloride exposure: Implications for work 
involving transgenic mice” Gene Expression: The Journal of Basic Liver Research. 
17#3, doi: 10.3727/105221617X695050 with permission Cognizant, LLC; 




 Olive oil and carbon tetrachloride were purchased from Sigma-Aldrich (St. Louis, 
MO) and Buprenex (buprenorphine HCL) was manufactured by Reckitt Benckiser 
Healthcare (UK, Ltd, Hull England) and distributed by Reckitt Benckiser 
Pharmaceuticals, Inc (Richmond, VA). The anesthetic used was a mixture containing 
Ketamine (Akom, Inc, Decator, IL), Xylazine (KetaVed, VedCO, Inc., St. Joseph, MO), 




 Animals were treated humanely and in accordance to protocols approved by the 
University of Kansas Medical Center (KUMC) Institutional Animal Care and Use 
Committee. Mice were housed in ventilated cages on a 10/14H light/dark cycle with 
access to standard mouse chow and water ad libitum. Wild-type C57BL/6J or C57BL/6N 
were purchased from Jackson Labs (Bar Harbor, ME) or Charles River (Wilmington, 
MA), respectively. Has3-/- animals (Bai et al., 2005) were derived from Has1/3 double 
knockout mice, a kind gift from Drs. Vince Hascall, Carol de la Motte, and Sean Kessler 
from Cleveland Clinic in Cleveland, Ohio and Hmmr-/- mice (Tolg et al., 2003) were a 
kind gift from Dr. Eva Turley from London Health Science Centre in Ontario, Canada 
and were bred at KUMC. Male knockout mice were utilized at 10-12 weeks of age and 




 Mice were ear punched and a small piece (~ 2 mm) of the end of the tail was 
collected when mice were 14-16 days old, prior to ossification of the distal most 
tailbones. The tail biopsy was snap frozen in liquid nitrogen and stored at -80°C until 
DNA was isolated. The tails were digested with ALT buffer and Proteinase K (DNeasy 
Kit, Qiagen, Valencia, CA) at 57°C overnight (16-18 hours). DNA was isolated using 
DNeasy Kit and eluted in AE buffer. PCR was completed using parameters specific for 
each reaction as follows and a MJ Research PTC-200 thermocycler (Bio-Rad). The 
individual master mixes are listed below and all primers are found in Table 2-1. 
 Nnt genotyping master mix included 1X PCR buffer, 2.5mM MgCl2, 0.67mM 
dNTPs, 1.0µM Nnt-Common primer, 0.33µM Nnt-Wild-type primer, 0.67µM Nnt-Mutant 
primer, and 1.25 units platinum Taq polymerase. The amplification procedure was as 
follows: initial melt 95°C for 5 minutes, amplification cycle 95°C for 45 seconds, 58°C for 
30 seconds, 72°C for 45 seconds for 35 cycles, and a final extension 72°C for 5 minutes 
(Navarro et al., 2012).  
 Has3 genotyping master mix included 1X PCR buffer, 2.0mM MgCl2, 0.8mM 
dNTPs, 1.0µM forward primer, 1.0µM reverse primer, and 2 units of platinum Taq 
polymerase. For Has3 wild-type the forward primer was Has3 KO3’ and the reverse was 
Has3 KO5’. For Has3 mutant the forward primer was Has3 KO3’ and the reverse was 
PGK promAS-1. The amplification procedure was as follows: initial melt 94°C for 5 
minutes, amplification cycle 94°C for 30 seconds, 67°C for 30 seconds, 72°C for 60 
seconds for 37 cycles, and a final extension 72°C for 10 minutes. 
 Hmmr genotyping master mix was the same as above for Has3. Each reaction 
required different amplification procedures and are as follows: For the wild-type 
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reaction, the initial melting was 94°C for 15 minutes, amplification cycle 94°C for 30 
seconds, 50°C for 1 minutes, 72°C for 1 minute repeated 39 times, and a final extension 
at 72°C for 10 minutes. For Hmmr knockout reaction, the initial melting was 94°C for 15 
minutes, amplification cycle 94°C for 30 seconds, 60°C for 1 minutes, 72°C for 1 minute 
repeated 39 times, and a final extension at 72°C for 10 minutes (personal 
correspondence with Connie Tolg, PhD).  
 All amplification products were kept at 4°C until they were ran on a 1% agarose 
gel containing 0.16µg/mL ethidium bromide using a sample loading buffer containing 
glycerol, bromophenol blue, and xylene cyanol. Gene products for Nnt were 579 base 
pairs for mutant (C57BL/6J background) and 743 base pairs for wild-type (C57BL/6N 
background). Has3 gene products were 320 base pairs for mutant and 320 base pairs 
for wild-type. Hmmr gene products were 400 base pairs for mutant and 650 base pairs 
for wild-type.  
 
Carbon tetrachloride exposure 
 Animals were given a subcutaneous injection of Buprenex as an analgesic at a 
concentration of 0.1mg/g body weight (BW). In acute studies, mice were given a single 
intraperitoneal injection of carbon tetrachloride (CCl4, 0.4mg/g BW diluted 1:3 in olive 
oil) 10 minutes after Buprenex. In the chronic studies, animals were given 2 injections 
per week for 5 weeks ramping up from 0.1mg/g BW (1 injection) to 0.2mg/g BW (1 
injection) to 0.4mg/g BW (8 injections). Control animals received Buprenex and olive oil 
injection(s). For acute CCl4 studies, mice were euthanized 12, 24 48, 72, or 96 hours 
post CCl4 exposure. For chronic CCl4 studies, mice were euthanized 72 hours after the 
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last injection. Animals were euthanized with either a drug cocktail containing ketamine 
(200mg/kg), xylazine (40mg/kg), and acepromazine (20mg/kg) or isoflurane exposure.  
 
Sample collection and storage 
 Blood was taken from the inferior vena cava or portal vein in deeply anesthetized 
mice, collected into a tube containing EDTA and aprotinin, and placed on ice. The 
diaphragm and aorta were cut to euthanize the animals and a hepatectomy was 
performed. The liver was weighed and the gall bladder removed. The liver was placed 
on a glass plate on ice and divided into several pieces: the left lobe of the liver was cut 
into slices, two slices were snap frozen in liquid nitrogen and saved for Western Blot 
analysis and another slice was placed in 10% formalin for 16-18 hours and 
subsequently transferred to 70% ethanol until it was processed. The right lobe was snap 
frozen to be used for triglyceride analysis and the large portion of the median lobe was 
embedded in optimal cutting temperature (OCT) medium, incubated on a bed of frozen 
isopentane until opaque and then wrapped in heavy-duty aluminum foil and stored at     
-80° C. The small half of the median lobe was placed in RNA later (Ambion, Austin, TX) 
at room temperature for 5-10 minutes, moved to 4°C for 18-24 hours then transferred to 
-20°C for further analysis. All remaining liver pieces were snap frozen in liquid nitrogen 
and stored at -80° for further analysis. Plasma was separated by spinning blood at 
10,000g for 3 minutes and 30 seconds at 4° and stored at -80°C for further analysis. 
 
Hepatocyte isolation and culture 
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 Ten to twelve week old C57BL/6N and C57BL/6J mice were anesthetized with a 
mixture of ketamine (200 mg/kg) and xylazine (10 mg/kg). Once mice were fully 
anesthetized, the abdomen was shaved using animal clippers. Mice were then affixed to 
a surgical platform using laboratory tape and the abdomen cleaned using 70% ethanol. 
The peritoneal cavity was then exposed, and the intestines moved to one side using a 
sterile cotton swab. Median and left lateral liver lobes were then moved to expose the 
inferior vena cava and the portal vein. Next, using a pair of sterile curved forceps, a 
sterile suture was directed under the vena cava and tied loosely around the vein. The 
vena cava was then cannulated with a 22 gauge i.v. catheter, needle removed, and 
ligature tightened around the catheter. Perfusion tubing was then attached to the 
catheter and perfusion started (8.2 mL/min, 100 total mL) using perfusion buffer (1X 
HBSS Ca2+, Mg2+-free, 100 U/mL penicillin, 100 µg/mL streptomycin, 10 mM HEPES). 
Immediately after starting the perfusion, the portal vein was cut to allow outflow of 
perfusate, and then the diaphragm was cut, and superior vena cava clamped using 
small hemostats. Perfusion continued using 100 mL of a second buffer (1X HBSS with 
Ca2+/Mg2+, 100 U/mL penicillin, 100 µg/mL streptomycin, 10 mM HEPES, 0.025 mg/mL 
Liberase (Roche)). Once complete, perfusion was halted and the liver dissected out of 
the mouse and placed into a sterile beaker containing 20 – 30 mL ice-cold disruption 
buffer (1X HBSS Ca2+, Mg2+-free, 100 U/mL penicillin, 100 µg/mL streptomycin, 10 mM 
HEPES, 1 x 10-7 M insulin). The liver was then cut into large pieces using sterile 
surgical scissors and then sterile forceps were used to gently agitate the dissected liver 
pieces in the ice-cold disruption buffer to liberate hepatic cells from the digested hepatic 
extracellular matrix. The cell suspension was then passed through 3 different sterile 
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filters (100, 70 and 30 µm mesh sizes) into successive 50 mL centrifuge tubes. The 
volume of the cell suspension was then brought to 50 mLs using ice-cold disruption 
buffer and centrifuged at 50 x g for 5 minutes at 4oC. The supernatant was removed by 
aspiration and cells washed 2 more times in the same buffer. After the third wash, 
hepatocytes were resuspended in complete Williams E medium (Williams E, 100 U/mL 
penicillin, 100 U/mL streptomycin, 100 nM insulin, 2 mM GlutaMAX and 5% FBS). 
Viable cells were counted using a hemacytometer after staining with Trypan blue and 
plated on collagen-coated plates at 0.5 x 106 cells per well in a 24-well plate. Remaining 
hepatocytes were snap frozen in liquid nitrogen for analysis of Cyp2e1 expression 
(details below). 
    
In vitro, carbon tetrachloride exposure and sample collection 
 Two to three hours after plating, medium was aspirated and cells were washed 
with 1 mL of pre-warmed D-PBS; this was repeated twice. After the second wash, 1 mL 
of medium (Williams E, 100 U/mL penicillin, 100 U/mL streptomycin, 100nM insulin, 2 
mM GlutaMAX, 5% FBS, 1% DMSO) with or without CCl4 (0, 1, 5, or 10 mM) was added 
to each well. One concentration of CCl4 was used per plate and each plate was sealed 
using Parafilm to limit interplate exposure to volatilized CCl4, and placed back into a 
humidified, 5% CO2 incubator. Media addition to each plate was staggered by 15 
minutes to allow for the collection of images, culture supernatants and cell lysates 24h 
after CCl4 exposure. A single representative image was taken from each of two replicate 
wells per treatment using a Zeiss Axio Observer A.1 inverted microscope (Peabody, 
MA) and Olympus DP71 camera operated by cellSens imaging software (Olympus, 
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Center Valley, PA). All culture medium (1 mL) was removed, placed into a 1.5 mL 
microfuge tube, and snap frozen in liquid nitrogen. Hepatocytes remaining in the well 
were rinsed in 1 mL of room temperature PBS and then lysed in 200 µL of ice-cold cell 
lysis buffer (25 mM HEPES, 5 mM EDTA, 0.1% CHAPS, 1 µg/mL pepstatin, 0.5 µg/mL 
leupeptin, 2 µg/mL aprotinin, 1X cOmplete, EDTA-free Protease Inhibitor Cocktail). The 
wells were scraped using a pipette tip to ensure release of hepatocytes from the bottom 
of each well. Then, the lysate was transferred to a 1.5 mL microfuge tube and allowed 
to sit at room temperature for 5 minutes prior to snap freezing in liquid nitrogen. Both 
cell culture media and cell lysates were stored at -80oC until use. Hepatocytes from one 
6N and one 6J mouse were used in each experiment, and the experiment was repeated 
3 times on three separate days with two technical replicates completed each day. 
 
Lactate dehydrogenase (LDH) assay 
 All samples were thawed only once and cell death was determined as described 
previously (Bajt et al., 2004). In brief, cell lysates were sonicated 2 X 3 seconds and 
centrifuged for 20 minutes at 20,000 x g at 4°C. A reaction buffer containing 9.64mM 
KH2PO4, 50.42mM K2HPO4, 0.91mM pyruvate, and 2.17mM NADH-Na2 was used for 
this assay. For LDH release in media, 100µL of media was combined with 700µL of 
reaction mixture and the kinetics of the reaction were measured at 340nm and the 
difference in the absorbance determined over time. For LDH contained in cells, 30µL of 
lysate plus 730µL of reaction mixture were used. The death ratio was determined by the 
amount of LDH release in the medium divided by the total LDH in the media and cell 
lysate. The mean of technical replicates (2) from each experimental condition was 
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calculated and then the mean of experimental replicates (3) was calculated.  The data 
are represented as the fold change over no CCl4 treatment and experimental replicates 
are graphed. 
 
CYP2E1 activity assay 
  Liver microsomes were prepared by homogenizing 100-150mg of frozen liver 
tissue in 1mL of ice-cold PBS with a loose fitting dounce homogenizer. The homogenate 
was centrifuged 9,000 x g for 15 min at 4°C. Any fat was removed and the supernatant, 
plus 10mL of ice-cold PBS, was ultracentrifuged at 105,000 x g for 1 hour at 4°C. The 
pellet was resuspended in 200µL 0.15M KCL. Total protein was determined using BCA 
assay (Pierce). The assay reaction mixture consisted of 100µg of protein, 4µL p-
nitrophenol, 10µL phosphate buffer (4mL 1M K2HPO4 + 1mL 1M KH2PO4 pH 7.4), water 
to bring volume to 100µL, and 10µL of 11mM NADPH. The hydroxylation of p-
nitrophenol to p-nitrocatechol was used to calculate CYP2E1 activity using the 
extinction coefficient method. Activity is expressed as nm/min/mg total protein (Wu and 
Cederbaum, 2008).  
 
Injury evaluation 
 Plasma alanine aminotransferase (ALT) activity was determined using ALT-SL 
reagent kit (Sekisui Diagnostics, Exton, PA), by combining 10 µL of sample and 90 µL 
of working reagent. The mean velocity was determined using Synergy2 multigrade plate 
reader by taking readings at 340nm every 30 seconds for 5 minutes. The extinction 
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coefficient method was used to calculate activity based on the extinction coefficent of 
NADH and the change in absorbance over time.  
 Formalin-fixed liver tissue was processed using an automated tissue processor 
(Leica ASP3005, Buffalo Grove, IL) and embedded in paraffin. For histological analysis 
of necrosis, 5.0 or 6.0 µm sections were stained with hematoxylin and eosin (H&E) 
using Leica Autostainer XL and coverslipper (Leica CV5030). Necrosis was defined as 
regions of tissue that were hyper-eosinophilic and lacked hepatocyte nuclei. Total area 
of necrosis was evaluated by a board certified pathologist by scanning the entire liver 
section or by using ImageJ to quantify the area of necrosis in three to five non-
overlapping images taken at 200x using an Olympus BX51 microscope fitted with an 
Olympus DP71 camera (Olympus, Waltham, MA). Infiltrating cells were counted in 5 
different necrotic areas using an EVOS FL Auto Cell Imaging System (Thermo Fisher, 
Waltham, MA) or ImageJ and images from an Olympus BX51 microscope fitted with an 
Olympus DP71 camera. Images were taken at 200X with each image containing at least 
one central vein. The area of necrosis was determined as defined above, the area of the 
central vein was subtracted, and the cells infiltrating the necrotic area were counted. 
Data are represented as the number of cells/µm2 (EVOS) or cells/pixel (ImageJ). A total 
of five distinct areas of necrosis were used to determine an average number of 
infiltrating cells for each mouse. 
  
Hepatic triglyceride determination 
 The right lobe of the liver was weighed and 50-100mg of tissue was transferred 
to a new 1.5mL microcentrifuge tube keeping the tissue frozen on dry ice. The liver was 
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digested with 3M KOH in 65% ethanol for 1 hour at 70°C, and vortexed every 20 
minutes. Digested samples were placed at room temperature for 24h. The next day, 
samples were diluted 1:5 in 2M Tris buffer, pH 7.5. One mL of triglyceride Glycerol 
Phosphate Oxidase (GPO) Reagent (Pointe Scientific, Canton, MI) was pre-warmed to 
37°, 10µL of diluted sample was added, and returned to 37° C for 5 minutes. A standard 
curve was created using GPO standard and then warmed to 37°C. Two-hundred µL of 
sample or standard was loaded into a 96-well plate and the absorbance was measured 
at 500nm. The total hepatic triglyceride (mg/g liver) was calculated using the standard 
curve and the starting weight of the liver.  
 
Gene expression 
 Twenty to thirty mg of liver preserved in RNA later (Ambion, Grand Island, NY) 
was homogenized using RLT (Qiagen RNeasy Mini Kit), 10µL/mL β-mercaptoethanol, 
and a bead homogenizer at 4m/s for 45 seconds (Fast prep 24, MP Biomedicals, Solon, 
OH). For RNA isolation from isolated primary mouse hepatocytes, 350µL of RLT + βME 
per 3 X 106 cells was added to pelleted cells. The hepatocytes were further disrupted by 
passing this lysate through an 18 gauge needle 4 times, followed by 4 times through a 
23 gauge needle. The remainder of the procedure was the same for whole liver and 
isolated primary hepatocytes. Total RNA was isolated using the Qiagen RNeasy Mini Kit 
and cDNA was synthesized using Retroscript Kit (Life Technologies/Ambion). QPCR 
was completed to compare genotypes and/or treatment groups using an Applied 
Bioscience 384-well qPCR machine (model C1000, Bio-rad, Hercules, CA) and SYBR 
green technology (Bio-rad) or Applied Biostysems 96-well qPCR machine (model Step 
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One Plus) and TaqMan technology (Applied Biosystems). Data were collected, and 
results were normalized to Rn18 (housekeeping gene) and analyzed using Livak 
method (2-ΔΔCt method). Primers used are included in Table 2-1. Sequences were from 
the Primer Bank (https://pga.mgh.harvard.edu/primerbank/) (Wang and Seed, 2003; 
Spandidos et al., 2008; Spandidos et al., 2010) unless otherwise stated.  
 
Immunoblotting 
 A 50-100mg slice of snap frozen liver was homogenized in 1X RIPA buffer 
containing 10mM sodium pyrophosphate, 40 µL/mL proteinase inhibitor (Roche, 
Indianapolis, Indiana), 10 µL/mL bacitracin, 10µL/mL leupeptin, 17.5 µL/mL aprotinin, 1 
µL/mL bestatin, and 10 µL/mL sodium orthovanadate using the FastPrep24 bead 
homogenizer at 4 m/sec for 45 seconds. Lysates were kept on ice for 15 minutes and 
then spun at 21,000 x g at 4°C for 15 minutes. The fat layer floating on top of the 
lysate/homogenate was removed by aspiration and the total protein concentration of the 
remaining supernatant was determined using the BCA assay (Pierce/ThermoFisher 
Scientific). Western blot samples were made to a final concentration of 400 µg/200µL in 
1X Laemmli buffer, boiled for 5 minutes, aliquoted and stored at -80°C (Pritchard et al., 
2007). SDS-PAGE gels were run and separated proteins were transferred to PVDF 
membranes using a semi-dry transfer apparatus (Bio-Rad, Hercules, CA). Equal protein 
loading was evaluated by staining membranes with fast green and recorded 
photographically. Membranes were washed in TBS-T and blocked in either 5% bovine 
serum albumin (BSA) or 5% non-fat dry milk. Antibodies were applied overnight at 4°, 
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Table 2-1: Primer table. 
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conjugated secondary antibodies for 1-2 hours at room temperature. Proteins of interest 
were visualized using enhanced chemiluminescent substrate (GE Healthcare, 
Piscataway, NJ) and luminescence was captured on radiographic film. ImageJ was 
used to quantify intensity of bands present for each protein of interest and loading 
normalization was done using GAPDH or HSC70. Antibodies used can be found in 
Table 2-2.  
 
Cytokine protein array  
 Plasma cytokine protein content was measured using a Proteome Profiler: 
Mouse Cytokine Array Panel A (R&D Systems, Minneapolis, MN) to evaluate 
inflammatory mediators present in pooled plasma samples from the mice exposed to 
CCl4 and euthanized 48 hours later or in animals exposed to olive oil (control). In brief, 
pooled plasma samples (n = 6–8 individual mice per group) were applied to the 
provided membrane impregnated with capture antibodies. Streptavidin-HRP-conjugated 
secondary antibodies were then applied, and chemiluminescent technology was used to 
detect proteins captured by the array. All arrays were done on the same day with the 
same exposure time. ImageJ was used to semi-quantify pixel density of resultant 
cytokine-positive areas recorded using radiographic film. 
 
Hepatic leukocyte esterase (chloracetate esterase, CAE) localization and 
quantification 
 Chloracetate esterase (CAE) was detected in liver sections from all mice using a 
naphthol-AS-D CAE kit, according to the manufacturer’s instructions (Sigma-Aldrich).  
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Antibody Clone Secondary Company 
αsma 1A4 anti-rabbit AbCam Cambridge, MA 
Cyclin D1 92g2 anti-rabbit Cell Signaling Danvers, MA 
Cyp2e1 n/a  anti-rabbit 
AbCam 
Cambridge, MA 
F4/80 MCA497 CI:A3-1 Bio-rad Hercules, CA 
Gapdh 14C10 anti-rabbit Cell Signaling 
Hmmr (CD168) EPR4054 anti-rabbit AbCam 
Hsc70 6i2 anti-rat Santa Cruz Dallas, TX 
Ki67 ab66155 anti-rabbit (fluorescent) AbCam 
Mmp13 n/a anti-rabbit AbCam 
Pcna PC10 anti-mouse EMD-Millipore Billerica, MA 
biotinylated goat anti-
rat n/a n/a Vector 
donkey anti-rabbit 
IgG-Alexa Fluor 488 
conjugate 
n/a n/a Life Technologies Waltham, WA 
goat anti-mouse IgG-
HRP n/a n/a Santa Cruz 
goat anti-rabbit IgG-
HRP n/a n/a AbCam 
Goat anti-rat IgG2b-
HRP n/a n/a BioRad 
 
Table 2-2: Antibody table. 
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Briefly, formalin-fixed, paraffin-embedded liver tissues were cut into 5.0 µM thick 
sections, heated to 60oC for 20 minutes, deparaffinized in 3 changes of Safeclear (5 
minutes each) and then rehydrated in a series of graded ethanols. After staining, 
sections were dehydrated and mounted for analysis.  Quantification of CAE+ cells was 
performed by an individual blinded to sub-strain and time point. Due to the small 




 Liver embedded in OCT medium was cut to 5.0 µM sections and placed on 
SuperFrost + slides (Fisher, Waltham, MA) and stored at -80°C for less than one week 
before use. Slides were removed from -80°C and allowed to warm at room temperature 
for 2 minutes and then fixed in 10% formalin for 10 minutes. The formalin was removed 
and slides were then incubated in 0.1% Triton X-100 in PBS for 15 minutes, washed in 
PBS 3 x 2 minutes, then blocked in 10% donkey serum in PBS for 1 hour at room 
temperature. Ki67 primary (see Table 2-2) antibody was applied to slides at a 
concentration of 1:500 in 1% donkey serum overnight at 4°C. The following day, slides 
were washed 3 x 2 minutes, incubated with a Alexa Fluor 488 conjugated donkey anti-
rabbit secondary antibody at a dilution of 1:500 for one hour, and washed again in PBS 
3 x 2 minutes. Nuclei were counter stained with 4’,6-diamidino-2-phenylidole (DAPI, 
Vector Labs) and clear nail polish was used to seal a glass coverslip over the sections. 
Three to five non-overlapping images were taken of each section using an Olympus 
BX51 microscope with an Olympus BH2RFLT3 burner and Olympus DP71 camera at 
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200X using DP Controller software (Olympus, Waltham, MA). Ki67-positive cells were 
manually counted using images taken through the GFP filter and ImageJ. 
 
αSMA immunohistochemistry 
 Formalin-fixed, paraffin-embedded liver tissues were cut into 5.0 µm sections, 
deparaffinized using Citrisolv (Fisher Scientific) and rehydrated in a series of graded 
ethanol. Antigens were exposed using 10% Reveal Decloaker (BioCare Medical, 
Concord, CA), and microwaving slides for 2 minutes at 50% power followed by 7 
minutes at 10% power. Slides were allowed to cool for 1 hour then washed in TBS 2 x 
15 minutes and endogenous peroxidase activity was blocked using 3% H2O2 for 15 
minutes. Following a wash in TBS, endogenous avidin and biotin (Vector Laboratories, 
Burlingame, CA) were blocked. Mouse-on-mouse (MOM) (Vector Laboratories) IgG 
blocking diluent was applied to sections for 1 hour. Next, slides were washed in TBS 
and MOM blocking diluent was applied for 5 minutes. αSMA antibody (see Table 2) was 
diluted 1:100 and applied to sections for 30 minutes. Slides were washed in TBS and 
then biotin-conjugated anti-mouse IgG reagent (MOM kit) was applied to slides for 10 
minutes. Following a TBS wash, the signal was amplified using avidin biotin-HRP 
complex (Vectastain ABC, Vector Laboratories). 3,3’-diaminobenzidine was used to 
detect positive staining, and hematoxylin was used as a counterstain. Slides were 
immersed in a bluing reagent, dehydrated in a series of graded ethanol and Citrisolv, 
and sealed using glass coverslips and Cytoseal mounting medium (Thermo Fisher 
Scientific). Five non-overlapping 200X images were taken of each section using an 
Olympus BX51 microscope and Olympus DP71 camera operated by DP Controller 
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software (Olympus, Waltham, MA). ImageJ was used to quantify the area of positive 
staining above a threshold that remained constant for all images. 
 
F4/80 immunofluorescence 
 Formalin-fixed, paraffin-embedded sections were cut to 5.0 µM sections. Paraffin 
was removed by SafeClear (Protocol/Thermo Fisher Scientific) and tissues were 
rehydrated by putting slides through a series of graded ethanols (100% 2 x 3 minutes, 
95% 1 x 3 minutes, 85% 1 x 3 minutes, 70% 1 x 3 minutes, 50% 1 x 3 minutes, and RO 
water). Slides were immersed in 1 X Reveal Decloaker and microwaved for 2 minutes at 
50% power followed by 7 minutes at 10% power then allowed to cool for 1 hour at room 
temperature. Slides were then washed in TBS-T, endogenous peroxidase was blocked 
using 3% H2O2 for 15 minutes, followed by another wash in TBS. Endogenous avidin 
and biotin were blocked using avidin/biotin blocking kit (Vector Labs). Slides were rinsed 
in TBS after both avidin and biotin blocking steps and 10% goat serum, 0.4% TritonX 
100 in TBS was used to block sections. F4/80 primary antibody (see Table 2-2) was 
diluted in blocking solution at a concentration of 1:100 and applied to sections overnight 
at 4°C. The following day, primary antibody was removed and slides were washed in 
TBS-T and incubated in biotinylated anti-rat secondary antibody diluted in block (10% 
goat serum, 0.4% TritonX 100 in TBS) 1:100 for 2 hours at room temperature. Following 
a wash in TBS-T slides were incubated in avidin/biotin complex (Vector Labs) to amplify 
signal, washed again in TBS-T, and a second amplification step was completed using 
tyramide signal amplification (TSA) kit (Perkin Elmer, Waltham, MA) diluted 1:400. 
Nuclei were stained with DAPI following a wash in TBS-T. Slides were cover slipped 
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and then sealed with clear nail polish. Three to five non-overlapping 200X images were 
taken of each section using an Olympus BX51 microscope with an Olympus BH2RFLT3 
burner and Olympus DP71 camera operated by DP Controller software (Olympus, 
Waltham, MA). ImageJ was used to quantify the area of positive staining above a 
threshold that remained constant for all images. 
 
Hyaluronan binding protein (HABP) staining for hyaluronan 
 Formalin-fixed, paraffin-embedded liver tissue was cut into 5.0 µM sections and 
rehydrated in Safe Clear (2 x 3 minutes) and a series of graded ethanols and PBS 
(100% 1 x 1 minute, 100% 1 x 2 minutes, 95% 1 x 1 minute, 95% 1 x 2 minutes, running 
water 1 minute, PBS 1 x 10 minutes). Endogenous avidin and biotin was blocked 
(avidin/biotin Blocking kit, Vector). Sections were incubated with normal goat serum at a 
concentration of 150 µL/10mL PBS for 20 minutes followed by a 1 hour incubation with 
1mg/mL hyaluronidase (Sigma) in 0.9% normal saline for negative controls or 0.9% 
normal saline. After a rinse in PBS, biotinylated-HABP (Calbiochem) at 1:100 in normal 
goat serum at a concentration of 150 µL/10mLwas applied to sections for 1 hour at 
room temperature. After washing with PBS, the signal was amplified using the 
Avidin/Biotin complex applied for 30 minutes. A second amplification step using TSA 
diluted 1:400 was followed by nuclear staining using DAPI, cover slipping, and sealing 
the sections with clear nail polish. Three to five non-overlapping 200X images were 
taken of each section using an Olympus BX51 microscope with an Olympus BH2RFLT3 
burner and Olympus DP71 camera operated by DP Controller software (Olympus, 
Waltham, MA). Each image was taken using the same exposure and ImageJ was used 
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to quantify the area and insensity of positive staining above a threshold that remained 
constant for all images.  
 
Hyaluronan plasma concentration 
 Because HA is a carbohydrate a traditional ELISA using antibody technology 
cannot be used. Therefore an “ELISA-like” assay was used to quantify HA, which 
utilized HA binding proteins (HABP) for both capture and detection reagents (R&D 
systems). The wells of a 96-well plate were coated with capture HABP and mouse 
plasma was diluted 1:40-1:100 with manufacturer-supplied calibrator diluent and applied 
to the wells. The plate was placed on an orbital microplate shaker (0.12” orbit) at 500 
rpm for 2 hours at room temperature, washed with supplied wash buffer, after which 
recombinant aggrecan-HRP conjugate was applied to the wells and the plate was again 
placed on the orbital microplate shaker at 500 rpm for 2 hours at room temperature. 
After a second wash, substrate was applied to the wells for 30 minutes and the reaction 
was stopped with the supplied stop solution. The plate was read at 450nm and 540nm 
to correct for wavelength. myassays.com was used to complete a four parametric 
analysis based on a standard curve prepared to determine total HA in each well.  
 
Hyaluronan size analysis 
 HMW-HA and LMW-HA were separated as described previously (Decleves et al., 
2012) with modifications.  Fifty µL of pooled plasma was digested 1:1 with 1mg/mL 
Proteinase K (Invitrogen, Grand Island, NY) with 0.01% SDS for 4 hours at 60°.  Saline 
was added to bring volume to 1mL and Centrisart® 1 Centrifugal Ultrafiltration units 
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(Sigma) with a molecular weight cut off of 100kDa or 300kDa were used to separate 
HMW-HA from LMW-HA. Quantikine HA ELISA-like assay was used as described 
above to quantify amount of HA in each fraction per manufacturer’s instructions. Similar 
to above, myassays.com was used to complete a four parametric analysis based on a 
standard curve prepared to determine total HA in each fraction.  
 
Sirius red staining 
 Formalin-fixed, paraffin-embedded liver tissue sections cut to 5.0 µM were 
heated at 60°C for 20 minutes. SafeClear II (Protocol, Pittsburgh, PA) was used to 
deparaffinize sections and a series of graded ethanols (100% 2 x 1 minute, 70% 1 x 1 
minute, 30% 1 x 1 minute, RO water 2 x 1 minute) were used to rehydrate the tissue. 
Slides were then immersed in 0.1% Sirius red solution (Direct Red 80, Sigma) for 40 
minutes to 1 hour at room temperature. Acidified water (0.5% acetic acid in water) was 
used to wash slides 3 times for 5 minutes each, then slides were dehydrated in a 100% 
ethanol 3 x 1 minute and 2 x 5 minutes SafeClear II solutions, mounted with Permount 
and allowed to dry. Three to five non-overlapping 200X images were taken of each 
section using an Olympus BX51 microscope and Olympus DP71 camera operated by 
DP Controller software. ImageJ was used to quantify area of positive staining above a 
threshold that was kept constant for all images.  
 
Hydroxyproline assay 
 Ten mg of snap frozen tissue was hydrolyzed using 100µL 12.1N HCl and 100µL 
water at 120°C for 3 hours, vortexing every 30 minutes. Samples were centrifuged at 
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10,000 x g for 10 minutes to remove particulate matter. A standard curve was made 
using 1mg/mL hydroxyproline and 10µL of standard and sample were added to a 96-
well plate. One hundred µL Chloramine T solution (45mM chloramine t, 10% 1-propanol 
in acetate-citrate buffer: 1.46M sodium acetate trihydrate, 239.43mM citric acid, 1.21% 
acetic acid, 850.06mM sodium hydroxide pH 6.5) was added to each well and plate was 
incubated at room temperature for 25 minutes. One hundred µL of Ehrlich’s solution 
(1.22M 4-(dimethylamino)benzaldehyde, 27% perchloric acid, 82% 1-propanol) was 
added to each well and the plate was incubated at 60°C for 35 minutes in a dry heat 
oven. Following incubation, absorbance of each well at 550nm was determined and 
hydroxyproline concentration was calculated from the standard curve. Collagen 
concentration was calculated by dividing hydroxyproline concentration by 12.5% (Reddy 
and Enwemeka, 1996). 
 
In situ zymography  
 Matrix metabolism was determined as described previously with modifications 
(Lindsey et al., 2001). Frozen tissue sections cut 7.0 µm thick were taken directly from   
-80°C and developing buffer (Tris, pH 7.4- final concentration 100mM, NaCl- 100mM, 
CaCl2- 5mM, Brij-35- 0.05%, PMSF- 0.25mM, and Oregon green, dye quenched (DQ) 
gelatin (Molecular probes)- 0.1mg/mL) was applied. Inhibitor for MMP13 (444283, 
Calbiochem, Billerica, MA) was added to one section in a subset of slides. The slides 
were incubated in a humid chamber at 37°C for 16-18 hours, washed in MQ-water, and 
DAPI mounting medium was used as a nuclear stain. Clear nail polish was used to seal 
tissue sections. Three to five non-overlapping 200X images were taken of each section 
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using an Olympus BX51 microscope with an Olympus BH2RFLT3 burner and Olympus 
DP71 camera operated by DP Controller software. ImageJ was used to quantify the 
area of positive staining above a threshold that remained constant for all images. 
 
Statistical analysis 
 All data are represented as mean ± standard error of mean. Significance was 
calculated by two-way analysis of variance (SAS Institute, Inc, Cary, NC or GraphPad 
Prism, La Jolla, CA). Post hoc analysis was done using Tukey’s, Dunnetts, or multiple t-
tests depending on comparisons being performed. The comparisons having p-value of 
less than 0.05 were considered statistically significant. For the cases having only two 
groups, Student’s t-test was used to determine significance. A Pearson’s correlation 
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Abstract 
Hyaluronan (HA) is a ubiquitous extracellular matrix (ECM) glycosaminoglycan 
synthesized by three different enzymes, hyaluronan synthase (HAS) 1, 2, and 3. HA 
synthesis mediated by HAS3 promotes inflammation and is pathogenic in animal 
models of human lung and intestinal disease.  Although plasma HA is a commonly used 
biomarker for liver disease, if and how HA contributes to disease pathogenesis remains 
unclear. Wound healing follows acute liver injury, and includes periods of inflammation, 
regeneration, and matrix remodeling. Here, we tested the hypothesis that HA 
synthesized by HAS3 enhances inflammation and wound healing. To test this 
hypothesis, we exposed wild-type or Has3-/- mice to carbon tetrachloride (CCl4) once to 
induce acute liver injury. Acute CCl4 induced expression of hepatic Has enzymes, 
increased plasma HA, and increased hepatic HA accumulation in both genotypes. 
Has3-/- mice had reduced plasma HA compared to wild-type but increased hepatic HA. 
Has3-/- mice also had a perturbation of LMW-HA/HMW-HA ratio compared to wild-type 
mice following liver injury. This was associated with an increase in injury and wound 
healing, including inflammation, regeneration, and matrix remodeling (specifically matrix 
degradation). Acute CCl4 exposure also induced the expression of the HA receptors 
CD44, TLR2, TLR4, and HMMR. Has3-/- mice had increased HMMR both at the mRNA 
and protein level compared to wild-type mice following acute CCl4 exposure. These data 
suggest that HA, and HA receptors, should be investigated further to determine their 
specific roles in liver injury and repair.  
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Introduction 
 Hyaluronan (HA) is a ubiquitous, non-sulfated glycosaminoglycan that is part of 
the extracellular matrix (ECM) (Jiang et al., 2011; Manasa et al., 2012). HA is 
synthesized by many cell types including fibroblasts and vascular endothelial cells 
(Stern et al., 2006; Jiang et al., 2007). HA is synthesized by three HA synthases (HAS1, 
2, or 3) (Itano et al., 1999; Jiang et al., 2011). These enzymes differ in their expression 
levels depending on cell type and tissue (Spicer and McDonald, 1998; Itano et al., 
1999). The three HAS enzymes also differ in their biosynthetic capacity and the size of 
HA produced (Itano et al., 1999; Rilla et al., 2013). For example, HAS1 and HAS2 make 
high molecular weight (HMW-HA) and HAS3 slightly smaller HA, although all 
endogenously produced HA is considered HMW-HA (described in more detail in 
Chapter 1) (Spicer and McDonald, 1998; Itano et al., 1999). HAS1 is least enzymatically 
active in euglycemic conditions while HAS3 is enzymatically active even in low glucose 
conditions (Itano et al., 1999; Rilla et al., 2013). 
 When tissues are injured, HA is synthesized and degraded and participates in 
the wound healing response (Fraser et al., 1997; Jiang et al., 2011). The size of HA 
dictates its signaling properties with low molecular weight HA (LMW-HA, ≤300kDa) 
promoting inflammation and HMW-HA (≥500kDa) promoting homeostasis (Stern et al., 
2006; Jiang et al., 2007). HMW-HA is a major component of healthy joints, the vitreous 
humor of the eye, and skin, and when synthesized in these injured tissues, dampens 
inflammation (Meyer and Palmer, 1934; Guidolin and Franceschi, 2014; Paliwal et al., 
2014). HA is degraded by hyaluronidases and reactive oxygen species under normal 
circumstances and when tissues are injured, into a polydisperse population containing 
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LMW-HA fragments (≤300 kDa), which exacerbate inflammation (McKee et al., 1996; 
Moseley et al., 1997; Csoka et al., 2001). Consistently, persistence of LMW-HA in 
chronically wounded tissue contributes to disease pathogenesis in animal models of 
idiopathic pulmonary fibrosis (Jiang et al., 2005). 
 The use of genetically deficient mice has led to great advances in understanding 
the role of HA in various diseases. Has2-/- mice are embryonic lethal due to abnormal 
cardiac development but conditional knockouts as well as whole body Has1-/- and 
Has3-/- mice have been utilized in a number of studies (Camenisch et al., 2000; Bai et 
al., 2005; Matsumoto et al., 2009). Has3-/- mice are protected from ventilator induced 
liver injury as well as dextran sodium sulfate (DSS) induced colitis (Bai et al., 2005; 
Kessler et al., 2015). It is suggested that this is due to the relatively smaller HA 
produced by HAS3 being more easily degraded into LMW-HA fragments (Bai et al., 
2005). 
 Elevated plasma HA is associated with liver disease (Engstrom-Laurent et al., 
1985; Laurent and Fraser, 1992). In fact, the more advanced the liver disease the 
higher plasma HA concentrations (Lee et al., 2010; Lee et al., 2013). This is likely due 
to a combination of increased HA synthesis by hepatic stellate cells (HSC) and other 
cells, as well as a reduced capacity for HA uptake by dysfunctional liver sinusoidal 
endothelial cells (LSEC) found in diseased liver (Gressner and Bachem, 1990; Harris et 
al., 2007; van den Broek et al., 2013). Despite this being known for over 30 years, little 
additional work has explored if a causative role exists for HA in liver disease. HA does 
play a role in skin wound healing, which is analogous to hepatic wound healing in that it 
follows the same steps: injury, inflammation, regeneration, and matrix remodeling 
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(Pellicoro et al., 2014; Balaji et al., 2015). More specifically, acute hepatic wound 
healing which does not result in scar formation is analogous to fetal wound healing 
where elevated HA levels are associated with the scarless wound healing that occurs in 
fetal tissue (Longaker et al., 1991; Leung et al., 2012). This led us to explore a role for 
HA in liver wound healing. 
  Because HAS3 is the most enzymatically active HAS enzyme, we chose to 
focus on Has3-/- mice. Additionally, previous literature supports a detrimental role for 
HA produced by HAS3 in models of lung and intestinal injury. Specifically, in ventilator 
induced lung injury, Has3-/- mice are protected from injury and inflammation compared 
to wild-type mice, and in a DSS-induced mouse model for colitis, Has3-/- mice are again 
protected from injury compared to wild-type mice (Bai et al., 2005; Kessler et al., 2015). 
In this study we tested the hypothesis that HAS3, or HA produced by HAS3, contributes 
to liver injury and inflammation, similar to what has been shown in the lung and 
intestine. To test this hypothesis, we utilized the well-characterized carbon tetrachloride 
(CCl4)-induced liver injury model in wild-type mice and mice deficient in HAS3 
(Constandinou et al., 2005). We evaluated parameters of injury, as well as the 
parameters for the subsequent wound healing response, including inflammation, 
regeneration, and matrix remodeling. Due to a lack of HA synthesized by HAS3, we 
predicted Has3-/- mice would exhibit reduced injury, inflammation, and wound healing 
compared to wild-type mice after acute CCl4 exposure, similar to the previously 





Hepatic Has gene transcript accumulation and plasma HA levels in wild-type and 
Has3-/- mice 
 Real time PCR was used to determine the relative amounts of Has1, 2, and 3 in 
livers from wild-type and Has3-/- mice, at baseline.  The accumulation of Has1 
transcripts was not different between genotypes (Figure 3-1A).  Has3 transcripts were 
most abundant in livers from wild-type mice and were ~5-fold more than Has1 
transcripts.  Has2 transcripts were least abundant in both genotypes, between 1 – 5 % 
of total Has1 levels.  However, Has2 was 40% greater in livers from Has3-/- mice 
relative to wild-type mice suggesting this enzyme may compensate, at least in part, for 
HAS3 deficiency at baseline.  
 Real time PCR was again used to evaluate hepatic Has gene transcript levels 
after acute CCl4 exposure.  In wild-type mice, Has1 levels were increased 20-fold above 
baseline 24 hours after CCl4 exposure and declined thereafter (Figure 3-1B).  In Has3-/- 
mice, hepatic Has1 transcripts also increased 24 hours after CCl4 exposure, but this 
level was not different from that found in wild-type mice (Figure 3-1B). Has1 transcript 
levels were higher in Has3-/- mice compared to wild-type mice 72 hours after CCl4 
exposure. Has2 transcripts peaked in wild-type mice 48 hours after CCl4 exposure, but 
only 1.8-fold above baseline, which was not significantly different from basal levels 
(Figure 3-1C). Has2 transcripts in Has3-/- mice also peaked 48 hours after CCl4 
exposure, and this difference was significant at 4-fold over baseline, and again 72 hours 
after CCl4 Has3-/- mice had increased Has2 transcript levels compared to wild-type 
mice  (Figure 3-1C). Finally, Has3 transcripts were induced approximately 20-fold over 
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baseline 24 and 48 hours after CCl4 exposure in wild-type mice and returned to baseline 
72 hours after CCl4 (Figure 3-1D). Taken together, acute CCl4 exposure induced all 3 
Has transcripts in liver; Has1 and Has3 were robustly induced. It is possible that the 
greater induction of Has1 and Has2 transcripts in Has3-/- mice was an attempt to 
compensate for the lack of the HAS3 enzyme.  
 Using an ELISA-like assay, we measured plasma HA levels in wild-type and 
Has3-/- mice.  Has3-/- mice had reduced plasma HA levels when compared to wild-type 
mice at baseline, 24 and 48 hours after CCl4 exposure (Figure 3-1E).  HA levels were 
similar between genotypes at 72 hours but greater in Has3-/- mice 96 hours after CCl4 
exposure (Figure 3-1E).  These data suggested that other HAS enzymes did not 
completely compensate for reduced HA biosynthetic capacity in Has3-/- mice.  Next, 
using specific molecular weight cut-off columns to fractionate plasma HA into three 
groups (<100 kDa, 100 – 300 kDa, and >300 kDa), we found that wild-type mice had 
more HA in the 100-300 kDa molecular weight range, compared to Has3-/- mice, while 
the absolute amounts of HA in the other fractions did not exhibit such large differences 
between genotypes (Figure 3-1F). However, relative to wild-type mice, Has3-/- mice 
exhibited an increased percentage of the <100 kDa HA fraction, decreased percentage 
of the 100 – 300 kDa fraction and increased percentage of the >300 kDa HA fraction at 
almost every time point after CCl4 exposure (Table 3-1). These data suggested that, in 
addition to a reduction in total HA level, HA molecular mass distribution was also 
perturbed in Has3-/- mice, favoring lower molecular weight populations, relative to wild-
type mice.   
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 We also evaluated HA content in the liver following acute CCl4 exposure using 
HA binding protein (HABP). Using this method, we detected HA in the centrilobular 
regions of livers from wild-type and Has3-/- mice after CCl4 exposure (Figure 3-1G). 
This is the same area where necrotic cell death occurs. There was no HA present at 
baseline or 24 hours following CCl4 (not shown), however HA was detected in Has3-/- 
mice 48 hours after CCl4 exposure; very little HA was observed in livers from wild-type 
mice at this time point (Figure 3-1G and H). Surprisingly, despite Has3-/- mice lacking 
one enzyme responsible for HA synthesis, there was more HA present in the Has3-/- 
mice compared to wild-type mice 48 and 72 hours after CCl4 exposure. Together, these 
data demonstrate that Has3 has the highest expression in wild-type mouse liver at 
baseline and acute liver injury increases expression of all Has enzymes in both wild-
type and Has3-/- mice. Increased Has expression in wild-type mice results in increased 
HA in the plasma and in the centrilobular region of the liver, however as the liver heals, 
the plasma HA and hepatic HA return to baseline. These data also demonstrate that 
Has3-/- mice compensate for the lack of HAS3 and have increased hepatic HA 
accumulation compared to wild-type mice. However, content and the size distribution of 
plasma HA is perturbed and could lead to differences in hepatic injury and healing 
following acute CCl4 exposure.  
  
Liver injury and steatosis after acute CCl4 exposure 
CCl4 induced liver injury in both strains of mice, but this injury was greater in 
livers from Has3-/- mice. Specifically, peak plasma ALT activity occurred in both wild-
type and Has3-/- mice 48 hours after CCl4 exposure but ALT activity was 41% greater in  
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Figure 3-1: Hepatic Has enzymes, plasma HA levels, and hepatic HA accumulation 
in wild-type and Has3-/- mice. 
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A. Real time PCR was used to measure basal levels of hepatic Has enzyme transcript 
accumulation in wild-type and Has3-/- mice. B – D.  Mice were exposed to CCl4 and 
euthanized 24, 48, 72 or 96 hours later. Control animals received an olive oil (Oil) 
injection. Real time PCR was used to measure hepatic Has1 (B), Has2 (C) and Has3 
(D) in livers from wild-type and HAS3-deficient mice. Here and throughout this chapter, 
data were calculated using the 2-ΔΔCt method after normalization to 18S. Data in A-D are 
expressed as fold change over wild-type hepatic Has1 content. An ELISA-like assay 
(see Material and Methods for details on this antibody-independent assay) was used to 
determine HA concentration in pooled plasma from wild-type and Has3-/- mice either 
before (E) or after (F) HA fractionation using molecular weight cut-off columns. In E and 
F, open symbols indicate wild-type mice while closed symbols indicated Has3-/- mice. 
Circles indicate HA pools less than 100 kDa, squares indicate HA pools between 100 – 
300 kDa and triangles indicate HA pools greater than 300 kDa. Statistical analysis was 
not performed on these pooled samples.  See Table 3-1 for additional details. G. 
Representative images and H. quantification of HABP staining used to localize hepatic 
HA accumulation in wild-type and Has3-/- mice 48, 72, and 96 hours after CCl4 
exposure. * denotes central veins and + signs denotes the portal triad in images.  All 
data is presented as mean + SEM and throughout this chapter black bars represent 
wild-type mice and grey bars represent Has3-/- mice. * represents p<0.05 when 
comparing CCl4 exposure to baseline within a genotype, + represents p<0.05 when 
comparing wild-type and Has3-/- mice within a time point n/a = not applicable.  N = 6 – 8 
























Oil 10 3 247 22 64 20 322 
24h 78 6 917 76 215 18 1210 
48h 109 7 1041 68 376 25 1526 
72h 38 7 330 58 199 35 567 
96h 7 3 135 65 66 32 208 
Has3-/- mice 
Oil 6 5 82 72 27 23 115 
24h 34 3 428 75 112 20 574 
48h 48 9 285 54 199 37 532 
72h 26 7 271 67 106 26 403 
96h 26 6 223 50 196 44 445 
 
Table 3-1: Total and fractionated plasma HA content in wild-type and Has3-/- mice after 
acute CCl4 exposure. 
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Has3-/- mice relative to control mice 48 hours after CCl4 exposure (Figure 3-2A). By 72 
hours post CCl4 exposure, ALT activity had decreased in both wild-type and Has3-/- 
mice, but Has3-/- mice still had higher ALT levels compared to wild-type mice. 
Consistent with increased plasma ALT values; hepatic architecture was more severely 
disrupted in Has3-/- mice 48 hours after CCl4 exposure (Figure 3-2D). Specifically, 
histopathological assessment revealed more necrosis in livers from Has3-/- mice 
compared to wild-type mice at peak injury, 48 hours post CCl4 exposure (Figure 3-2B 
and D).  
 Hepatic triglyceride accumulation increased 24 hours after CCl4 in both 
genotypes, and was 31% greater in HAS3-deficient mice compared to controls (Figure 
3-2B). Liver histology paralleled this biochemical measure of the liver’s response to 
CCl4 in wild-type and Has3-/- mice (Figure 3-2D). Increased macrovesicular steatosis 
was more abundant in livers from Has3-/- mice compared to wild-type mice 24 hours 
after CCl4 (Figure 3-2D). Together, these data demonstrate Has3-/- mice have 
increased injury and steatosis compared to wild-type mice following acute CCl4 
exposure.  
CCl4 must be bioactivated by cytochrome P450 2E1 (CYP2E1) to reactive 
metabolites to induce hepatotoxicity (Wong et al., 1998; Weber et al., 2003).  To ensure 
that the increased liver injury in Has3-/- mice was not due to differences in CCl4 
bioactivation, we measured CYP2E1 protein levels (Figure 3-3A and B). There was no 
difference in baseline CYP2E1 protein between genotypes. We also measured CYP2E1 
activity by measuring the hydroxylation of p-nitrophenol to p-nitrocatechol. Again, similar 




Figure 3-2: Liver injury and steatosis in wild-type and Has3-/- mice. 
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Mice were exposed to CCl4 and euthanized 24, 48, 72 or 96 hours later.  Control 
animals received an olive oil (oil) injection. A. Plasma ALT activity was determined using 
an enzymatic assay. B. Histopathologic assessment of the percent necrosis. C.  Total 
hepatic triglycerides were measured using a biochemical assay. D. Representative H&E 
histology in wild-type and Has3-/- mice (200X).  * denotes central veins and + signs 
denotes the portal triads in H&E images. The necrotic areas are outlined with black 
dashed lines. * represents p<0.05 when comparing CCl4 exposure to baseline within a 
genotype, + represents p<0.05 when comparing wild-type and Has3-/- mice within a 






Figure 3-3: CYP2E1 content and activity in wild-type and Has3-/- mice. 
 
A. Representative CYP2E1 immunoblot using samples from olive oil-treated wild-type 
and Has3-/- mice. GAPDH was used as a loading control. B. Semi-quantification of 
hepatic CYP2E1 content after normalization to GAPDH. Data are expressed as fold 
change over wild-type mice C.  Hepatic CYP2E1 activity assay using microsomes 
isolated from wild-type and Has3-/- mice at baseline (before CCl4 exposure). The data 
are expressed as fold-change over wild-type. N = 6 mice per experimental group. Pos 
cont: microsomes prepared from a single mouse fed an ethanol-containing diet for 5 
weeks (ethanol increases CYP2E1). Neg cont: microsomes prepared from a single 
mouse exposed to CCl4 and euthanized 24h later (CCl4 consumptively depletes 
CYP2E1).  
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suggesting that a difference in CCl4 bioactivation was not contributing to the increase in 
liver injury observed in Has3-/- mice. Surprisingly, and in contrast to the pathogenic role 
HAS3 plays in injury in other animal models of human disease, our data suggest that 
HA produced by HAS3 plays a protective role in the liver after acute CCl4 exposure. 
 
Hepatic inflammatory environment after acute CCl4 exposure in wild-type and 
Has3-/- mice 
 Inflammation follows injury and can both exacerbate injury and contribute to 
tissue repair (Duffield et al., 2005; You et al., 2013; Mohanraj et al., 2014). Thus, we 
next investigated the impact of HAS3-deficiency on hepatic inflammation. While pro-
inflammatory markers increased in livers from both strains of mice after CCl4 exposure, 
these markers tended to be greater in Has3-/- mice compared to wild-type mice. 
Specifically, Ccl2 transcripts, a chemokine vital to macrophage migration (Lu et al., 
1998; Baeck et al., 2012), are increased in Has3-/- mice compared to wild-type mice 48 
hours after CCl4 exposure (Figure 3-4A). Similarly, hepatic transcript levels of Cxcl10, 
another chemokine important for the migration of inflammatory cells including 
macrophages (Tomita et al., 2016), showed the same trend as Ccl2. Cxcl10 is induced 
in both wild-type and Has3-/- mice following CCl4 exposure and was greater in Has3-/- 
mice compared to wild-type mice 48 hours post CCl4 exposure (Figure 3-4B). Hepatic 
transcript levels of Cxcl1, a chemokine that is more important in neutrophil migration 
following injury (Dominguez et al., 2009; Chang et al., 2015a), increased in both wild-
type and Has3-/- mice, but the increase was not different between genotypes at any 
time point (Figure 4C). Consistent with the gene expression analysis, using a cytokine 
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protein array to evaluate plasma inflammatory mediator levels 48 hours after CCl4, we 
found plasma CCL2, CXCL10, and CXCL1 chemokine proteins were also increased in 
Has3-/- mice compared to wild-type mice at the time of peak injury (Figure 3-4D – F).  
Evaluation of the mouse macrophage marker Emr1 revealed a peak of hepatic 
transcripts 72 hours post CCl4 exposure (Figure 3-4G). Has3-/- mice had increased 
Emr1 levels compared to wild-type mice 48 hours post CCl4 exposure. High Cd11b 
expression is associated with pro-inflammatory, infiltrating macrophages after acute 
liver injury (Mohanraj et al., 2014), however there was no difference in the accumulation 
of Cd11b transcripts at any time point between wild-type and Has3-/- mice (Figure 3-
4H). Ccr2, the receptor for CCL2, increased in both genotypes following acute CCl4 
exposure, but was not different between wild-type and Has3-/- mice at any time point 
(Figure 3-4I). This suggests that although the inflammatory microenvironment is 
increased, there may not be an increase in hepatic macrophage content.  
 
Hepatic regeneration following acute CCl4 exposure in wild-type and Has3-/- mice. 
 The wound healing process continues following injury and inflammation and 
includes regeneration. Acute CCl4 exposure causes massive centrilobular necrosis 
leading to loss of liver mass and function so liver regeneration is required to restore the 
functional capacity of the liver (Michalopoulos and DeFrances, 1997). We evaluated the 
hepatic expression of proteins vital to the cell cycle. Ccnd1 (Cyclin D1) is important 
throughout the cell cycle and Ccnd1 transcripts were increased in both genotypes 
following acute CCl4 exposure (Figure 3-1A), peaking at 48 hours post CCl4 exposure. 











Mice were exposed to CCl4 and euthanized 24, 48, 72, and 96 hours later. Control 
animals received an olive oil (oil) injection. Real time PCR was used to measure relative 
levels of A. Ccl2, B. Cxcl10, and C. Cxcl1 transcripts in both genotypes. Data are 
expressed as fold change over each genotypes’ own oil. Plasma isolated from blood 
collected 48 hours after CCl4 exposure and pooled to determine the relative amounts of 
CCL2 (D), CXCL1 (E), CXCL10 (F) peptides using a protein array.  For this assay, 
plasma samples were pooled per experimental group (n = 6 – 8 mice). The bar graphs 
in D – F were created after semi-quantification of chemokine spot density from the array 
shown directly below each graph. Real time PCR was used to measure hepatic 
transcript levels of G. Emr1, H. Cd11b, and I. Ccr2 in wild-type and Has3-/- mice after 
acute CCl4 exposure. Data are expressed as fold change over each genotypes’ own oil. 
* represents p<0.05 when comparing CCl4 exposure to baseline within a genotype, + 
represents p<0.05 when comparing wild-type and Has3-/- mice within a time point N = 4 
– 7 mice per experimental group. 
 
83	
and 72 hours after CCl4 exposure. Cyclin D1 protein levels increased in both genotypes, 
and similar to Ccnd1 expression pattern, the levels were higher in Has3-/- mice, 
compared to baseline, 48 and 72 hours after CCl4 exposure (Figure 3-5B and C). 
Hepatic accumulation of proliferating cell nuclear antigen (Pcna) transcript, another 
component of cell cycle regulation, showed a delay in regeneration in Has3-/- mice with 
the levels of Pcna being lower in Has3-/- mice compared to wild-type mice 24 and 48 
hours after CCl4 exposure (Figure 3-5D). This trend is opposite that seen in Ccnd1 
mRNA expression. However, PCNA protein follows a similar trend as Cyclin D1 protein. 
PCNA was higher in Has3-/- mice compared to wild-type mice at both 48 and 72 hours 
after CCl4 exposure (Figure 3-5E and F). Has3-/- mice also had increased Ki67 positive 
cells at 48, 72, and 96 hours post CCl4 exposure compared to wild-type mice (Figure 3-
6A and B). Together, these data suggest that following increased injury and increased 
pro-inflammatory microenvironment, hepatic regeneration is increased in Has3-/- mice 
compared to wild-type mice. 
 
Matrix remodeling following acute CCl4 exposure in wild-type and Has3-/- mice. 
Matrix remodeling consists of two stages: matrix synthesis and matrix 
degradation. Acute CCl4 exposure induces activation of HSC, cells integral to hepatic 
wound healing. HSC are the main cell type in the liver that produce ECM components, 
including HA, after acute liver injury (Friedman, 2008a; Perepelyuk et al., 2013).  Many 
factors contribute to HSC activation including proinflammatory cytokines, oxidative 
stress, and phagocytosis of tissue debris (Nieto et al., 2002; Imamura et al., 2005; Zhan 
et al., 2006; Friedman, 2008a; He et al., 2015). Because liver injury and inflammation  
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Figure 3-5: Hepatic regeneration following acute CCl4 exposure. 
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Mice were exposed to CCl4 and euthanized 24, 48, 72, and 96 hours later. Control 
animals received an olive oil (oil) injection. A. Hepatic Ccnd1 transcript levels were 
measured using real-time PCR. B. Quantification and C. representative Cyclin D1 
western blot. HSC70 was used as a loading control. D. Real-time PCR was used to 
evaluate hepatic Pcna transcript levels. E. Quantification and F. representative PCNA 
Western blot. HSC70 was used as a loading control. All data are expressed as fold 
change over each genotype’s own baseline. * represents p<0.05 when comparing CCl4 
exposure to baseline within a genotype, + represents p<0.05 when comparing wild-type 







Figure 3-6: Ki67 positive hepatocytes after acute CCl4 exposure. 
 
Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. A. Representative 
images of Ki67-positive, regenerating hepatocytes. * denotes central veins and + signs 
denotes the portal triads in images. B. Quantification of the number of Ki67-positive 
hepatocytes per 200X image, 3-5 images counted per sample. + represents p<0.05 
comparing wild-type and Has3-/- mice within a time point. N = 4 – 7 mice per 
experimental group. 
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 were increased in Has3-/- mice after acute CCl4 exposure and we observed increased 
hepatic HA content in Has3-/- mice compared to wild-type mice, we predicted that HSC 
activation would also be increased. After acute CCl4 exposure, markers associated with 
HSC activation were increased in both mouse strains.  Several of these markers were 
greater in livers from Has3-/- mice. Specifically, using real-time PCR, we found that 
hepatic pro-fibrotic growth factor transcript accumulation, transforming growth factor 
(Tgf) b1, and connective tissue growth factor (Ctgf), were increased in both wild-type 
and Has3-/- mice following acute CCl4. Both transcripts were increased in livers from 
Has3-/- mice compared to wild-type mice at 48 hours after CCl4 exposure (Figure 3-7A 
and B). Consistent with a role for these mediators in HSC activation, hepatic Acta2 (α 
smooth muscle actin, αSMA) transcript, a marker for HSC activation, is also increased 
in Has3-/- mice relative to wild-type mice 48 and 72 hours post-CCl4 exposure (Figure 
3-7C). Despite increased transcript accumulation, the protein level of αSMA was not 
different between genotypes at any time point after CCl4 exposure (Figure 3-7D and E). 
Activated HSC make type I collagen (Col1a1, Col1a2), mRNAs for which increased in 
both wild-type and Has3-/- mice following CCl4 exposure (Figure 3-7F and G). Col1a1 
transcript accumulation was greater 48 and 72 hours after CCl4 exposure in Has3-/- 
mice relative to wild-type mice at the same time point. Similarly, Col1a2 transcript levels 
were higher in Has3-/- mice compared to wild-type mice 72 hours after CCl4 exposure. 
Serpinh1 transcripts (the gene for heat shock protein (HSP) 47-a collagen-specific 
chaperone) increased following acute CCl4 exposure in both wild-type and Has3-/- mice 
and was increased in Has3-/- mice relative to wild-type mice at 48 and 72 hours after 




Figure 3-7: Hepatic stellate cell activation markers in wild-type and Has3-/- mice 
after acute CCl4 exposure. 
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Mice were exposed to CCl4 and euthanized 24, 48, 72, or 96 hours later. Control 
animals received an olive oil (oil) injection. Hepatic A. Tgfb1, B. Ctgf, C. Acta2, were 
measured using real time PCR and are expressed as fold change over each strain’s oil 
control. D. Quantification and E. representative αSMA western blot. GAPDH was used 
as a loading control. Hepatic F. Col1a1, G. Col1a2 and H. Serpinh1 were measured 
using real-time PCR. The data are expressed as fold change over each strain’s oil 
control. I. Quantification and J. representative HSP47 western blot. GAPDH was used 
as a loading control. * represents p<0.05 when comparing CCl4 exposure to baseline 
within a genotype, + represents p<0.05 when comparing wild-type and Has3-/- mice 
within a time point. N = 4 – 7 mice per experimental group. 
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levels were not different between the genotypes (Figure 3-7I andJ). Collectively, these 
data demonstrate that increased injury and inflammation in Has3-/- mice is associated 
with more robust expression of genes involved in the hepatic wound healing response 
after acute CCl4 but not an increase in the proteins associated with HSC activation. 
Matrix remodeling includes not only matrix synthesis by activated HSC but also 
matrix degradation, which is primarily accomplished by recruited macrophages (Duffield 
et al., 2005; Fallowfield et al., 2007b). There are several matrix metalloproteinases 
(MMPs) synthesized following hepatic injury. Mmp2 and Mmp9 are two gelatinases 
(Hemmann et al., 2007; Duarte et al., 2015) that increase following CCl4 exposure in 
both genotypes. Mmp2 transcripts did not increase until 96 hours after CCl4 exposure 
and were not different between wild-type and Has3-/- mice at any time point (Figure 3-
8A). Mmp9 increased earlier relative to Mmp2 in both genotypes, increasing above 
baseline levels at 24 and 48 hours post CCl4 exposure but again was not different 
between genotypes (Figure 3-8B). Mmp13 is the main mouse collagenase and is 
equivalent to Mmp1 in humans (Hemmann et al., 2007). Hepatic transcripts of Mmp13 
were induced 24 and 48 hours after CCl4 exposure in both genotypes (Figure 3-8C). 
These transcripts were higher in Has3-/- mice compared to wild-type mice 48 and 72 
hours post-CCl4 exposure. Tissue inhibitors of MMPs (TIMPs) inhibit MMPs (Hemmann 
et al., 2007). Timp1 was increased in both genotypes following CCl4 exposure and was 
not different between genotypes at any time point (Figure 3-8D).  
Real time PCR does not provide data on MMP enzymatic activity.  To determine 
this, alternative techniques must be used. In situ zymography (ISZ) is a technique that 
allows visualization of active areas of matrix degradation (Lindsey et al., 2001; Yan and 
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Blomme, 2003).  To perform ISZ, a dye quenched gelatin or collagen suspended in an 
enzymatically permissive buffer is layered on top of freshly cut, OCT-embedded liver 
sections and placed at 37oC overnight.  Any place in the liver section where gelatinase 
or collagenase activity is present will result in green fluorescence, which can be 
recorded and quantified using standard morphometry techniques (Lindsey et al., 2001; 
Yan and Blomme, 2003). We used ISZ to evaluate matrix degradation activity in livers 
from Has3-/- and wild-type mice and it revealed that Has3-/- mice had increased 
gelatinase activity (matrix degradation) relative to wild-type mice 72 hours post CCl4 
exposure (Figure 3-8E-G). Because MMP13 can activate MMP2 and MMP9 (Leeman et 
al., 2002), these data suggest that the observed increase in matrix degradation 
observed in Has3-/- mice is likely due to the increased Mmp13 seen at the transcript 
level. 
 
HA receptor expression in wild-type and Has3-/- mice following acute CCl4 
exposure. 
 HA interacts with several different receptors expressed on various cell types. 
Using real time PCR, we evaluated the expression of many of these receptors in wild-
type and Has3-/- mice following acute CCl4 exposure. Cd44 is the most well 
characterized HA receptor and plays a role in cell migration and adhesion (Marhaba and 
Zoller, 2004; McDonald and Kubes, 2015). Cd44 expression increased in both 
genotypes following acute CCl4 exposure and at 48 hours post CCl4 it was increased in 
Has3-/- mice compared to wild-type mice (Figure 3-9A). Toll like receptors (TLR) also 
interact with HA and are required for HA-stimulated inflammatory signals  
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Figure 3-8: Hepatic matrix degradation after acute CCl4 exposure. 
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Mice were exposed to CCl4 and euthanized 24, 48, 72, or 96 hours later. Control mice 
received an olive oil (oil) injection. Hepatic transcript accumulation of A. Mmp2, B. 
Mmp9, C. Mmp13, D. Timp1 were measured using real-time PCR. Data are expressed 
as fold change over each strain’s own oil control. E. Representative in situ zymography 
showing active matrix metabolism. * denotes central veins and + signs denotes the 
portal triads in images.  F. Area and G. intensity of positive in situ zymography as a 
measure of total matrix metabolism. * represents p<0.05 when comparing CCl4 
exposure to baseline within a genotype, + represents p<0.05 when comparing wild-type 
and Has3-/- mice within a time point N. = 4 – 7 mice per experimental group. 
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(Jiang et al., 2005; Jiang et al., 2011; Sokolowska et al., 2014). Tlr2 increases in both 
genotypes following acute CCl4 exposure and the transcript levels were higher in   
Has3-/- mice compared to wild-type mice 48 hours post CCl4 exposure (Figure 3-9B). 
Similarly, Tlr4 expression increased in both wild-type and Has3-/- mice following CCl4 
exposure, however the increase was not different between genotypes at any time point 
(Figure 3-9C). The receptor with the highest induction after acute CCl4 and the biggest 
differential expression between genotypes was HA mediated motility receptor (Hmmr). 
HMMR plays roles in macrophage and fibroblast migration (Zaman et al., 2005; Tolg et 
al., 2012) and in spindle pole stability (Maxwell et al., 2003; Tolg et al., 2010). Transcript 
levels for Hmmr were not increased above baseline until 48 hours in either genotype, 
however they were then robustly increased (Figure 3-9D). At 48 and 72 hours post 
CCl4, expression of Hmmr was almost 200-fold higher in Has3-/- mice compared to wild-
type mice (Figure 3-9D). HMMR protein showed a similar trend, albeit not as dramatic. 
HMMR protein was increased in Has3-/- mice compared to wild-type mice 48 hours post 
CCl4 and there was a trend toward a difference 72 hours post CCl4 (Figure 3-9E and F). 
Taken together, the many differences observed between wild-type and Has3-/- mice in 
injury, inflammation, regeneration, and matrix remodeling suggest that HA and possibly 
interactions between HA with one or more of its receptors play critical roles in liver injury 
and wound healing following acute CCl4 exposure. 
 
Discussion 
 Despite a well-appreciated role for plasma HA as a hepatic function biomarker, 
few studies have explored a possible role for HA in the pathogenesis of liver disease  
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Figure 3-9: Hepatic HA receptor expression following acute CCl4 exposure. 
 
Mice were exposed to CCl4 and euthanized 24, 48, 72, or 96 hours later. Control mice 
received an olive oil (oil) injection. Real time PCR was used to measure hepatic 
accumulation of A. Cd44, B. Tlr2, C. Tlr4, and D. Hmmr transcript levels. Data are 
expressed as fold change over each strain’s own oil control. E. Quantification and F. 
representative Western blot for hepatic HMMR. GAPDH was used as a loading control. 
* represents p<0.05 when comparing CCl4 exposure to baseline within a genotype, + 
represents p<0.05 when comparing wild-type and Has3-/- mice within a time point. N = 
4 – 7 mice per experimental group. 
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(Engstrom-Laurent et al., 1985; Lee et al., 2013; Neuman et al., 2016). We provide the 
first evidence to suggest that HAS3, and presumably HA produced by HAS3, plays 
opposing roles in liver injury and wound healing after hepatotoxin mediated acute liver 
injury.  Specifically, we show that HAS3, or HA produced by HAS3, protects the liver 
after acute liver injury by dampening hepatic inflammation. However, this alters 
subsequent wound healing by also dampening regeneration and matrix remodeling. Our 
data suggest that this protective effect may be due to the total amount and relative 
proportions of critical molecular weight HA pools and/or may be related to the amount of 
HA deposited in the liver following acute liver injury.  
 It is known that HSC can synthesize HA and do so in response to partial 
hepatectomy, a surgical model of liver regeneration (Vrochides et al., 1996). In addition, 
treating mice with HMW-HA (780, 900 or 1200 kDa), but not LMW-HA (250 and 470 
kDa), can prevent T-cell mediated liver injury (concanavalin A and 
galactosamine/lipopolysaccharide models) and this occurs through a reduction in pro-
inflammatory cytokines, including tumor necrosis factor α (TNFα), interferon gamma, 
macrophage inflammatory protein 2 (MIP2) and interleukin 4 (Nakamura et al., 2004). 
Administration of human umbilical vein HA (HMW-HA) also exerts some protection 
against CCl4-induced liver injury, lipid peroxidation, and fibrosis in rats when used in 
combination with chondroitin sulfate, but not when either molecule was used alone 
(Campo et al., 2004). Collectively, these studies, as well as our study, suggest that HA 
can exhibit a protective effect in animal models of acute liver disease.  
 While no one has yet explored the effect of HAS enzyme deficiency in animal 
models of liver injury, investigators have evaluated the impact HAS3-deficiency has in 
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other animal models of human disease; these studies largely support a pathogenic role 
for HAS3. For example, in the lung, Bai et al., demonstrated that high-tidal volume 
ventilator-induced pulmonary MIP2 production and neutrophil infiltration is robust in 
wild-type mice, but suppressed in mice deficient in HAS3 (Bai et al., 2005). The 
increase in inflammation in wild-type mice is associated with increased pulmonary 
accumulation of HA favoring lower molecular weight species (178 – 370 kDa); this was 
not observed in Has3-/- mice. Likewise, Kessler et al., demonstrated that HAS3-null 
mice are protected from DSS-induced colitis when compared to wild-type mice (Kessler 
et al., 2015). In the absence of HAS3, HA deposition and leukocyte infiltration are 
profoundly attenuated and associated with reduced weight loss and reduced pro-
inflammatory cytokine production after DSS exposure (Kessler et al., 2015). In both of 
these studies, and in contrast to our study, HAS3 drives tissue inflammation.  
The specific mechanisms behind the pathogenic function of HAS3 in the lung and 
in the gut remain controversial. One hypothesis is that because HAS3 can make smaller 
HA polymers compared to HAS1 and HAS2 (Spicer and McDonald, 1998; Itano et al., 
1999), perhaps HAS3-synthesized HA is small enough to be pro-inflammatory on its 
own. Conversely, perhaps LMW-HA synthesized by HAS3 is not directly pro-
inflammatory but because it is smaller initially, it is more rapidly degraded into HA 
species which are pro-inflammatory. Another possible explanation is that HAS enzymes 
are differentially expressed in various tissues, cell types or in response to different 
stimuli (Jacobson et al., 2000).  Therefore, loss of one enzyme could profoundly 
influence the nature of the inflammatory response to injury in a tissue or cell type-
specific fashion (Spicer and McDonald, 1998). Therefore HAS3’s differential effect, 
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pathologic vs protective depending on animal model, should be explored further by 
evaluating in which cell types HAS3 is expressed as well as by elucidating the local 
production and turnover of HA after tissue injury. Indeed, in the DSS-induced colitis 
model, HAS3 expression is predominantly localized to the endothelial cells found in gut 
microvessels where it produces a leukocyte-adhesive HA and contributes to 
inflammation (Kessler et al., 2015). Further exploration of cell-type specific hepatic HAS 
enzyme expression, hepatic HA accumulation and hepatic HA molecular weight 
distribution during liver disease pathogenesis is required to understand the differences 
between our study and the other studies discussed above.  
 In this study, we observed increases in hepatic mRNA and plasma protein levels 
for several pro-inflammatory chemokines in Has3-/- mice compared to wild-type mice 
after acute CCl4 exposure (Mohanraj et al., 2014). These chemokines can attract a 
number of cells involved in innate and adaptive immune responses to tissue injury 
including monocytes/macrophages (CCL2, CXCL10), neutrophils (CXCL1), natural killer 
cells (CXCL10), dendritic cells (CCL2, CXCL12) and T-cells (CCL2, CXCL10). We 
believe that chemokine production is at a critical nexus between the promotion of liver 
injury and, paradoxically, wound healing. Indeed, while CYP2E1-mediated bioactivation 
is required for CCl4’s hepatotoxic effects (Wong et al., 1998), macrophages and 
macrophage recruitment also contribute to liver injury in this model. For example, if 
macrophages are depleted using gadolinium chloride, liver injury after CCl4 exposure is 
reduced (Edwards et al., 1993). Similarly, mice deficient in CCL2 or the CCL2 receptor, 
CCR2, exhibit reduced plasma ALT activities, intrahepatic inflammatory cytokine 
expression and macrophage recruitment after CCl4 exposure (Zamara et al., 2007; 
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Mitchell et al., 2009a). Therefore, increased chemokine production in Has3-/- mice 
could be contributing to increased inflammatory macrophage recruitment, which could 
contribute to increased injury after CCl4 exposure. Future work should evaluate markers 
of macrophage mediated TNFα and ROS as well as protein levels of macrophage 
markers by IHC or FACS analysis to determine if this is occurring in Has3-/- mice. 
 In addition to contributing to liver injury, inflammation promotes hepatic 
regeneration. We observed increased inflammatory microenvironment in Has3-/- mice 
compared to wild-type mice and it is possible that this may also play a role in the 
increased regeneration in the Has3-/- mice. TNFα treatment in vitro increases rat 
hepatocyte proliferation, suggesting a role for pro-inflammatory mediators in “priming” 
hepatocytes for regeneration (Webber et al., 1998). In addition, treating mice with a 
CCR2 antagonist following a partial hepatectomy results in decreased mitotic figures 
associated with a decrease in hepatic macrophage content (Nishiyama et al., 2015). 
Likewise, depletion of Kupffer cells using clodronate-encapsulated liposomes, results in 
a decrease of ethanol-induced DNA synthesis (Owumi et al., 2014). While we observed 
increased chemokine expression, further work should be completed (as described 
above) to determine if there is in fact increased macrophage infiltration or if there is 
increased TNFα production, but overall our data suggest that increased inflammation 
may also provide a mechanism to improve liver regeneration.  
 Additionally, hepatic macrophages and macrophage recruitment are also critical 
determinants of ECM regulation. Macrophages are the primary source of MMPs 
required for matrix degradation/metabolism, which can also influence regeneration and 
is required to restore hepatic structure and function (You et al., 2013; Duarte et al., 
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2015). In this study, we found increased matrix metabolism in livers from Has3-/- mice 
compared to wild-type mice. Treatment of mice following a partial hepatectomy with a 
broad spectrum MMP inhibitor limited regeneration (Alwayn et al., 2008). This suggests 
that, similar to the increased inflammation, the increased matrix metabolism may also 
be aiding in the increased regeneration seen in Has3-/- mice. It is likely that increased 
matrix metabolism is caused by the increase in Mmp13 transcript accumulation in the 
Has3-/- mice. Mmp13 transcript accumulation is increased following low dose D-
galactosamine exposure in rats and is associated with survival (Yata et al., 1999). 
However in high dose D-galactosamine exposure, Mmp13 transcript expression is 
dysregulated and associated with non-survival (Yata et al., 1999). HA oligosaccharides 
are known inducers of MMP13 (Fieber et al., 2004). It is tempting to speculate that 
increased HA levels found in Has3-/- mice after exposure to CCl4 may have contributed 
to the increase in Mmp13 levels we found in this study. Together these data suggest 
that the increased matrix metabolism in the Has3-/- mice is promoting the wound 
healing process, and this may be caused by the imbalance in LMW-HA and HMW-HA 
fragments or increased hepatic HA found in Has3-/- mice following acute CCl4.  
 Finally, we evaluated HA receptor expression in wild-type and Has3-/- mice after 
acute liver injury. We observed increased expression of all receptors evaluated, CD44, 
TLR2, and TLR4, but the largest differential expression was in HMMR. This was 
mirrored, although to a lesser degree relative to mRNA, in the hepatic HMMR protein 
content. This receptor is unique in that it can be both intracellular and extracellular and it 
can play a role in cell migration, for macrophage and fibroblasts, as well as cell 
proliferation (Tolg et al., 2006; Tolg et al., 2012; Chen et al., 2014). The increased 
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expression of Hmmr, may therefore be contributing to several aspects of the wound 
parameters that were found to be different in Has3-/- mice compared to wild-type mice 
after acute CCl4. This possible contribution of HMMR to liver wound healing will be 
explored further in the following chapter.   
 Despite increased plasma HA levels being linked to liver disease severity for 
years, we are the first to show a link between HA and acute hepatic wound healing. We, 
conclude that HA produced by HAS3 protects against hepatotoxin-induced liver injury. 
However in Has3-/- mice, we uncovered an unexpected increase in hepatic HA, which is 
associated with increased hepatic wound healing, including inflammation, regeneration, 
and matrix remodeling. We also observe an induction in hepatic Has enzymes, hepatic 
HA content, and the transcription of several HA receptors following acute liver injury, 






Chapter 4: HA mediated motility receptor (HMMR) is required 





 Hepatic wound healing occurs following acute liver injury and includes stages of 
inflammation, regeneration, and matrix remodeling. Hyaluronan (HA) is a ubiquitous 
glycosaminoglycan that is increased following dermal injury and plays a role in the skin 
wound healing process.  HA is also increased in the plasma of patients with liver 
disease, however a role for HA in the hepatic wound healing process has not been 
investigated. We showed in Chapter 3 that mice deficient in HAS3 have increased injury 
and increased wound healing associated with increased HA and HA mediated motility 
receptor (HMMR) expression after acute carbon tetrachloride (CCl4) exposure. HMMR 
plays a role in the migration of fibroblasts and macrophages to wounded tissue and in 
mitotic spindle stability and proliferation. We therefore hypothesized that HMMR aids in 
wound healing following acute liver injury. Using Hmmr-/- and wild-type mice, we 
induced liver injury and evaluated parameters of wound healing. We found that Hmmr-/- 
mice have reduced pro-inflammatory cytokine and chemokine expression compared to 
wild-type mice that is independent of injury. This was associated with reduced matrix 
degradation. Further evaluation indicated that removal of dead tissue was delayed in 
mice lacking HMMR. Hmmr-/- mice also have delayed hepatic regeneration compared 
to wild-type mice. Finally, Hmmr-/- mice have delayed hepatic HA deposition. Together, 
our data suggest a role for HMMR and HA in both macrophage localization and hepatic 
regeneration after toxin induced acute liver injury. We propose macrophages are 
utilizing HA via an interaction with HMMR to localize to the necrotic area and aid in 




 Toxins like acetaminophen or alcohol, when consumed in large quantities, are a 
primary cause of acute liver injury in developed countries like the United States (Penny, 
2013; Jaeschke, 2015). Once toxin-mediated injury occurs, the liver works to heal itself. 
This process is analogous to skin wound healing and includes periods of inflammation, 
regeneration, and matrix remodeling (Balaji et al., 2015). Hepatic wound healing after 
acute injury is analogous to fetal wound healing and results in minimal scar formation. If 
injury is sustained, this process becomes deregulated and results in liver fibrosis, 
analogous to adult dermal wound healing (Guo and Friedman, 2007; Friedman, 2008b). 
If injury and inflammation continue to persist, fibrosis can progress to cirrhosis and even 
hepatocellular carcinoma at which point a liver transplant becomes necessary for 
survival (Rai, 2013; Tsochatzis et al., 2014). Studying the mechanisms of acute liver 
wound healing can provide novel insight into the progression of chronic liver disease 
and lead to possible therapeutic options to avoid the need for a transplant.  
 Hyaluronan is a non-sulfated, ubiquitous, glycosaminoglycan implicated in a 
number of disease pathologies (Jiang et al., 2011). For example, the molecular weight 
and concentration of HA in articular joints decreases as we age and is associated with 
the progression of osteoarthritis (Campo et al., 2011; Band et al., 2015). In fact, intra-
articular HMW-HA injections are currently used as a treatment for osteoarthritis, 
demonstrating the importance of HMW-HA in preventing inflammation (Guidolin and 
Franceschi, 2014). In lung injury, HA fragments accumulate and can induce an 
inflammatory response via interaction with toll like receptor (TLR) 2 and 4 (Jiang et al., 
2005). HA is increased in the plasma of patients with liver disease, and this increase is 
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correlated with the disease severity (Engstrom-Laurent et al., 1985; Lee et al., 2010; 
Lee et al., 2013). 
 HA is synthesized by three different hyaluronan synthase (HAS) enzymes, HAS1, 
HAS2, and HAS3 (Jiang et al., 2011). These enzymes differ in their tissue-specific 
expression and synthetic capacity, but each creates high molecular weight HA (HMW-
HA) (Spicer and McDonald, 1998; Itano et al., 1999). We have shown previously 
(Chapter 3), that mice bearing an enzymatically inactive HAS3 have increased injury 
compared to wild-type controls following acute liver injury induced by carbon 
tetrachloride (CCl4). These mice also have increased wound healing, evident by 
increased liver regeneration and matrix remodeling after acute injury. Interestingly, 
these mice have increased hepatic HA accumulation and also display an increase in the 
expression of the HA receptor, HA mediated motility receptor (HMMR) at both the 
mRNA and protein level compared to wild-type controls.  
 HMMR is a unique HA receptor in that it does not contain a transmembrane 
domain, and it can be either intracellular or extracellular (Savani et al., 2000; Jiang et 
al., 2010). Extracellular HMMR interacts with HA in the extracellular matrix (ECM) and 
promotes the migration of fibroblasts and macrophages to wounded tissue to facilitate 
dermal wound healing (Tolg et al., 2006; Tolg et al., 2012). Intracellular HMMR plays a 
role in cell proliferation; specifically it is a component of the mitotic spindle complex and 
promotes progression through the cell cycle (Maxwell et al., 2003; Chen et al., 2014). 
Cells lacking functional HMMR arrest at the G2/M transition of the cell cycle, resulting in 
either delayed mitosis or mitotic arrest (Chen et al., 2014).  Because of the unique 
properties of HMMR in migration and cell proliferation, as well as HMMR expression 
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being associated with increased wound healing observed in Has3-/- mice, we sought to 
examine hepatic wound healing in Hmmr-/- mice following acute CCl4 exposure. We 
hypothesized that Hmmr-/- mice would exhibit a delay in inflammation, regeneration, 
and matrix metabolism after acute liver injury, the reciprocal of what we observed in 




Hmmr expression pattern in C57Bl/6N mice mirrors that of C57Bl/6J mice 
 As described previously, Has3-/- mice have increased wound healing, which is 
associated with increased HMMR levels (see Chapter 3). In addition, because HMMR 
has been implicated in cell migration and regeneration, we hypothesized that Hmmr-/- 
mice would have delayed wound healing (Tolg et al., 2006; Tolg et al., 2010; Tolg et al., 
2012; Chen et al., 2014) after acute liver injury. The Hmmr-/- mice are on a C57Bl/6N 
background, which is in contrast to the Has3-/- mice, which are on a C57Bl/6J 
background (See Figure 6-9). Therefore, we first evaluated Hmmr expression and 
protein levels in C57Bl/6N wild-type mice. Similar to the C57Bl/6J mice used in the 
Has3-/- studies, Hmmr expression was induced only at 48, 72, and 96 hours post CCl4 
exposure, peaking at 48 hours (Figure 4-1A). A similar pattern was seen when HMMR 
protein levels were measured (Figure 4-1B). Thus indices of liver injury, inflammation, 
and repair were measured only at 48, 72, and 96 hours post CCl4 Hmmr-/- mice and 







Figure 4-1: Hepatic Hmmr expression in C57BL/6N mice. 
 
Mice were exposed to CCl4 and euthanized 12, 24, 48, 72, or 96 hours later. Control 
mice received an olive oil (oil) injection. A. Wild-type hepatic Hmmr expression was 
evaluated using real time PCR. Data were normalized to 18s and expressed as fold 
change over oil. B. Western blot samples were pooled and separated on a SDS-PAGE 
gel, transferred to a PVDF membrane, and probed for HMMR. GAPDH served as a 
loading control. All data are represented as mean + SEM throughout this chapter. * 
represents p<0.05 compared to oil. N = 5 – 6 mice per group. 
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Liver injury in Hmmr-/- and wild-type mice following acute CCl4 exposure 
 Plasma ALT activity and the area of necrosis in H&E stained liver sections were 
used to assess liver injury following CCl4 exposure in Hmmr-/- mice and wild-type 
controls. Plasma ALT activity was elevated in both genotypes 48 hours after CCl4 
exposure, and there was no difference between genotypes (Figure 4-2A). While there 
was no difference in peak necrosis at 48 hours between wild-type and Hmmr-/- mice, by 
72 hours after CCl4 exposure, there was more necrosis remaining in Hmmr-/- mice 
compared to wild-type mice. This suggests a delay in necrotic cell removal (Figure 4-2B 
and C). Similar to the Has3-/- mice (Chapter 3), there was no difference in basal 
CYP2E1 protein or activity levels between Hmmr-/- mice and wild-type mice (Figure 4-
3A-C). Taken together, these data suggest that wound repair is delayed in Hmmr-/- 
mice and this effect is independent of liver injury.  
 
Hepatic inflammation in Hmmr-/- and wild-type mice following acute CCl4 
exposure 
 Because HMMR plays a role in cell migration, we evaluated the number of cells 
infiltrating into the necrotic area. Hmmr-/- mice had lower infiltrating cells at 48 hours, 
but trended toward an increase at 72 hours compared to wild-type. This could account 
for the delay in necrotic healing but the ability for Hmmr-/- mice to recover to wild-type 
levels by 96 hours (Figure 4-4A). In fact, the number of infiltrating cells is negatively 
correlated to the area of necrosis (Figure 4-4B). While this does not distinguish between 
types of cell infiltrating necrotic areas or if they are removing tissue debris, it does 
suggest that HMMR is important for early cell infiltration after acute liver injury. 
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Figure 4-2: Hepatic injury in wild-type and Hmmr-/- mice following acute CCl4 
exposure. 
 
Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. Control mice 
received an olive oil (oil) injection. A. Plasma ALT activity and B. the area of necrosis 
was measured to evaluate hepatic injury. Necrosis was defined as hypereosinophilic 
tissue area with the absence of hepatic nuclei. C. Representative H&E stained liver 
sections with the necrotic area outlined with a black dashed line. * denotes central vein 
and + denotes portal veins in the images. Throughout this chapter, black bars represent 
wild-type mice and grey bars represent Hmmr-/- mice. In the graphs, * represents 
p<0.05 when compared to each genotype’s own oil control, + represents p<0.05 when 




Figure 4-3: Basal CYP2E1 expression and activity in wild-type and Hmmr-/- mice. 
 
Control mice received olive oil (oil) injections and were euthanized 72 hours later. A. 
Representative blot for CYP2E1 protein. GAPDH was used as a loading control. B. 
Quantification of CYP2E1 protein levels were completed using ImageJ. C. CYP2E1 
activity was measured in microsomes isolated from the livers of control mice. + cont 
samples were from mice exposed to ethanol, a known inducer of CYP2E1 and – cont 
samples were from mice exposed to CCl4, known to deplete CYP2E1 levels. * 
represents p<0.05. N = 6 – 9, N = 2 for positive and negative controls. 
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HMMR is important for macrophage migration in skin wound healing (Tolg et al., 2012). 
Macrophages are important in both initial injury and hepatic wound healing, but there 
was no difference in hepatic injury (Figure 4-2) and HMMR is only expressed when 
hepatic repair is ongoing (Figure 4-1). We therefore hypothesized that HMMR is more 
important in hepatic wound healing rather than initial injury (Duffield et al., 2005; 
Zigmond et al., 2014). Ccl2 (encodes CCL2, also known as monocyte chemoattractant 
protein 1, MCP1) and aids in the recruitment of macrophages to the damaged liver 
(Zamara et al., 2007). Ccl2 transcripts were induced in both wild-type and Hmmr-/- mice 
48 hours post CCl4, and the transcript levels were lower in the Hmmr-/- mice compared 
to wild-type mice at this time point (Figure 4-4C). Ccr2, the receptor for MCP1 and a 
marker of recruited macrophages (Mitchell et al., 2009a), was elevated above baseline 
in both wild-type and Hmmr-/- mice 48 hours post CCl4 exposure and remained 
elevated in Hmmr-/- mice through 96 hours post CCl4 exposure (Figure 4-4D). Emr1 
transcripts, which encode for F4/80, a mouse macrophage marker, increased in wild-
type mice by 48 hours post CCl4 exposure and were significantly lower at that same 
time point in Hmmr-/- mice (Figure 4-4E). In fact, Emr1 transcript levels were not 
elevated above baseline until 72 hours post CCl4 exposure in Hmmr-/- mice. Tnfa, the 
gene for the pro-inflammatory cytokine TNFα, is produced mainly by macrophages 
(Mohanraj et al., 2014). Hepatic Tnfa transcript levels increased in both wild-type and 
Hmmr-/- mice 48 hours after CCl4 exposure, however this increase was greater in wild-
type mice (Figure 4-4F). Together, these data suggest that due to a decrease in pro-
inflammatory chemokine gene expression, macrophage recruitment may be delayed. 
However as evidenced by sustained levels of Ccr2 transcripts in Hmmr-/- mice, 
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recruited macrophages may persist in the liver compared to macrophages from wild-
type mice. These gene expression analyses do not mean that macrophages are 
recruited to the necrotic area where they are required to clear the dead and dying 
hepatocytes (Kinoshita et al., 2010; Ikarashi et al., 2013). In fact, when evaluating F4/80 
staining, there is a trend towards a decrease in total area of F4/80+ cells in liver from 
Hmmr-/- mice compared to wild-type mice (Figure 4-4G and H). In addition, F4/80+ cells 
in wild-type mice are infiltrating the necrotic area, while the F4/80+ cells in Hmmr-/- mice 
are not yet infiltrating into the necrotic area (Figure 4-4H). Combined with the sustained 
necrosis level in Hmmr-/- mice, this suggests that macrophage localization to necrotic 
tissue was delayed in Hmmr-/- mice.  
 
Hepatic regeneration in wild-type and Hmmr-/- mice following acute CCl4 
exposure 
 Hepatic regeneration is a vital step in hepatic wound healing after acute CCl4 
exposure (Cienfuegos et al., 2014). HMMR is unique in that it is not only important in 
cell motility, but it also plays a role in cell cycle progression, and is particularly important 
during the G2/M phase transition (Tolg et al., 2010; Hatano et al., 2012). Inflammatory 
cytokines including TNFα, aid in the priming of hepatocytes for regeneration (Webber et 
al., 1998; Owumi et al., 2014). Due to the reduced Tnfa transcripts and the role of 
HMMR in proliferation, we predicted that Hmmr-/- mice would have decreased or 
delayed hepatic regeneration following acute CCl4 exposure. To test this hypothesis, we 
evaluated several indices of cell proliferation associated with liver regeneration.  Hepatic 
Pcna transcripts were induced in both wild-type and Hmmr-/- mice following CCl4  
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Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. Control mice 
received an olive oil (oil) injection. A. Cells that had infiltrated the necrotic area were 
counted and represented as number of cells/pixel of necrotic area. B. The infiltrating 
cells were correlated with % necrotic tissue for mice euthanized 48 and 72 hours after 
CCl4 exposure. Real time PCR was used to evaluate hepatic accumulation of C. Ccl2, 
D. Ccr2, E. Emr1, and F. Tnfa transcripts. Data are expressed as fold change over own 
oil. G. Quantification of total area of positive staining and H. representative histology of 
F4/80 staining 72 hours after CCl4 exposure. * denotes central veins and + denotes 
portal veins in the images. In the graphs, * represents p<0.05 compared to each 
genotype’s own oil, + represents p<0.05 comparing the two genotypes at one timepoint. 
N = 6 – 13 mice per group. 
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exposure, however, 48 hours after exposure wild-type mice had increased Pcna 
transcript compared to Hmmr-/- mice (Figure 4-5A). PCNA protein increased in both 
genotypes in response to CCl4, but there were no differences at any time point between 
wild-type and Hmmr-/- mice (Figure 4-5B and C). Ccnd1, the gene that encodes Cyclin 
D1, was induced in both wild-type and Hmmr-/- mice by 48 hours after CCl4 exposure; 
there were no differences in transcript levels between the genotypes at any time point 
(Figure 4-5D). A similar trend was observed in Cyclin D1 protein (Figure 4-5E and F). 
Ki67, a marker for cell proliferation, was used to observe actively proliferating 
hepatocytes in liver sections. Despite limited differences in Cyclin D1 and PCNA 
protein, wild-type mice had almost twice as many Ki67 positive cells 48 hours after CCl4 
exposure compared to Hmmr-/- mice (Figure 4-6A and 4-6B). Together, these data 
suggest that despite similar gene expression profiles, Hmmr-/- mice have a delay in 
hepatocyte proliferation following acute liver injury.  
 
Matrix remodeling in wild-type and Hmmr-/- mice following acute CCl4 exposure. 
 Matrix remodeling is another vital component of the hepatic wound healing 
process and includes both matrix synthesis and matrix degradation. In addition to 
HMMR’s role in macrophage migration, it also plays a role in fibroblast migration in 
dermal wound healing (Tolg et al., 2006). In the injured liver, hepatic stellate cells (HSC) 
are activated and transdifferentiate into myofibroblasts, cells phenotypically and 
functionally similar to the fibroblasts that participate in skin would healing (Wells and 
Schwabe, 2015). A common marker for myofibroblasts is αSMA, a protein that is 
encoded by the Acta2 gene (Wells and Schwabe, 2015). Hepatic Acta2 transcripts 
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Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. Control mice 
received an olive oil (oil) injection. A. Hepatic Pcna transcript accumulation was 
measured using real time PCR. B. Quantification and C. representative blot for PCNA 
protein. E. Hepatic Ccnd1 transcripts were measured using real time PCR. F. 
Quantification and G. representative Cyclin D1 Western blot. Data are expressed as fold 
change over each genotype’s own oil. * represents p<0.05 compared to each 
genotype’s own oil. + represents p<0.05 when comparing the two genotypes at one time 
point. N = 6 – 13 mice per group. 
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Figure 4-6: Ki67 positive hepatocytes following acute CCl4 exposure in wild-type 
and Hmmr-/- mice. 
 
Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. A. Quantification 
and B. representative histology of Ki67 positive hepatocytes. Data are expressed as 
number of positive hepatocytes per 200X image. * denotes central veins and + denotes 
portal veins in the images. In the graphs, + represents p<0.05 when comparing the two 
genotypes at one time point. N = 6 – 13 mice per group. 
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increased in both genotypes above baseline following CCl4 exposure but there was no 
difference between genotypes at any time point (Figure 4-7A). The amount of αSMA 
protein was actually lower in Hmmr-/- mice compared to wild-type mice 48 hours after 
CCl4 exposure (Figure 4-7B and C).  This suggests that HMMR may not be required for 
HSC activation following acute liver injury, however it does not prove conclusively that 
HMMR is not important for HSC localization to injured areas of the liver.  
 As mentioned above, matrix remodeling consists of not only matrix synthesis by 
activated HSC, but also of matrix degradation. This degradation occurs due to a 
coordinated effort by several matrix metalloproteinases (MMPs), synthesized primarily 
by macrophages (Fallowfield et al., 2007b; Duarte et al., 2015). Due to the apparent 
decrease in hepatic inflammation, we hypothesized that Hmmr-/- mice would have 
decreased matrix degradation. MMP13 is the main mouse collagenase, and hepatic 
Mmp13 transcripts were elevated in both wild-type and Hmmr-/- mice 48 hours after 
CCl4 exposure. However, this induction was not different between genotypes (Figure 4-
8A). MMP13 degrades collagen molecules to gelatin that are then degraded by 
gelatinases (Chung et al., 2004). Expression of Mmp2, a mouse gelatinase, increased 
in both genotypes, however not until 72 hours after CCl4 exposure (Figure 4-8B). The 
transcript levels were not different between genotypes at any time point. Mmp9 
transcripts, which encode for another mouse gelatinase, increased in both wild-type and 
Hmmr-/- mice 48 hours after CCl4 exposure (Figure 4-8C). In contrast to our hypothesis, 
Mmp9 transcript levels were increased in Hmmr-/- mice compared to wild-type mice 72 





Figure 4-7: Hepatic stellate cell activation in wild-type and Hmmr-/- mice after 
acute CCl4 exposure. 
 
Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. Control mice 
received olive oil (oil) injection. A. Real time PCR was used to measure hepatic Acta2 
transcripts. B. Quantification and C. representative blot for αSMA protein levels. HSC70 
was used as a loading control. Data are expressed as fold change over each 
genotype’s own oil control. * represents p<0.05 compared to each genotype’s own oil. + 
represents p<0.05 when comparing the two genotypes at one time point. N = 6 – 13 
mice per group. 
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MMP activity following acute liver injury. Timp1 transcripts also increased in both 
genotypes but the increase was greater in wild-type mice 48 hours after CCl4 exposure 
(Figure 4-8D). Using in situ zymography (described in Chapter 2 and Chapter 3), active 
matrix remodeling was decreased in Hmmr-/- mice compared to wild-type mice 72 hours 
post CCl4 exposure (Figure 4-9A, B, and C). These data demonstrated that despite no 
difference, or an increase in the expression level of any MMP evaluated, and in spite of 
the decreased Timp1 expression, Hmmr-/- mice have decreased matrix metabolism. 
This suggests that Hmmr-/- mice are able to induce gene expression to promote wound 
healing, but may be unable to localize cells to the necrotic area to facilitate matrix 
metabolism.  
 
Hyaluronan accumulation in wild-type and Hmmr-/- following acute CCl4 exposure 
 HMMR is a receptor for HA, and blocking this interaction can effect dermal 
wound healing (Tolg et al., 2012). It was therefore important to evaluate plasma HA and 
intrahepatic HA levels in Hmmr-/- and wild-type mice. Plasma HA levels increased 
following CCl4 exposure in the wild-type mice, but not the Hmmr-/- mice (Figure 4-10A). 
While very little HA is present in healthy liver, hepatic HA increased in livers from both 
genotypes following injury. However, HA accumulation at 48 hours post CCl4 exposure 
was less in Hmmr-/- mice compared to wild-type mice (Figure 4-10B and C). By 72 
hours after CCl4 exposure, hepatic HA levels in Hmmr-/- mice had increased to the level 
of wild-type mice.  This suggests that there was a delay in HA synthesis following injury 








Figure 4-8: Hepatic matrix remodeling transcripts in wild-type and Hmmr-/- mice 
after CCl4 exposure. 
 
Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. Control mice 
received olive oil (oil) injection. Hepatic A. Mmp13, B. Mmp2, C. Mmp9, and D. Timp1 
mRNAs were measured using real time PCR. Data are expressed as fold change over 
own oil. * represents p<0.05 compared to each genotype’s own oil. + represents p<0.05 






Figure 4-9: Matrix remodeling following acute CCl4 in wild-type and Hmmr-/- mice. 
 
Mice were exposed to CCl4 and euthanized 72 hours later. A. Representative in situ 
zymography histology and quantification of B. area of positive signal and C. intensity 
were used to evaluate active matrix metabolism following acute CCl4 exposure. * 
denotes central vein, + denotes portal veins in the images. In the graphs, + represents 




Figure 4-10: Plasma and hepatic HA content following acute CCl4 exposure in 
wild-type and Hmmr-/- mice. 
 
Mice were exposed to CCl4 and euthanized 48 or 72 hours later. Control mice received 
an olive oil (oil) injection. A. An ELISA-like assay was used to measure plasma HA 
content. B. Quantification and C. representative histology of HABP staining used to 
localize hepatic HA content. * denotes central vein, + denotes portal veins in the 
images. In the graphs, * represents p<0.05 compared to each genotype’s own oil. N = 6 
– 9 mice per group. 
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Discussion 
 HMMR is a unique HA receptor in that it has both intracellular and extracellular 
localization and has different effects on cell behavior depending on its location (Jiang et 
al., 2010; Telmer et al., 2011). Extracellular HMMR is tethered to the cellular membrane 
via a GPI anchor and acts with CD44 in aiding in cell migration and motility (Tolg et al., 
2006; Nikitovic et al., 2013). Intracellular HMMR interacts with the mitotic spindle and 
binds to microtubules aiding in cell proliferation (Jiang et al., 2010; Telmer et al., 2011). 
Healthy adult tissue has very low levels of HMMR, however, following injury HMMR 
expression is drastically upregulated (Tolg et al., 2006). In addition, tissues with 
extensive proliferation, like testis and bone marrow, express high levels of HMMR 
(Jiang et al., 2010). HMMR is implicated in a number of biological process and diseases 
including dermal wound healing and lung inflammation (Zaman et al., 2005; Tolg et al., 
2006). We provide the first evidence of a role for HMMR in hepatic wound healing 
following hepatotoxin induced liver injury, with possible implications for both 
inflammation and regeneration associated with wound repair.  
 In dermal wound healing, HMMR plays a role in both macrophage and fibroblast 
migration. HMMR and CD44 are required for ERK1/2 phosphorylation and subsequent 
migration of fibroblasts in vitro (Tolg et al., 2006). Using a HMMR mimetic that prevents 
HMMR from interacting with HA, Tolg, et. al., show a decrease in both inflammation and 
fibrogenesis following full-thickness skin wounds (Tolg et al., 2012). Specifically, the 
mimetic decreased macrophage and fibroblast numbers in the wound bed and this was 
associated with a decrease in wound collagen content (Tolg et al., 2012). Our study 
closely mimics the inflammatory data from this published study in that we show a 
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decrease in the inflammatory microenvironment (i.e. decreased Ccl2 and Tnfa 
expression) in the liver following acute hepatotoxin exposure. Decreased matrix 
metabolism suggests a decreased ability for the wound healing macrophages to localize 
to the necrotic area and aid in clean up. This is further supported by the delay in 
necrotic tissue removal. Hmmr-/- mice are able to recover to wild-type levels in terms of 
necrosis removal and inflammation, which may be due to compensation by another HA 
receptor CD44, which plays roles in cell migration as well.  
 HMMR plays a role in macrophage migration in other models of human diseases. 
A HMMR blocking antibody prevented macrophage migration both in vitro and in vivo in 
the lung following bleomycin exposure (Zaman et al., 2005). Similarly, blocking HMMR 
prevented macrophage migration in response to the known macrophage chemotaxis 
stimulator, surfactant protein A (SPA), in a Boyden chamber assay (Foley et al., 2012). 
Additionally, Hmmr-/- bone marrow derived macrophages have decreased migration in 
response to SPA, HA, or TGFβ (Foley et al., 2012). We have shown in this study, that 
mice lacking HMMR have a lower inflammatory microenvironment compared to wild-
type mice after acute CCl4. These mice also have decreased necrotic tissue removal 
and decreased matrix degradation. All of these things together strongly suggest a role 
for HMMR in macrophage migration in the liver following toxin induced acute liver injury.  
 HA is induced during injury and implicated in wound healing in other tissues, 
however no one has evaluated a role for HA in hepatic wound healing (Jiang et al., 
2007; Cowman et al., 2015). What is interesting to note in our study is the delay in 
hepatic HA accumulation in Hmmr-/- mice compared to wild-type mice. This could be an 
indirect response to the decreased inflammation, specifically the delayed Tnfa 
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expression observed in the Hmmr-/- mice. In human umbilical cord vein endothelial cells 
(HUVEC), TNFα induces HAS2 expression and subsequently HA synthesis (Vigetti et 
al., 2010). This increased HA, in turn, increases the adhesion of U937 cells, a human 
monocyte cell line, to HUVEC, in vitro (Vigetti et al., 2010). Conversely, reduced 
accumulation of hepatic HA in Hmmr-/- mice may be why inflammation was reduced 
relative to inflammation in wild-type mice. For example, LMW-HA induces expression of 
TNFα in peritoneal macrophages, in vitro (Jiang et al., 2005). Additionally, persistent 
LMW-HA in mouse lungs following bleomycin-induced injury is associated with 
increased inflammation (Teder et al., 2002). Because we see both a decrease in 
inflammation and a decrease in hepatic HA in Hmmr-/- mice compared to wild-type 
mice, it is impossible to distinguish if the HA is stimulating the inflammation or aiding in 
macrophage migration into the wound. It might also be possible that there exists a feed-
forward loop involving inflammation and HA synthesis, where inflammation influences 
HA synthesis and subsequent HA and/or HA degradation influences inflammation.  It is 
known that a transient increase in inflammation is required for wound repair, but we 
propose that the transient increase in HA synthesis and its subsequent degradation, 
coupled to HMMR-mediated recruitment of macrophages to injured tissue are critical 
and previously unrecognized components of the hepatic wound healing process. 
 HMMR plays a role in fibroblast migration during dermal wound healing (Tolg et 
al., 2006; Tolg et al., 2012). In fact, Hmmr-/- mice have a delay in fibroblast localization 
and defective wound repair (Tolg et al., 2012). Despite this, no one has evaluated a role 
for HMMR in HSC migration in injured liver. Following liver injury, HSC become 
activated and differentiate into myofibroblasts that then begin synthesizing ECM 
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components, including HA (Vrochides et al., 1996; Chang et al., 2015b). While we 
evaluated HSC activation, we do not know if HMMR deficiency impaired the migration of 
HSC to the injured areas of the liver, or if that could be the cause of the delayed hepatic 
HA accumulation. Regardless, we did not observe a difference in HSC activation 
between genotypes, as evident by Acta2 transcript levels and αSMA protein 
quantification. Interestingly, while HA supplementation results in increased macrophage 
migration and faster dermal wound healing, this is not associated with an increase in 
αSMA staining or collagen content (Tolg et al., 2014). This increased wound healing 
induced by HA required HMMR and CD44 (Tolg et al., 2014) and suggests that HMMR 
may be important for fibroblast localization, but not fibroblast activation. This stresses 
the importance of assessing HSC localization in Hmmr-/- mice following acute CCl4 
exposure. 
 The processes described above are all in relation to extraceullar HMMR and the 
receptor’s interaction with HA. However, as noted, HMMR can be intracellular as well. 
Intracellular HMMR is not as well studied with the majority of work having been done in 
vitro, and it is currently unknown whether its actions are HA dependent or independent 
(Savani et al., 2000; Tolg et al., 2010; Esguerra et al., 2015). Our data suggest that 
HMMR is playing a role in hepatocyte proliferation, either directly within hepatocytes or 
indirectly by influencing inflammation. HMMR binds microtubules and is important in the 
G2/M phase transition of the cell cycle (Tolg et al., 2010; Chen et al., 2014). In fact, 
HMMR deficiency results in multi-pole mitotic spindles in mouse embryonic fibroblasts 
(Tolg et al., 2010). The silencing of HMMR in HeLa cells results in an increase in 
multinucleated cells and cells with spindle pole defects (Chen et al., 2014). HMMR 
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silenced HeLa cells were, however, able to initiate proliferation, but became stalled mid-
mitosis, suggesting a problem with the final proliferative stages, not the initiation of 
proliferation (Chen et al., 2014). If hepatocytes are able to initiate cell proliferation, but 
become “stuck” mid-mitosis, this may be why we see no difference in PCNA or Cyclin 
D1 protein levels, but a decrease in Ki67 positive hepatocytes. 
 The delay in regeneration observed in HMMR deficient mice could be secondary 
to the delay in inflammation observed. It is well known that inflammation plays a critical 
role in hepatocyte proliferation following hepatic wound healing (Webber et al., 1998; 
Nishiyama et al., 2015). Specifically, complement protein proteolytic fragments C3a and 
C5a as well as TNFα prime rat hepatocytes for proliferation in vitro (Webber et al., 1998; 
Strey et al., 2003), and Kupffer cell depletion limits DNA synthesis following ethanol 
induced liver injury in vivo (Owumi et al., 2014). In our study, we observed a decrease in 
the expression of pro-inflammatory molecules, Tnfa and Ccl2, which could contribute to 
the delay in regeneration we observe. HMMR deficiency could therefore be the indirect 
cause of the delayed regeneration due to decreased inflammation. HMMR is present on 
macrophages, which further supports this idea (Zaman et al., 2005). In fact, when we 
evaluated Hmmr expression in hepatocytes and non-parenchymal cells (NPC), the NPC 
fraction had approximately 20 times the amount of Hmmr expression compared to the 
hepatocyte fraction at both 48 and 72 hours after CCl4 exposure (data not shown). 
Despite this, no one has specifically evaluated HMMR in hepatocytes, or proliferation of 
hepatocytes with or without HMMR. Therefore, further exploration into cell type specific 
expression patterns should be completed to determine if HMMR is contributing to 
hepatocyte regeneration directly or indirectly via inflammation.   
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 Our initial interest in HMMR came from the increased HMMR expression 
observed in Has3-/- mice, which occurred concomitant with hepatic wound healing after 
acute liver injury (see Chapter 3). Specifically, Has3-/- mice have increased injury and 
inflammation but, in turn, they also display increased regeneration and matrix 
metabolism. This was associated with increased HMMR expression compared to wild-
type mice. Conversely, in HMMR mice, we observe no difference in liver injury, but a 
delay in inflammation, regeneration, and matrix remodeling. This inverse relationship 
between Has3-/- and Hmmr-/- mice strongly suggests a positive role for HMMR in 
hepatic wound healing and will be further discussed in Chapter 7.  
 In conclusion, we are the first to show that HMMR is involved in liver repair.  This 
is supported by our data which demonstrated that mice lacking HMMR exhibit 
decreased hepatic inflammation despite no differences in liver injury, delayed clearance 
of necrotic tissue, decreased hepatic HA deposition, delayed hepatocyte proliferation, 
and decreased matrix remodeling. This suggests roles for HMMR in multiple cell types, 
including macrophages, HSC, and perhaps even hepatocytes, and lays the foundation 



















Portions of this chapter are adapted from 1) McCracken, JM et al. “Differential effects of 
hyaluronan synthase 3 deficiency after acute vs chronic liver injury in mice” 
Fibrogenesis and Tissue Repair 2016; Licensed under Creative Commons Attribution 
4.0 International License 
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Abstract 
 Following acute liver injury, the liver undergoes periods of inflammation, 
regeneration, and matrix remodeling and completely restores normal structure and 
function. Following chronic injury, persistent inflammation results in activation of hepatic 
stellate cells that synthesize extracellular matrix resulting in fibrosis. If the injurious 
agent is removed, matrix degradation can remodel and remove the scar. We have 
previously shown that HA and the HA receptor HMMR play a role in hepatic wound 
healing following acute liver injury. Specifically, mice deficient in HAS3 have increased 
injury but they also have increased matrix metabolism. This led us to hypothesize that 
Has3-/- mice will have a similar increase in matrix metabolism following chronic carbon 
tetrachloride (CCl4) exposure resulting in less fibrosis compared to wild-type mice. We 
have also shown that mice deficient in HMMR have similar injury after acute CCl4 
exposure but decreased matrix metabolism compared to wild-type mice. We therefore 
hypothesize that Hmmr-/- mice will have increased fibrosis after chronic CCl4 due to 
decreased matrix metabolism. To induce fibrosis, we exposed each genotype to CCl4 
twice a week for five weeks and evaluated both matrix synthesis and matrix degradation 
parameters. Has3-/- mice had increased fibrotic transcript levels, but similar fibrosis 
compared to wild-type mice. This disconnect was attributed to increased matrix 
metabolism in Has3-/- mice, likely due to increased MMP13 activity. Hmmr-/- mice had 
lower levels of pro-fibrotic transcripts, but no difference in frank fibrosis compared to 
wild-type mice. Like Has3-/- mice, this disconnect was attributed to decreased matrix 
metabolism in Hmmr-/- mice. Together these data suggest that HA and HMMR play a 
role in chronic liver injury. 
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 Introduction 
  Chronic liver injury can be caused by a number of etiologic agents including viral 
hepatitis, obesity, and chronic alcohol abuse (Sebastiani et al., 2014; Stal, 2015; Crespo 
Yanguas et al., 2016). Liver disease can progress from simple steatosis to early and 
advanced fibrosis if exposure to the etiologic agent persists (Bataller and Brenner, 
2005; Crespo Yanguas et al., 2016). Following acute liver injury, there are periods of 
inflammation, regeneration, and matrix remodeling that result in a complete recovery, or 
regenerative repair (Bohm et al., 2010; Balaji et al., 2015; Pritchard and McCracken, 
2015). In chronic liver injury, inflammation is sustained and fibrosis can occur 
(Friedman, 2008b; Pellicoro et al., 2014). Fibrosis is characterized by an excess 
accumulation of extracellular matrix (ECM), primarily type-I collagen fibers (Bataller and 
Brenner, 2005; Friedman, 2008b). The excess ECM disrupts normal tissue structure 
and function (Bataller and Brenner, 2005; Crespo Yanguas et al., 2016). Fibrosis can 
resolve, to a point, but if it progresses to advanced stages such as cirrhosis, a liver 
transplant becomes the only treatment option (Bataller and Brenner, 2005; Tsochatzis 
et al., 2014; Crespo Yanguas et al., 2016). Due to the shortage of livers available, as 
well as the cost and invasiveness of organ transplant, there is need for novel 
therapeutics to halt and reverse the progression of fibrosis (Saidi et al., 2012; Rai, 
2013).  
Hyaluronan (HA) is a non-sulfated glycosaminoglycan that is synthesized by one 
of three hyaluronan synthases (HAS1, 2, or 3) (Jiang et al., 2007; Jiang et al., 2011). 
These enzymes differ in their synthetic capacity and expression profiles depending on 
tissue and developmental stage (Spicer and McDonald, 1998; Itano et al., 1999). 
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Following tissue injury, HA is both synthesized and degraded and has different signaling 
capabilities depending on the size of HA and HA receptors present (Turley et al., 2002; 
Decleves et al., 2012; Tolg et al., 2014). There are several cell surface receptors that 
can interact with HA and our focus is on HA mediated motility receptor (HMMR) due to 
its unique properties related to wound repair (Savani et al., 2001; Turley et al., 2002). 
For example, HMMR can be both intracellular and extracellular and plays roles in cell 
migration and cell proliferation, respectively (Savani et al., 2000; Jiang et al., 2010; 
Telmer et al., 2011). In the context of chronic injury and fibrotic wound repair, it is likely 
that extracellular HMMR plays a more prominent role. For example, in mice, following 
an excisional skin wound, HMMR promotes macrophage and fibroblast migration and 
wound closure, two processes that are vitally important in liver fibrosis progression (Tolg 
et al., 2006; Tolg et al., 2012). We raise the question-does HA or HMMR play a role in 
chronic liver injury and fibrosis. 
 We have previously shown (Chapters 3 and 4), that HA and HMMR play a role in 
the hepatic response to acute carbon tetrachloride (CCl4) exposure. Specifically, mice 
deficient in HAS3, one of the enzymes that makes HA, have increased liver injury and 
inflammation compared to wild-type mice after acute CCl4 exposure. They also had, 
however, increased matrix metabolism. These differences were associated with an 
increase in hepatic HA content in Has3-/- mice compared to wild-type mice and 
upregulation of several HA receptors, including HMMR. This led us to examine Hmmr-/- 
mice after acute liver injury. We showed in Chapter 4, that these mice had decreased 
matrix metabolism, despite no difference in liver injury compared to wild-type mice after 
acute CCl4 exposure. Based on the data collected following acute CCl4 (Chapters 3 and 
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4), we hypothesize that Has3-/- mice will have increased matrix remodeling compared 
to wild-type after chronic CCl4 exposure which would result in decreased fibrosis. 
Further we hypothesize that Hmmr-/- mice will have a delayed wound healing including 
matrix remodeling resulting in increased fibrosis compared to wild-type mice. To test 
these hypotheses, we used chronic CCl4 exposure to induce fibrosis in wild-type,   




Fibrosis in wild-type and Has3-/- mice following chronic CCl4 exposure 
 To evaluate a possible role for HA in hepatic fibrosis and resolution, wild-type 
and Has3-/- mice were exposed CCl4 twice a week for five weeks. Has3-/- mice have 
increased injury and inflammation following acute liver injury induced by a single 
exposure to CCl4. They also display faster wound healing, including increased matrix 
metabolism. We therefore hypothesized that Has3-/- mice will have decreased fibrosis 
following chronic CCl4 exposure. Following chronic CCl4, hepatic Acta2 increased in 
both wild-type and Has3-/- mice and this induction was higher in Has3-/- mice compared 
to wild-type mice (Figure 5-1A). Despite this increase in Acta2 transcripts, there was no 
difference in αSMA protein after chronic CCl4 between wild-type or Has3-/- mice (Figure 
5-1B and C). Hepatic transcripts for Col1a1, Col1a2, and Serpinh1 (the gene encoding 
for HSP47-a collagen specific chaperone) were all increased in both genotypes 
following chronic CCl4 exposure (Figure 5-1D-F). The induction in each of these 




Figure 5-1: Hepatic stellate cell activation in wild-type and Has3-/- mice following 
chronic CCl4. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. Hepatic transcript accumulation of A. Acta2 was evaluated using real time PCR. 
B. Quantification and C. representative blot for αSMA protein. GAPDH was used as a 
loading control. Real time PCR was used to measure transcript accumulation of D. 
Col1a1, E. Col1a2, and F. Serpinh1 in wild-type and Has3-/- livers following chronic 
CCl4 exposure. Black bars represent wild-type mice and grey bars represent Has3-/- 
mice for figures 1-6. Data are presented as fold change over each genotypes own oil. * 
represents p<0.05 comparing each genotypes CCl4 value to its own oil, + represents 
p<0.05 comparing CCl4 between genotypes. N = 5 – 6 
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 increase in the pro-fibrotic environment.  
 Surprisingly, despite the increased pro-fibrotic signature observed in Has3-/- 
mice compared to wild-type mice, there is not increased fibrosis in Has3-/- mice. 
Picrosirius red staining was used to evaluate ECM accumulation, and while there was 
an increase in hepatic ECM in both wild-type and Has3-/- mice following chronic CCl4, 
there was not a difference between genotypes (Figure 5-2A and B). Similarly, there is 
no difference in total collagen content (extrapolated from measured hydroxyproline 
content) between wild-type and Has3-/- mice following chronic CCl4 (Figure 5-2C). 
These data suggest that there are increased hepatic pro-fibrotic signatures in 
chronically injured livers from Has3-/- mice, but this did not lead to an increase in 
fibrosis in Has3-/- mice compared to wild-type mice.  
 
Matrix remodeling in Has3-/- and wild-type mice following chronic CCl4 exposure 
 Fibrosis is counterbalanced by matrix metaloproteinases (MMPs) produced 
primarily by recruited macrophages. Because there was an obvious disconnect between 
pro-fibrotic gene signatures in the liver and the extent to which this influenced fibrosis, 
we hypothesized that there was an increase in matrix metabolism in Has3-/- mice 
compared to wild-type mice. This is similar to what we observed in Has3-/- mice 
compared to wild-type mice after acute CCl4 exposure. Hepatic accumulation of mRNAs 
encoding for Mmp2, a mouse gelatinase, increased in both genotypes after chronic CCl4 
exposure and this induction was not different between Has3-/- and wild-type mice 
(Figure 5-3A). A similar trend was seen for Mmp9, another mouse gelatinase (Figure 5-





Figure 5-2: Hepatic fibrosis in wild-type and Has3-/- mice following chronic CCl4 
exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. A. Quantification and B. representative histology of picrosirius red staining used 
to measure ECM accumulation by morphometry in wild-type and Has3-/- livers following 
chronic CCl4 exposure. * denotes central veins and + denotes the portal triads in 
images. C. Hydroxyproline was measured and extrapolated to collagen content in both 
wild-type and Has3-/- mice. * represents p<0.05 comparing each genotypes CCl4 value 
to its own oil, N = 6 – 7 
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induced by repeated CCl4 exposure, and similar to what we observed in acute CCl4 
exposure, this induction was higher in Has3-/- mice compared to wild-type mice (Figure 
5-3C). MMP enzymes are released into the extracellular space in a pro-form and must 
be cleaved to their active form (Duarte et al., 2015). We, therefore, measured the ratio 
of active to pro form of MMP13 in liver following chronic CCl4 exposure and found this 
ratio was increased in Has3-/- mice compared to wild-type mice, suggesting increased 
MMP13 activity (Figure 5-3D and E). Tissue inhibitors of MMPs (TIMPs) inhibit MMP 
activity and provide a counterbalance to matrix metabolism (Duarte et al., 2015). Timp1 
transcripts were increased in both genotypes following chronic CCl4 exposure and this 
induction was not different between genotypes (Figure 5-3F).  
 While transcript and protein data suggest that matrix remodeling is increased in 
Has3-/- mice compared to wild-type mice following chronic CCl4 exposure, this is not a 
direct measurement of matrix degradation. In order to evaluate the actual matrix 
metabolism, in situ zymography was used (described in detail in Chapters 2 and 3) 
Chronic CCl4 exposure increased both the area and intensity of signal measured in wild-
type and Has3-/- mice (Figure 5-4A-C). This matrix metabolism (area and intensity) was 
increased in Has3-/- mice compared to wild-type mice. Due to the difference in Mmp13 
mRNAs, as well as the increased ratio of active-MMP13 to pro-MMP13, we utilized a 
MMP13 specific inhibitor to inhibit MMP13 activity. When the inhibitor was used, matrix 
degradation in Has3-/- mice was inhibited while the matrix degradation in wild-type mice 
was unaffected.  These data together demonstrate that matrix metabolism was  
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Figure 5-3: Markers for matrix metabolism in wild-type and Has3-/- mice following 
chronic CCl4 exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. Real time PCR was used to evaluate hepatic transcript accumulation of A. 
Mmp2, B. Mmp9, and C. Mmp13 in wild-type and Has3-/- mice after chronic exposure to 
CCl4. Data are presented as fold over each genotypes own oil. D. Quantification and E. 
representative blot for the active and pro form of MMP13. GAPDH was used as a 
loading control. Data are presented as a ratio of active to pro form. F. Hepatic transcript 
levels of Timp1 were measured using real time PCR. Data are presented as fold change 
over each genotypes own oil. * represents p<0.05 comparing each genotypes CCl4 
value to its own oil, + represents p<0.05 comparing CCl4 between genotypes. N = 6 – 7 
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Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. A. Representative in situ zymography (ISZ) histology used to evaluate active 
matrix metabolism in fresh frozen liver sections of wild-type and Has3-/- mice. The top 
panel is ISZ for wild-type mice and the bottom panel is ISZ for Has3-/- mice. The left-
most column is DAPI staining for nuclei, the middle column is Oregon green signal, and 
the right most column is the merged images. An MMP13-specific inhibitor was used to 
determine MMP13’s contribution to matrix metabolism. B. Quantification of the total area 
above a set threshold and C. intensity of the signal. * denotes central veins and + 
denotes the portal triads in images. Data are presented as fold change over own oil. * 
represents p<0.05 comparing each genotypes CCl4 value to its own oil, + represents 
p<0.05 comparing CCl4 between genotypes, # represents p<0.05 between CCl4 and 
CCl4 + Inh within each genotype. N = 6 – 7  
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increased in Has3-/- mice compared to wild-type mice likely due to increased MMP13 
activity. 
 
Macrophage accumulation following chronic CCl4 exposure in wild-type and 
Has3-/- mice 
 The primary source of matrix degrading enzymes is recruited macrophages 
(Duarte et al., 2015). We therefore evaluated macrophage accumulation following 
chronic CCl4 exposure in both wild-type and Has3-/- mice. As a surrogate marker for 
macrophage content, we evaluated the hepatic transcript accumulation of two 
macrophage markers, Emr1 and Cd11b. Emr1 (the gene that encodes for F4/80) 
transcripts trend toward an increase in both genotypes, however neither genotype was 
significantly higher than its own baseline (Figure 5-5A). Hepatic Cd11b accumulation 
was increased in Has3-/- mice but not in wild-type mice in response to chronic CCl4 
(Figure 5-5B). Immunofluorescent staining for F4/80 showed no difference between 
wild-type and Has3-/- mice in total amount of F4/80 positive cells in the liver following 
chronic CCl4 (Figure 5-5C and D). This demonstrates that there was no increase in 
macrophage recruitment to the liver, but it does not prove there is no difference in 
localization of those macrophages to fibrotic septae. In fact, the increased matrix 
metabolism suggests either there was increased macrophage localization to the fibrotic 
scar or that each macrophage reaching the fibrotic scar had greater matrix degrading 
activity in Has3-/- mice than wild-type mice. Future work should be done to more closely 
evaluate macrophage localization.  
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Figure 5-5: Macrophage accumulation in wild-type and Has3-/- mice following 
chronic CCl4 exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. Real time PCR was used to evaluate hepatic transcript accumulation of A. Emr1 
and B. Cd11b. Data are presented as fold change over each genotypes own oil. C. 
Quantification and D. representative histology for F4/80 positive macrophages in wild-
type and Has3-/- livers after chronic CCl4 exposure. The green signal is F4/80 and DAPI 
was used to visualize nuclei. * denotes central veins and + denotes the portal triads in 
images.  * represents p<0.05 comparing each genotypes CCl4 value to its own oil. N = 6 
– 7 
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HA and HMMR levels in Has3-/- and wild-type mice following chronic CCl4 
exposure 
 Following acute CCl4 exposure, hepatic HA content was greater in Has3-/- mice, 
despite lacking one enzyme that makes HA. Following chronic CCl4, there was limited 
HA accumulation near the fibrotic scar in both wild-type and Has3-/- mice (Figure 5-6A 
and B). This accumulation was not different between the two genotypes.  
 We took a particular interest in the HA receptor HMMR due to its role in cell 
migration, including migration of macrophages and fibroblasts. HMMR induction was 
increased in Has3-/- mice compared to wild-type mice following acute CCl4 exposure. 
Similarly, hepatic Hmmr transcripts were induced following chronic CCl4 in both 
genotypes and this induction was greater in Has3-/- compared to wild-type mice (Figure 
5-6C). HMMR protein levels were increased above baseline in Has3-/- mice but not 
wild-type mice following chronic CCl4 (Figure 5-6D and E). Taken together, although we 
observed increased pro-fibrotic transcripts, there was not increased fibrosis, likely 
because of the increased matrix metabolism in Has3-/- mice compared to wild-type 
mice.  
 
Hepatic fibrosis following chronic CCl4 exposure in wild-type and Hmmr-/- mice 
 Due to the importance of macrophage migration in fibrosis resolution, HMMR’s 
role in macrophage migration following excisional skin wounds, and the induction of 
HMMR after chronic CCl4 we wanted to explore a possible role for HMMR in hepatic 
fibrosis. To do this we exposed wild-type and Hmmr-/- to CCl4 twice a week for five 




Figure 5-6: HA accumulation and HMMR levels in wild-type and Has3-/- mice 
following chronic CCl4 exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. A. Quantification and B. representative histology for hepatic HA accumulation 
measured using HA binding protein (HABP). The green signal is HABP and DAPI was 
used to visualize nuclei.  * denotes central veins and + denotes the portal triads in 
images. C. Real time PCR was used to measure hepatic accumulation of Hmmr in wild-
type and Has3-/- livers after chronic CCl4 exposure. D. Quantification and E. 
representative blot for HMMR protein. GAPDH was used as a loading control. Data are 
presented as fold change over each genotypes own oil. * represents p<0.05 comparing 
each genotypes CCl4 value to its own oil, + represents p<0.05 comparing CCl4 between 
genotypes. N = 6 – 7 
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 Hmmr-/- mice have a delay in wound healing, including matrix metabolism. This led us 
to hypothesize that Hmmr-/- mice would have increased fibrosis compared to wild-type 
mice after chronic CCl4.  
 Hepatic Acta2 mRNAs were increased in wild-type mice following chronic CCl4 
but not in Hmmr-/- mice (Figure 5-7A). Similar to what was found in Has3-/- mice, 
protein levels of αSMA were not different in either wild-type or Hmmr-/- mice after 
chronic CCl4 (Figure 5-7B and C). Transcript levels of Col1a1 and Col1a2, the genes 
that encode for type 1-collagen proteins, were induced in both genotypes after chronic 
CCl4 and this induction was greater in wild-type mice compared to Hmmr-/- mice (Figure 
5-7D and E). This trend was similar for Serpinh1, the gene encoding HSP47-a collagen 
specific chaperone; this transcript was induced in both genotypes but the induction was 
stunted in Hmmr-/- mice compared to wild-type mice (Figure 5-7F). These transcript 
data suggest that HSC activation is impaired in Hmmr-/- mice compared to wild-type 
mice after chronic CCl4 exposure. 
 To evaluate frank fibrosis, picrosirius red was again used to measure total ECM 
accumulation. Despite the decreased fibrotic markers observed in Hmmr-/- mice, there 
was no difference in ECM accumulation between genotypes (Figure 5-8A and B). This 
is further supported by no difference in collagen levels, extrapolated from measured 
hydroxyproline content, between wild-type and Hmmr-/- mice following chronic CCl4 
exposure (Figure 5-8C). Together, these data demonstrate that despite a decrease in 
pro-fibrotic transcripts, the frank fibrosis was not different between wild-type and   




Figure 5-7: Hepatic stellate cell activation in wild-type and Hmmr-/- mice following 
chronic CCl4 exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. A. Real time PCR was used to evaluate Acta2 transcript levels in livers of wild-
type and Hmmr-/- mice following chronic CCl4 exposure. B. Quantification and C. 
representative blot for αSMA protein. GAPDH was used as a loading control. Hepatic 
accumulation of D. Col1a1, E. Col1a2, and F. Serpinh1 transcripts were measured 
using real time PCR. Data are presented as fold change over each genotypes’ own oil. 
Black bars represent wild-type mice and grey bars represented Hmmr-/- mice for figures 
7-10. * represents p<0.05 comparing each genotypes CCl4 value to its own oil, + 





Figure 5-8: Hepatic fibrosis in wild-type and Hmmr-/- mice following chronic CCl4 
exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. A. Quantification and B. representative histology of picrosirius red staining, 
which was used to evaluate ECM accumulation, in wild-type and Hmmr-/- livers 
following chronic CCl4 exposure. * denotes central veins and + denotes the portal triad 
in images. C. Collagen content was measured via extrapolation from hepatic 
hydroxyproline content. * represents p<0.05 comparing each genotypes CCl4 value to 
its own oil. N = 6 – 7 
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Matrix remodeling following chronic CCl4 exposure in wild-type and Hmmr-/- mice 
 After acute CCl4, matrix metabolism was lower in Hmmr-/- mice compared to 
wild-type mice. We, therefore, hypothesized that decreased matrix metabolism could 
account for the disconnect between lower collagen transcripts and no difference in 
fibrosis between wild-type and Hmmr-/- mice after chronic CCl4. There was no 
difference in the induction of Mmp2 transcripts between wild-type and Hmmr-/- mice 
after chronic hepatotoxin exposure (Figure 5-9A). Mmp9 transcripts, however, were 
induced in wild-type mice following chronic CCl4 but not in Hmmr-/- (Figure 5-9B). 
MMP13 appeared to be the main player in the increased matrix remodeling observed in 
Has3-/- mice, but Mmp13 induction was not different between wild-type and Hmmr-/- 
mice following chronic CCl4 exposure (Figure 5-9C). Timp1, the primary inhibitor of 
MMPs, was also not different after chronic CCl4 exposure between wild-type and Hmmr-
/- mice (Figure 5-9D).  
 Again, transcript levels cannot evaluate matrix metabolism directly, so in situ 
zymography was used (Figure 5-9E). After chronic CCl4, there was a trend toward a 
decrease (p=0.07) in the total area matrix degrading activity in Hmmr-/- mice compared 
to wild-type mice (Figure 5-9F) and the intensity of the signal detected was lower in 
Hmmr-/- compared to wild-type mice (Figure 5-9G). These data suggest that matrix 
metabolism is lower following chronic CCl4 exposure in Hmmr-/- mice compared to wild-
type mice. This helps to explain the lower pro-fibrotic transcripts but lack of a difference 
in frank fibrosis between genotypes.  
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Figure 5-9: Matrix remodeling in wild-type and Hmmr-/- mice following chronic 
CCl4 exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. Real time PCR was used to evaluate hepatic transcript accumulation of A. 
Mmp2, B. Mmp9, C. Mmp13, and D. Timp1. Data are presented as fold change over 
each genotypes’ own oil. E. Representative histology for in situ zymography to evaluate 
matrix remodeling. The green signal indicates active matrix metabolism and DAPI was 
used to visualize nuclei. * denotes central veins and + denotes the portal triad in 
images. F. Area and G. intensity of positive signal in arbitrary units. * represents p<0.05 
comparing each genotypes CCl4 value to its own oil, + represents p<0.05 comparing 
CCl4 between genotypes. N = 5 – 7 
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Macrophage accumulation following chronic CCl4 exposure in wild-type and 
Hmmr-/- mice 
 Macrophages that have localized to the fibrotic scar are the primary source of 
MMPs contributing to fibrosis regression. HMMR is important in macrophage migration 
in skin wound healing, so we hypothesized that Hmmr-/- mice would have decreased 
macrophage accumulation in the liver, which would then account for the decreased 
matrix metabolism we observe in Hmmr-/- mice compared to wild-type mice. We 
evaluated transcripts for the macrophage markers Emr1, Cd11b, and Ccr2. Emr1 
transcripts increased in both genotypes following chronic CCl4 exposure and this 
accumulation was not different between wild-type and Hmmr-/- mice (Figure 5-10A). 
Unlike Emr1, Cd11b and Ccr2 transcripts were increased above baseline in wild-type 
mice following chronic CCl4 but not in Hmmr-/- mice (Figure 5-10B and C). These 
transcript data, together with decreased matrix remodeling, suggests that there was a 
decrease in macrophage accumulation in Hmmr-/- mice relative to macrophage 
accumulation in wild-type mice, although more work should be done to localize 
macrophages in situ.  
 
Discussion 
 Chronic inflammation is a hallmark of organ fibrogenesis and HA is implicated in 
the pathogenesis of chronic inflammatory diseases including asthma and irritable bowel 
disease (IBD). Specifically, HA is increased in the bronchial alveolar lavage fluid (BALF) 
from asthma patients compared to healthy controls and is associated with increased 








Figure 5-10: Macrophage accumulation in wild-type and Hmmr-/- mice following 
chronic CCl4 exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. Real time PCR was used to evaluate total hepatic accumulation of A. Emr1, B. 
Cd11b, and C. Ccr2 in wild-type and Hmmr-/- liver following chronic CCl4 exposure. * 
represents p<0.05 comparing each genotypes CCl4 value to its own oil, + represents 
p<0.05 comparing CCl4 between genotypes. N = 5 – 7 
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HA is also found in the BALF from patients with idiopathic lung fibrosis and correlates 
with white blood cell counts (Bjermer et al., 1989). Patients with IBD have increased HA 
deposition in their colon, and this HA is thought to form cable-like structures that bind 
and trap leukocytes and promote chronic inflammation, which can lead to fibrosis (de la 
Motte et al., 2003; Kessler et al., 2008; de la Motte, 2011). HA is increased in the 
plasma of patients with chronic liver disease (Engstrom-Laurent et al., 1985; Gudowska 
et al., 2016). In fact, this increase is correlated to disease severity (Lee et al., 2010; 
Gudowska et al., 2016). Like other solid organs, chronic hepatic injury results in chronic 
inflammation and fibrosis (Pellicoro et al., 2014). Despite the connection between HA 
and fibrosis and the use of HA as a biomarker for liver disease, little work has been 
done to investigate if a pathogenic role for HA in advanced liver disease exists. In order 
to investigate a role for HA in the progression of liver fibrosis, we utilized Has3-/- and 
wild-type mice and exposed them to chronic CCl4 injections. Following acute liver injury, 
Has3-/- mice display increased matrix metabolism compared to wild-type mice. 
Therefore, we hypothesized that Has3-/- mice would also have increased matrix 
metabolism compared to wild-type mice following chronic CCl4 exposure, resulting in 
decreased fibrosis in Has3-/- mice. While we did observe increased matrix metabolism 
in Has3-/- mice compared to wild-type mice, we also found increased pro-fibrotic 
transcripts. This disconnect between matrix synthesis and matrix metabolism resulted in 
similar fibrosis between wild-type and Has3-/- mice after chronic CCl4 exposure.  
 While chronic inflammation promotes fibrosis, a decrease in recruited 
macrophages can also be detrimental when it comes to regression of the hepatic scar. 
In fact, Duffield, et al, used CD11b-DTR transgenic mice to deplete macrophages at 
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various stages of fibrosis and found that depleting macrophages during CCl4 induced 
fibrosis progression attenuated fibrosis, but deleting them after fibrosis was established 
attenuated the removal of the fibrotic scar (Duffield et al., 2005). The macrophages 
responsible for matrix degradation, scar-associated macrophages (SAMs), are the main 
source of MMPs including MMP13 and this MMP13 activity is vital to removing the 
fibrotic scar formed after chronic CCl4 exposure (Fallowfield et al., 2007b). We found 
that Has3-/- mice have an increase in active MMP13 and a subsequent increase in 
matrix remodeling. This helps to explain the disconnect between the pro-fibrotic 
transcript levels and frank fibrosis in Has3-/- mice. It also suggests that Has3-/- mice are 
better able to recruit macrophages to the fibrotic scar compared to wild-type mice after 
chronic CCl4 exposure, although more work should be done to localize SAMs to the 
fibrotic septae. Additionally, Has3-/- mice have increased HMMR, a receptor known to 
promote macrophage migration, suggesting the HA:HMMR interaction may be important 
for macrophage migration and subsequent matrix degradation. 
 HA itself is a known inducer of MMP13 (Fieber et al., 2004), and because Has3-/- 
mice have increased hepatic HA deposition following acute CCl4 exposure, it is possible 
that they also have increased HA deposition following chronic CCl4 exposure, which 
leads to increased matrix metabolism. Although, we do see increased hepatic HA 
accumulation following chronic CCl4 exposure in both wild-type and Has3-/- mice, we do 
not observe any differences between the two genotypes. Additionally, this increase is 
not the same extent as we observed following acute CCl4 exposure. This does not, 
however, conclusively rule out any differences in hepatic HA deposition between 
genotypes, since we only measured a single time point in a process that occurs over 
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several days. Thus it is possible we missed the peak of hepatic HA accumulation, and a 
more thorough characterization of the resolution of fibrosis in Has3-/- mice should be 
done. 
 Similar to results found in acute CCl4 studies (Chapter 3), Has3-/- mice had an 
increase in Hmmr transcript accumulation compared to wild-type mice following chronic 
CCl4 exposure. HMMR protein levels in Has3-/- mice were elevated above baseline 
after chronic CCl4 exposure; this was not the case in wild-type mice. HMMR plays a role 
in macrophage and fibroblast migration and wound healing in models of excisional skin 
wounds, resulting in a collagen scar similar to that observed in hepatic fibrosis (Tolg et 
al., 2006; Tolg et al., 2012). Therefore, we hypothesized that HMMR is playing a role in 
hepatic fibrogenesis and/or fibrosis regression. In order to investigate HMMR’s role in 
hepatic fibrosis more closely, Hmmr-/- mice were exposed to chronic CCl4 and fibrosis, 
and subsequent matrix metabolism parameters were measured. After acute liver injury, 
Hmmr-/- mice had decreased matrix metabolism, and we hypothesized a similar 
phenomenon would occur after chronic CCl4 exposure, resulting in increased fibrosis in 
Hmmr-/- mice compared to wild-type mice.  
 We first evaluated several pro-fibrotic transcripts to evaluate matrix synthesis. 
We found that hepatic pro-fibrotic markers were lower in Hmmr-/- mice compared to 
wild-type mice following chronic CCl4 exposure. This, however, did not translate to 
decreased fibrosis. In fact, the Hmmr-/- mice had the same amount of fibrosis as their 
wild-type controls after chronic hepatotoxin exposure. Although we did not observe 
increased fibrosis in Hmmr-/- mice compared to wild-type mice, the disconnect between 
lower pro-fibrotic transcripts and no difference in fibrosis still supports our hypothesis.  
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 HMMR contributes to the macrophage migration in both the skin and the lung 
(Zaman et al., 2005; Tolg et al., 2012). Specifically, a HMMR mimetic delays 
macrophage migration into an excisional skin wound (Tolg et al., 2012). Similarly, a 
HMMR blocking antibody prevents the accumulation of macrophages following 
bleomycin induced lung injury (Zaman et al., 2005). In the current study, we observed a 
decrease in hepatic Cd11b and Ccr2 transcripts, two macrophage-associated markers, 
in Hmmr-/- mice compared to wild-type mice after chronic CCl4 exposure. We also 
showed a decrease in the matrix metabolism measured by in situ zymography in the 
Hmmr-/- mice compared to wild-type mice. Our data demonstrate that the absence of 
HMMR is associated with a decrease in macrophage localization to the fibrotic scar. By 
contrast, in Has3-/- mice, increased HMMR levels may be contributing to the increased 
macrophage localization and subsequent increase in matrix metabolism compared to 
wild-type mice following chronic CCl4 exposure. This suggests that HMMR likely plays a 
role in the localization of macrophages to the hepatic scar for its subsequent 
degradation following chronic CCl4 exposure. Therefore, we propose that HMMR, likely 
on macrophages, plays a role in the regression of the fibrotic scar after chronic liver 
injury and not in the development of fibrosis.  Future work will directly explore the impact 
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Abstract 
 Biological differences exist between strains of laboratory mice, and it is becoming 
increasingly evident that there are differences between sub-strains. In the C57BL/6 
mouse, the primary sub-strains are 6J and 6N. Previous studies have demonstrated that 
6J and 6N mice differ in response to many experimental models of human disease. The 
aim of our study was to determine if differences exist between 6J and 6N mice in terms 
of their response to acute and chronic carbon tetrachloride (CCl4) exposure. Mice were 
given CCl4 once and were euthanized 12 to 96 hours later or given CCl4 twice a week 
for five weeks and euthanized 72 hours after the last injection. Control mice received 
olive oil injection(s). Relative to 6J mice, we found that 6N mice had increased liver 
injury but more rapid repair. This was due to the increased speed with which necrotic 
hepatocytes were removed in 6N mice and was directly related to increased recruitment 
of macrophages to the liver. In parallel, enhanced liver regeneration was observed in 6N 
mice relative to 6J mice. Hepatic stellate cell activation occurred earlier in 6N mice, but 
there was no difference in matrix metabolism between sub-strains. Following chronic 
CCl4 exposure, 6N mice had increased pro-fibrotic markers and increased fibrosis. 
Taken together, these data demonstrate specific and significant differences in how the 
C57BL/6 sub-strains respond to acute and chronic CCl4, which has important 
implications for all mouse studies utilizing this model, including those in the previous 
chapters involving Has3-/- and Hmmr-/- mice.  
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Introduction 
 Differences in biological responses between strains of mice have been known for 
several years and recently biological differences have been discovered between sub-
strains of mice. The C57BL/6 mouse strain has several sub-strains, the two most 
common being C57BL/6N (6N) and C57BL/6J (6J). Recently, there have been reports 
on these two sub-strains having differential responses in several models including in 
alcohol preferences and diet-induced obesity (Ramachandra et al., 2007; Nicholson et 
al., 2010). These two sub-strains are characterized by having a wild-type nicotinamide 
nucleotide transhydrogenase (Nnt), 6N, or mutated Nnt, 6J. Nnt is important for the 
production of NADPH in the inner mitochondrial membrane and is used in mitochondrial 
antioxidant defense. 
 Sub-strain differences are also important to consider when using genetically 
modified mice. For example, two separate laboratories reported conflicting results on 
the role JNK2 plays in acetaminophen (APAP)-induced liver injury. Nakagawa, H. et al. 
reported that Jnk2-/- mice are partially protected from APAP-induced liver injury while 
Bourdi et al. reported that Jnk2-/- mice have exacerbated liver injury relative to wild-type 
mice. It was determined that each lab used a different B6 sub-strain as a control, and 
that these two sub-strains (6N and 6J) differentially responded to APAP exposure 
(Bourdi et al., 2008; Nakagawa et al., 2008; Bourdi et al., 2011). Recetly, Duan, L et al. 
reported that the 6N mice have increased liver injury, likely due to increase APAP 
adduct formation and increased mitochondrial dysfunction (Duan et al., 2016). Not only 
does this point out the importance of utilizing the correct sub-strain as a control for any 
genetically modified mouse study, but it raises the question of a potential differential 
161	
response between these sub-strains in other commonly used mouse models of liver 
injury. 
 Given the findings in APAP-induced liver injury, we hypothesized that a 
differential response would occur between 6N and 6J mice after acute and chronic CCl4 
exposure; another commonly used model of liver injury and disease. CCl4 causes 
centrilobular necrosis shortly after exposure (Weber et al., 2003). This liver injury and its 
subsequent repair is analogous to the well-established model of wound healing that 
occurs in the skin; the stages include inflammation, regeneration, and matrix remodeling 
(Pellicoro et al., 2014; Balaji et al., 2015). In the liver, inflammatory chemokines and 
cytokines are synthesized primarily by Kupffer cells, liver resident macrophages, which, 
in turn, recruit circulating neutrophils and monocytes to the liver that continue to 
synthesize inflammatory mediators (Aziz-Seible et al., 2011; Dixon et al., 2013). These 
infiltrating cells can exacerbate injury as well as remove dead and dying hepatocytes 
and, therefore, also actively participate in wound healing (Ramaiah and Jaeschke, 2007; 
Kiso et al., 2012; Mochizuki et al., 2014; Moles et al., 2014; Zigmond et al., 2014). 
Following injury, the liver regenerates to restore normal mass and function (Cienfuegos 
et al., 2014; Mao et al., 2014). Similar to skin wound healing, matrix remodeling occurs 
at the later stages of liver repair. This involves matrix synthesis, primarily by activated 
hepatic stellate cells (HSC), as well as matrix metabolism, primarily by macrophages 
(Guo and Friedman, 2007; Friedman, 2008a). Here we explored whether or not 
differences exist in hepatic injury and wound healing, including the inflammation, 
regeneration, and matrix remodeling stages, following acute CCl4 exposure between 6J 
and 6N mice.   
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 Following chronic liver injury, there are repeated cycles of injury and wound 
healing (Bataller and Brenner, 2005; Friedman, 2008b). The wound healing process 
becomes deregulated and excess extracellular matrix accumulates resulting in a fibrotic 
scar (Bataller and Brenner, 2005; Friedman, 2008b). Because 6N mice have increased 
injury following acute APAP overdose and we believe that a similar increase in 6N injury 
will be observed after acute CCl4 exposure, we hypothesized that 6N mice will have 
increased fibrosis after chronic liver injury. We induced chronic liver injury and fibrosis 
by exposing mice to CCl4 twice a week for five weeks (Constandinou et al., 2005). Any 
differences observed in injury, the wound healing response, or fibrosis between these 
two sub-strains is particularly important for this dissertation because the genetically 




Liver injury and steatosis after CCl4 exposure 
 To determine if 6N and 6J mice have a differential response to acute CCl4 
exposure, liver injury was evaluated by measuring plasma ALT activity.  This enzyme is 
released into circulation by dead and dying hepatocytes. Both strains had increased 
plasma ALT activity following CCl4 exposure, but 6N mice had greater plasma ALT 
activity compared to 6J mice 48 hours after CCl4 exposure (Figure 6-1A). By 72 hours 
after CCl4 exposure, ALT activity in 6N mice was not different than baseline, while ALT 
activity remained elevated in 6J mice (Figure 6-1A). By 96 hours after CCl4 exposure, 
plasma ALT returned to baseline in 6J mice (Figure 6-1A).  Because CCl4 causes 
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centrilobular necrosis, we also evaluated liver injury by histopathology.  Necrosis 
increased in both sub-strains following CCl4, however the area of necrosis increased in 
6N mice 12 hours following CCl4 exposure while the area of necrosis did not increase 
above baseline in the 6J mice until 48 hours after CCl4 exposure (Figure 6-1B and D). 
At 96 hours post-CCl4 exposure, 6N mice had less necrosis compared to 6J mice 
(Figure 6-1B and 1D). Together, these data demonstrate that 6N mice had increased 
injury, but also a faster recovery from that injury, after acute CCl4 exposure. 
  Hepatic triglyceride accumulation, measured biochemically and evident in H&E-
stained liver sections, also increased in both strains following CCl4 exposure (Figure 6-
1C and D). Contrary to plasma ALT levels and area of necrosis, 6J mice had more 
hepatic triglyceride than 6N mice 24h post CCl4 exposure. While the triglyceride levels 
in 6N mice returned to baseline by 48h post CCl4 exposure, levels in 6J mice did not 
return to baseline until 72h post CCl4 exposure (Figure 6-1C and D). 
 
Baseline CYP2E1 protein and activity  
 In order for CCl4 to induce liver injury it must undergo bioactivation by CYP2E1 
(Weber et al., 2003). Therefore, to eliminate the possibility that differential CYP2E1 
activity accounted for variation in the liver injury between sub-strains, we measured 
baseline hepatic CYP2E1. There was no difference in hepatic CYP2E1 mRNA or 
protein levels between 6N and 6J mice (Figure 6-2A - C) or in Cyp2e1 mRNA from 
isolated primary hepatocytes (Figure 6-2D). Similarly, there was no difference in the 
CYP2E1 activity between the two sub-strains as assessed by the hydroxylation of p-
nitrophenol to p-nitrocatechol using microsomes isolated from whole liver (Figure 6-2E).  
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Figure 6-1: Hepatic injury following acute CCl4 exposure. 
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Mice were exposed to CCl4 and euthanized 12, 24, 48, 72, or 96 hours later. A. Plasma 
ALT was determined by enzymatic assay. B. Quantification of necrosis evaluated by a 
board-certified pathologist blinded to experimental group. C. Total hepatic triglyceride 
content was determined by a biochemical assay. D. Representative histology of 
hematoxylin and eosin (H&E) stained liver sections showing necrosis around the central 
veins (+) of the liver, asterisks (*) indicate portal veins. A black dashed line outlines 
necrotic areas, defined as hyper-eosinophilic and lacking hepatocyte nuclei. The yellow-
boxed area is enlarged in the right panel next to each image to better depict steatosis at 
each time point. Throughout the chapter, the black squares/bars/solid lines represent 
data from 6J mice and white circles/bars/dashed lines represent data from 6N mice. 
Data are presented as mean ± standard error of mean. n=5-6, *, p ≤ 0.05 when 
comparing sub-strains at a single time point; + , p ≤ 0.05 when comparing the indicated 
CCl4 time point to the oil (control) of the same sub-strain 
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These findings suggest that the observed differences in liver injury were not due to sub-
strain specific differences in CCl4 bioactivation. 
 
In vitro hepatocyte sensitivity to CCl4 
 To determine if the increased liver injury observed in 6N mice was due to an 
increase in hepatotoxin sensitivity, primary hepatocytes from 6N and 6J mice were 
exposed to CCl4 for 24 hours at three different CCl4 concentrations. The higher 
concentrations (5 and 10mM) induced hepatocyte cell death detectable by lactate 
dehydrogenase (LDH) release 24h after CCl4 exposure (Figure 6-2F); morphological 
changes were obvious at all CCl4 concentrations (Figure 6-2G). However, there was no 
difference in the cell death between the two sub-strains (Figure 6-2F). This suggests 
that increased hepatocyte sensitivity to CCl4 is not responsible for the increased injury 
observed in the 6N mice compared to the 6J mice. 
 
Antioxidant defense following CCl4 
 6J mice have a mutation in the Nnt gene, which can attenuate antioxidant 
defense (Arkblad et al., 2005; Sheeran et al., 2010; Ronchi et al., 2013). However, 
reduced NNT activity does not make 6J mice more sensitive to CCl4-mediated liver 
injury as one might expect. In fact, the reverse was true: 6N mice are more sensitive to 
CCl4-induced liver injury than 6J mice. Therefore, we evaluated two additional 
parameters associated with antioxidant defense to determine if they were increased in 
6J mice to compensate for lack of functional NNT and perhaps responsible for the 
observed protection from CCl4-induced liver injury. Gclc, glutamate-cysteine ligase 
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Figure 6-2: CYP2E1 expression, protein content, and activity in vitro and in vivo. 
 
A – C. Control mice given an olive oil injection and euthanized 72 hours later were 
evaluated for A. Cyp2e1 mRNA and B, C. CYP2E1 protein from whole liver. D. Cyp2e1 
expression was determined in isolated hepatocytes.  E. CYP2E1 activity in microsomes 
isolated from whole liver was determined by the hydroxylation of p-nitrophenol to p-
nitrocatechol. F, G. Primary hepatocytes were isolated from 6N and 6J mice and 
exposed to 0, 1, 5, 10mM CCl4 for 24 hours. F. Death ratio was calculated from the 
amount of LDH released in the media verses the total amount of LDH in the cells and 
media. G. Cell morphology was evaluated in micrographs taken at the end of the 24h 
incubation. 
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 catalytic domain, is the rate-limiting step in glutathione synthesis, and important for 
antioxidant defense after CCl4 induced liver injury (Ip and Ko, 1996; Wong et al., 2014). 
Gclc mRNA increases rapidly in liver in both sub-strains of mice early following CCl4 
exposure and is not different between sub-strains at any time point (Figure 6-3A). Nqo1, 
NAD(P)H dehydrogenase, is another vital part of the liver’s antioxidant defense against 
many hepatotoxins (Hwang et al., 2015). While hepatic Nqo1 mRNA is increased in 6N 
mice compared to the 6J mice 12, 48 and 72 hours after CCl4 (Figure 6-3B), hepatic 
NQO1 protein levels in 6N mice do not parallel these changes.  In fact, NQO1 protein 
decreases over time in both strains (Figure 6-3C and D).  Although a trend to a 
decrease in NQO1 protein is observed in 6N mice 72 and 96 hours after CCl4 exposure, 
NQO1 protein is not different between sub-strains when plasma ALT levels are different 
between sub-strains  (compare Figure 6-1A and Figure 6-3C, D). Together, these data 
suggest that antioxidant defense is equivalent between 6J and 6N mice following CCl4 
exposure and does not account for observed differences in CCl4-induced liver injury 
between sub-strains. 
 
Inflammation following CCl4 exposure: Hepatic neutrophil accumulation  
 Because hepatocyte sensitivity to CCl4 and anti-oxidant defenses were not 
different between sub-strains, we hypothesized that another mechanism must be 
responsible for increased liver injury observed in 6N mice. Neutrophils are recruited 
rapidly after CCl4-mediated injury and can exacerbate hepatocyte cell death (Ramaiah 
and Jaeschke, 2007; Moles et al., 2014), therefore we measured several neutrophil-





Figure 6-3: Expression of antioxidants after acute CCl4 exposure. 
 
Mice were exposed to CCl4 and euthanized 12, 24, 48, 72, or 96 hours later and the 
hepatic transcript accumulation of A. Gclc and B. Nqo1 was determined. Individual 
mouse liver samples were pooled to evaluate NQO1 protein concentration throughout 
the time course. C. Immunoblot and D. densitometry of the immunoblot shown in C. 
n=5-6 per group, *, p ≤ 0.05 when comparing sub-strains at a single time point; +, p ≤ 
0.05 when comparing the indicated CCl4 time point to the oil (control) of the same sub-
strain. 
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 neutrophil chemotactic protein and its receptor, respectively, at the mRNA level. Cxcl2 
transcripts increased in 6J and 6N mice 12 hours after CCl4 and are not different 
between sub-strains (Figure 6-4A). However, 24 and 48 hours after CCl4 exposure, 6N 
mice have increased Cxcl2 expression (Figure 6-4A). Cxcr2 is increased 12 hours after 
CCl4 and remains elevated in both strains until 48 hours post CCl4 exposure (Figure 6-
4B).  Thereafter, Cxcr2 transcripts decrease in 6N mice but remain elevated in 6J 
(Figure 6-4B).  
To further evaluate neutrophils, we localized chloracetate esterase (CAE), a 
leukocyte esterase, in livers from 6J and 6N mice. CAE was not found in control livers 
from either sub-strain (Figure 6-4C and D).  However, CAE-positive cells were apparent 
in livers from both sub-strains 12 and 24 hours after CCl4 exposure (Figure 5-4C and 
D). Although there was a trend to an increase in CAE-positive cells in livers from 6N 
mice when compared to 6J mice 24 hours after CCl4, this difference was not significant 
(p=0.0682, Figure 6-4C and D). No CAE-positive cells were found in livers from mice 
48, 72 or 96 hours after CCl4 exposure (data not shown). Taken together, these data 
suggest that neutrophil-mediated hepatocyte injury may partially contribute to increased 
liver injury observed in 6N mice. It is interesting to note that CAE staining data do not 
parallel hepatic Cxcr2 transcript levels (Figure 6-4B). This suggests that the sustained 
rise in Cxcr2 mRNA observed, in particular, in 6J mice, is due to Cxcr2 expression in 
other hepatic cells, such as hepatocytes, as observed following APAP overdose and 





                
Figure 6-4: Hepatic neutrophil accumulation after acute CCl4 exposure. 
 
Mice were exposed to CCl4 and euthanized 12, 24, 48, 72, or 96 hours later. A. Cxcl2 
and B. Cxcr2 transcripts were quantified in whole liver cDNA samples using real time 
PCR. C. Quantification of CAE staining used to assess the number of neutrophils in the 
liver at baseline (oil) and 12 and 24h after CCl4. D. Representative images of CAE+ 
cells with neutrophil morphology (pink staining within the dotted black lines, area within 
solid red line is enlarged to the right).  The + indicates central veins in the images.  n=5-
6 per group, *, p ≤ 0.05 when comparing sub-strains at a single time point; +, p ≤ 0.05 
when comparing the indicated CCl4 time point to the oil (control) of the same sub-strain. 
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Inflammation after CCl4 exposure: Hepatic macrophage accumulation 
Macrophages are also recruited to the liver after injury and can play roles in 
sustaining injury as well as promoting repair (You et al., 2013; Zigmond et al., 2014). 
Because we observed a more rapid removal of necrotic tissue in livers from 6N mice, 
we hypothesized that cell recruitment was increased in this sub-strain and contributed to 
more rapid repair, compared to 6J mice. To determine whether or not this relationship 
existed, we first counted the number of non-parenchymal cells (NPC) within the 
pericentral (necrotic) areas in livers from 6J and 6N mice. There were very few NPC in 
the necrotic area 12 and 24 hours after CCl4 (not quantified). However by 48 hours, 
NPC increased in necrotic areas from both sub-strains (Figure 6-1D, 6-5A), and at 72 
and 96 hours post CCl4 exposure, 6N mice had more necrosis-infiltrating cells 
compared to 6J mice (Figure 6-1D and 6-5A). While infiltration of cells into necrotic 
areas 72 and 96 hours after CCl4 does not support a role for inflammation-mediated 
exacerbation of liver injury in 6N mice, it does support a role for these cells in removal of 
necrotic hepatocytes. In fact, the number of infiltrating cells was negatively correlated 
with the area of necrosis (Figure 6-5B).  
 Next, we wanted to verify that macrophages were associated with this repair 
response. After CCl4-exposure, resident hepatic macrophages and other liver cells 
produce chemokines, which attract peripheral monocytes into the liver leading to an 
increase in hepatic macrophage number (Dixon et al., 2013). Ccl2 is the gene that 
encodes monocyte chemoattractant protein 1 (MCP1), a chemokine that aids in the 
recruitment of inflammatory cells, including macrophages (Baeck et al., 2012). Hepatic 
Ccl2 transcripts increased above baseline 12 hours after CCl4 exposure in both 6N and 
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6J mice (Figure 6-5C). However, 6N mice had increased Ccl2 transcripts 24 and 48 
hours post CCl4 relative to 6J mice at the same time point (Figure 5-5C). Conversely, 96 
hours post CCl4, Ccl2 transcripts were higher in 6J mice relative to 6N mice (Figure 6-
5C). To assess hepatic macrophage content, we examined expression of Emr1, the 
F4/80 gene, a common mouse macrophage marker. Emr1 transcripts initially decreased 
in both sub-strains following CCl4 exposure (Figure 6-5D). By 48 hours post CCl4 
exposure, Emr1 transcripts increased above baseline in 6N mice (Figure 6-5D). 
However, it was not until 72 hours after CCl4 that Emr1 transcripts increased above 
baseline in 6J mice; Emr1 transcripts were still greater in 6N mice at this time point 
(Figure 6-5D). Consistent with earlier and increased Emr1 transcript levels, 6N mice 
exhibited increased F4/80-positive staining compared to 6J mice 96 hours after CCl4 
exposure (Figure 6-5E and F).   
Tumor necrosis factor α (Tnfa) is a cytokine produced mainly by macrophages 
(Dixon et al., 2013). TNFα can induce hepatocyte death or drive liver regeneration 
depending on cellular context (Webber et al., 1998; Malhi et al., 2010; Seki et al., 2012; 
Deshpande et al., 2016). Therefore, we evaluated Tnfa transcripts in liver after CCl4 
exposure.  Tnfa increased above baseline in 6N mice earlier (12 hours) and was greater 
than in 6J mice (24 and 48 hours) (Figure 6-5G). While Tnfa transcripts returned to 
baseline by 96 hours in 6N mice, these transcripts remained elevated in 6J mice (Figure 
6-5G).  
Together, all of these data suggest that 6N mice exhibited a greater capacity to 
recruit cells, including macrophages, into the liver where they participated in more rapid 




Figure 6-5: Infiltrating cells and macrophages in liver after acute CCl4 exposure. 
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A. The number of non-parenchymal cells infiltrating the necrotic area was counted in 
livers from mice euthanized 48, 72, and 96 hours post CCl4 exposure. B. The number of 
cells was correlated to the % necrosis determined from H&E stained sections. Indices of 
macrophage accumulation were evaluated by determining hepatic transcript 
accumulation of C. Ccl2, and D. Emr1 by real time PCR.  E. Quantification of F4/80+ 
macrophages determined by immunofluorescence 72 and 96h after CCl4 exposure.  F. 
Representative F4/80 immunofluorescence images. In each image, central veins are 
marked with a + and portal veins are marked with a *. G. Quantification of Tnfa 
transcripts by real time PCR. n=5-6 per group, *, p ≤ 0.05 when comparing sub-strains 
at a single time point; +, p ≤ 0.05 when comparing the indicated CCl4 time point to the 
oil (control) of the same sub-strain. 
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the increased cell recruitment observed in 6N mice may have also promoted increased 
liver injury, perhaps through increased TNFα-induced hepatotoxicity. 
 
Liver regeneration following CCl4 exposure 
 Following the massive necrosis caused by CCl4 and subsequent inflammation, 
the liver regenerates to restore normal mass and function (Hogaboam et al., 1999; 
Cienfuegos et al., 2014). This occurs at the later time points, 48, 72, and 96 hours, post 
CCl4 exposure. We evaluated regeneration by analyzing hepatic gene expression and 
protein levels of proliferating cell nuclear antigen (Pcna), a DNA protein clamp essential 
for replication, and Cyclin D1 (Ccnd1), a protein required for cell cycle progression. 
Hepatic Pcna transcript levels increased in both genotypes following CCl4 exposure. 
The increase in the 6N mice occurred earlier, at 48 hours post CCl4 exposure, 
compared to 6J mice, which increased 72hours post CCl4 exposure (Figure 6-6A). 
PCNA protein increased in both sub-strains 48 hours post CCl4 exposure, however, in 
parallel to mRNA data, 6N had higher PCNA levels compared to 6J mice (Figure 6-6B, 
C). The PCNA protein levels remained elevated in both sub-strains 96 hours post CCl4 
exposure. Ccnd1 expression increased following CCl4 exposure in both sub-strains 48 
hours post CCl4 exposure; there was no difference in Ccnd1 transcript levels between 
6N and 6J mice (Figure 6-6D). CCND1 protein levels also increased in both sub-strains 
following CCl4 exposure, however there was no difference between sub-strains at any 
time point (Figure 6-6E, F). Ki67, which is present throughout the active phases of the 
cell cycle, increased in both sub-strains following CCl4 exposure, however with different 
kinetics (Figure 6-6G, H). Specifically, Ki67-positive cells were present 48 hours after 
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CCl4 exposure in 6N mice but were not present until 72 hours post CCl4 exposure in 6J 
mice (Figure 6-6G, H). Together, these data suggest that 6N mice initiated regeneration 
earlier than 6J mice.  
 
Matrix remodeling following CCl4 exposure 
 The final stage of wound healing is matrix remodeling (matrix synthesis and 
degradation) and similar to regeneration, it occurs at 48, 72, and 96 hours post CCl4 
exposure (Balaji et al., 2015; Deshpande et al., 2016). Activated hepatic stellate cells 
(HSC) contribute to matrix synthesis (Friedman, 2008a). HSC transdifferentiate into 
myofibroblasts and begin expressing α smooth muscle actin (Acta2) and synthesize 
type 1 collagen (Col1a1) (Friedman, 2008a). Hepatic Acta2 transcript levels increased 
following CCl4 exposure in both 6J and 6N mice; Acta2 transcript levels were higher in 
6N mice 48 hours after CCl4 exposure when compared to 6J mice (Figure 6-7A). 
Expression of Col1a1 also increased in both sub-strains following CCl4 exposure and 
was higher in 6N mice at 48 and 72 hours post CCl4 exposure compared to 6J mice 
(Figure 6-7B). Immunohistochemistry revealed that αSMA increased in both sub-strains 
following CCl4 exposure (Figure 6-7C and D).  However, αSMA increased over baseline 
in 6N mice at 72 hours post CCl4 exposure while αSMA protein did not increase above 
baseline in 6J mice until 96 hours post CCl4 exposure (Figure 6-7C and D). At this point, 
αSMA levels were not different from baseline in 6N mice (48 hours is not included due 
to high non-specific staining in the necrotic tissue) (Figure 67C and D).  
Matrix synthesis is opposed by matrix metabolism, which can be evaluated using 
in situ zymography (Lindsey et al., 2001; Yan and Blomme, 2003). Very little matrix 
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Figure 6-6: Hepatic regeneration following acute CCl4 exposure. 
 
Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. Pcna was 
evaluated at both the A. mRNA and B, C. protein level, by real time PCR or Western 
blotting, respectively. Ccnd1 was evaluated at both the D. mRNA and E, F. protein level. 
G. Ki67 immunofluorescence was performed to identify proliferating hepatocytes. DAPI 
was used to visualize nuclei. In each image, central veins are marked with a + and 
portal veins are marked with a *.  H. Quantification of Ki67-positive cells.  n=5-6 per 
group, * represents p ≤ 0.05 when comparing sub-strains at a single time point; +, p ≤ 
0.05 when comparing the indicated CCl4 time point to the oil (control) of the same sub-
strain. 
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 metabolism occurred at baseline (Figure 6-7E, top panels, not quantified) or early time 
points (not shown), but matrix metabolism did occur 72 and 96 hours post CCl4 
exposure in both sub-strains. However, matrix metabolism was not different (area or 
intensity) between 6J and 6N mice at either time point (Figure 6-7F and G). These data 
together suggest that matrix remodeling was only partially different (synthesis but not 
metabolism) between sub-strains. 
 
Fibrosis in 6N and 6J mice following chronic CCl4 exposure 
 Following acute liver injury induced by CCl4 exposure, 6N mice have increased 
injury and inflammation. We, therefore, hypothesized that 6N mice would have 
increased fibrosis following chronic CCl4. 6N and 6J mice were exposed to CCl4 twice a 
week for five weeks to establish liver fibrosis. Hepatic transcript accumulation of Acta2, 
the gene encoding αSMA, a marker for HSC activation is increased in both 6N and 6J 
mice following chronic CCl4 exposure and was not different between sub-strains (Figure 
6-8A). Hepatic content of mRNAs that make up type 1 collagen, Col1a1 and Col1a2, 
were increased in both sub-strains after chronic CCl4 and were greater in 6N compared 
to 6J (Figure 6-8B and C). Picrosirius red was used to monitor ECM accumulation in 
both sub-strains after chronic CCl4 and shows a similar trend as collagen transcripts, 
increasing in both sub-strains and having more in 6N than 6J (Figure 6-8D and E). 
These data support the hypothesis that 6N mice have increased fibrosis following 
chronic CCl4 exposure compared to 6J mice, and shows the importance of choosing the 
correct sub-strain for controls in order to avoid data interpretation errors when using 









Mice were exposed to CCl4 and euthanized 48, 72, or 96 hours later. Hepatic transcript 
accumulation of A. Acta2 and B. Col1a1 were evaluated by real time PCR. C. 
Immunohistochemistry for αSMA, the Acta2 gene product, was performed and D. 
quantified as the percent area of positive staining in each image. E. In situ zymography 
was used to detect matrix metabolism in frozen liver sections at baseline, 72 and 96 
hours post CCl4 exposure. The green fluorescence indicates areas of matrix 
metabolism. DAPI was used to visualize nuclei. F. The area and G. intensity above a 
set threshold was quantified after in situ zymography. Baseline matrix metabolism was 
too low to quantify. Central veins are marked with a + and portal veins are marked with 
a *.  n=5-6 per group, *, p ≤ 0.05 when comparing sub-strains at a single time point; +, p 




Figure 6-8: Hepatic fibrosis in C57BL/6J and C57BL/6N mice, after chronic CCl4 
exposure. 
 
Mice were exposed to CCl4 twice a week for five weeks and euthanized 72 hours after 
the last injection. Control mice received olive oil (oil) injections twice a week for five 
weeks. Real time PCR was used to evaluate hepatic transcript levels of A. Acta2, B. 
Col1a1, and C. Col1a2 in 6J and 6N mice. Data are normalized to 18s and expressed 
as fold change over each genotypes own oil. D. Representative histology images of 
picrosirius red and E. quantification to evaluate ECM accumulation. Central veins are 
marked with a + and portal veins are marked with a *.  Data are expressed as fold 
change over own oil. n=6-7 per group. *, p ≤ 0.05 when comparing sub-strains at a 





Genotypes of genetically modified mice used in this dissertation 
 As stated above, the use of improper controls has caused data interpretation 
errors (Bourdi et al., 2011). Bourdi, et al. discovered the reason for the discrepancy of 
Jnk2-/- mice being protected versus having exacerbated liver injury following acute 
APAP overdose was due to which sub-strain the Jnk2-/- were compared (Bourdi et al., 
2011). The differences in the wound healing response following acute CCl4 exposure 
we observe in our study is important for our studies because the genetically modified 
mice used throughout this dissertation are on two different backgrounds. Specifically 
Has3-/- mice are on a 6J background with a mutant Nnt enzyme and Hmmr-/- mice are 




 One goal of this study was to determine whether C57BL/6 sub-strains differed in 
their response to a single exposure to CCl4. We evaluated indices central to liver injury 
and wound healing, including inflammation, regeneration, and matrix remodeling. 
Similar to APAP-induced liver injury (Bourdi et al., 2011; Duan et al., 2016), we report 
here that 6N mice have increased injury compared to 6J mice; this increased injury was 
not due to differences in CYP2E1 bioactivation, or hepatocyte sensitivity to CCl4 
between sub-strains, but might be due to increased numbers of neutrophils and/or 







Figure 6-9: Nnt genotypes of genetically modified mice used in this dissertation. 
 
Genomic DNA was isolated from livers of purchased 6J and 6N mice as well as in-
house bred Has3-/- and Hmmr-/- mice and genotyped for Nnt status. Using appropriate 
primers described in Chapter 2, wild-type Nnt is 579 bp and mutant Nnt is 743 bp. 
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Paradoxically, the increase in TNFα in 6N mice may have also contributed to the 
more rapid onset of liver regeneration in 6N mice, relative to 6J mice, after CCl4 
exposure (Webber et al., 1998; Bohm et al., 2010). This apparent dichotomy may be 
due, in part, to the location where hepatocytes are exposed to TNFα. For example, the 
stressed hepatocytes found immediately around the necrotic pericentral area may be 
more sensitive to TNFα-mediated cell death, while the hepatocytes found in the 
periportal area may be more sensitive to TNFα-mediated promotion of liver 
regeneration. Our own data support this notion, as the area of necrosis was greater in 
6N mice compared to 6J mice 48h after CCl4, while at the same time point, hepatocytes 
in the periportal areas of 6N expressed Ki67 while 6J mice did not; these phenomena 
occurred when Tnfa expression was greatest in 6N liver. Subsequently, increased 
infiltration of NPC, including macrophages, 72 and 96 hours after CCl4, into the necrotic 
areas was correlated to more rapid clearing of the necrotic tissue in the 6N mice 
compared to the 6J mice. While matrix synthesis began earlier in 6N mice, matrix 
metabolism was similar between 6J and 6N mice. Therefore, despite increased liver 
injury in 6N mice, liver repair was more rapid when compared to repair in the less-
injured 6J mice.  This is likely due to the more rapid inflammatory, regenerative and 
HSC responses observed in 6N mice.  
 Because CCl4 causes mitochondrial damage, mutations in the Nnt gene would 
be expected to exacerbate injury due to the decreased antioxidant capacity in 6J mice. 
Despite this, and similar to APAP-induced liver injury, we report here that liver injury is 
increased in 6N mice compared to 6J mice. Cellular lipid membranes are disrupted after 
CCl4 bioactivation. This bioactivation also causes mitochondrial damage and oxidative 
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stress reflected in a decrease in mitochondrial GSH/GSSG ratio (Ip and Ko, 1996; 
Wong et al., 2014). In addition, CCl4-induced liver damage can be attenuated using 
antioxidants to raise the mitochondrial GSH/GSSG ratio. This, in turn, decreases cell 
damage and lowers plasma ALT levels (Ip and Ko, 1996; Wong et al., 2014). Nnt 
mutant mice have a decreased basal GSH/GSSG ratio. Thus, it should follow that the 
Nnt mutant mice would have increased injury (Ronchi et al., 2013). However, this does 
not occur after APAP (Bourdi et al., 2011; Duan et al., 2016) or CCl4-induced liver injury 
(described in this study), which suggests that factors other than the mutated Nnt may 
play a more prominent role in sub-strain-specific responses to hepatic injury triggered 
by APAP and CCl4. We also report that there is no difference in hepatocyte sensitivity to 
cell death caused by CCl4, in vitro, which further supports the idea that other factors, 
besides the mutated Nnt gene, are responsible for increased sensitivity of 6N mice to 
CCl4-induced liver injury. 
 Studies demonstrating that 6J mice are more sensitive to oxidative stress 
contradict our findings that 6N mice exhibited increased injury following acute CCl4 
exposure. In a number of model systems, mutated Nnt results in several redox 
alterations, including higher rates of H2O2 release and the spontaneous oxidation of 
NADPH, along with a reduced GSH/GSSG ratio (Arkblad et al., 2005; Sheeran et al., 
2010; Ronchi et al., 2013). Mutant Nnt is a genetic modifier in two separate, transgenic 
mice. Bcl2l2 encodes for BCL-W, which protects cells from apoptosis during cellular and 
oxidative stress (Ross et al., 1998). When Bcl2l2-/- mice are on an Nnt mutant (6J) 
background, they display increased embryonic lethality compared to Bcl2l2-/- on an Nnt 
wild-type (6N) background (Ross et al., 1998; Navarro et al., 2012). Similarly, mice 
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deficient in mitochondrial superoxide dismutase (Sod2-/-) exhibit enhanced tissue 
damage and increased lethality shortly after birth when they are on an Nnt mutant 
background compared to Sod2-/- mice on an Nnt wild-type background (Huang et al., 
2006). In contrast to what is observed after APAP overdose (Bourdi et al., 2011; Duan 
et al., 2016) or after acute CCl4 in the present study, these studies show that a mutant 
Nnt leads to increased sensitivity to oxidative stress.  
 Additional studies comparing 6J and 6N mice in models of diet-induced obesity 
show that the Nnt mutation is linked to glucose intolerance and reduced insulin 
secretion (Freeman et al., 2006a; Freeman et al., 2006b). Although both sub-strains are 
sensitive to diet-induced obesity, after high fat diet (60% of calories from fat) feeding, 6J 
mice gain more weight and display increased glucose intolerance compared to 6N mice 
(Nicholson et al., 2010). Rescuing the mutated Nnt back to wild-type using bacterial 
artificial chromosomes improves glucose tolerance (Freeman et al., 2006b). These data 
suggest that the mutated Nnt gene itself is at least partially responsible for the 
difference in glucose intolerance between the 6J and 6N mice (Freeman et al., 2006b). 
However, after feeding these sub-strains a diet that contains 45% calories from fat, 6N 
mice display greater hepatic inflammation despite having a functional NNT enzyme 
(Freeman et al., 2006b), which is similar to what we observe after acute CCl4 exposure. 
Collectively, and similar to APAP overdose (Bourdi et al., 2011; Duan et al., 2016) and 
to acute CCl4 exposure, a mutant Nnt can help protect mice from liver inflammation 
despite leading to impaired glucose tolerance. When thinking about these published 
studies and the data presented here, one must begin to consider what other factors, 
besides a mutated Nnt, are contributing to sub-strain specific differences in various 
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animal models of human disease, particularly when inflammation, liver damage, and 
hepatic repair are concerned.  
 Additional investigations document single nucleotide polymorphisms (SNPs) 
between the two sub-strains, which may account for differences between 6J and 6N 
mice, dependent or independent of Nnt status. Indeed, eleven different SNPs exist 
between 6J and 6N mice (Mekada et al., 2009; Zurita et al., 2011). Most of the SNPs 
map to non-coding regions of the genome, but 5 SNPs are linked to specific genes 
including Naaladl2 (N-acetylated alpha-linked acidic dipeptidase-like 2), Aplp2 (amyloid 
precursor-like protein 2), Lims2 (LIM and senescent cell antigen-like-containing domain 
protein 1), Fgf14 (Fibroblast growth factor 14), and Snap29 (Synaptosomal-associated 
protein 29) (Mekada et al., 2009; Zurita et al., 2011). Although it is beyond the scope of 
this study, it is possible that one or more of these SNPs alone or together with the well-
established Nnt mutation may contribute to the differences seen between the 6J and 6N 
mice following acute CCl4 exposure.  
 Another explanation for the, at first, unexpected results found here may be 
explained by “hormesis”. Hormesis can be defined as low doses of a stressor being 
beneficial to survival while high doses of the same stressor are detrimental. It often 
refers to a chemical insult, but can also refer to adaptations to stress (Milisav et al., 
2012). If hormesis is considered in this scenario, 6J mice, which have had a non-
functional NNT enzyme for decades, have likely adapted to the lower antioxidant 
capacity in other ways. Therefore, they can withstand higher oxidative stress, relative to 
non-adapted mice, resulting in reduced cell death and subsequently a limited 
inflammatory response. It is not until an injurious insult has overcome this new 
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homeostasis that robust injury and inflammation occurs. This concept has been applied 
to several phenomena in toxicology (Counts and Goodman, 1995; Williams and 
Iatropoulos, 2002). To determine if 6J mice compensated for reduced NNT activity by 
increasing other antioxidant defenses according to the principals of hormesis, we 
evaluated Gclc and Nqo1 mRNA and NQO1 protein; we found little difference in these 
antioxidant molecules between the sub-strains.  While beyond the scope of this study, 
further studies should evaluate additional antioxidant defense pathways in 6J and 6N 
mice to determine if differences in the observed antioxidant response contribute to 
differences in liver injury and subsequent inflammation noted in these sub-strains after 
acute CCl4 exposure.  
 Our thorough characterization of differences between sub-strains after acute 
CCl4 exposure is a critical first step in understanding differences between 6J and 6N 
mice. Our study shows, for the first time, that despite the fact that CCl4-induced liver 
injury is worse in 6N mice, liver repair was more rapid when compared to repair in the 
less-injured 6J mice.  This is likely due to the more robust inflammatory, regenerative, 
and HSC responses observed in 6N mice, but other mechanisms may also be involved.  
In addition to exploration of whether or not hormesis is involved in protecting 6J mice 
from CCl4-induced liver injury relative to 6N mice as suggested above, it might be 
beneficial to determine if a zone-specific role for TNFα exists in driving hepatocyte 
death versus hepatocyte proliferation 48 hours after CCl4 exposure. Additionally, further 
evaluation of the role neutrophils play in exacerbation of liver injury in 6N mice is also 
warranted.  These would be excellent next steps to understanding sub-strain differences 
in this commonly used model of acute hepatotoxin exposure. 
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 We also investigated potential differences in frank fibrosis between these two 
sub-strains following chronic CCl4 exposure. In accordance with the acute data, we 
hypothesized that 6N mice would have increased hepatic fibrosis. They did in fact have 
increased pro-fibrotic transcripts and increased ECM accumulation evaluated by 
picrosirius red staining. Similar to acute data, this is surprising due to the mitochondrial 
defect in 6J mice. In fact, in a genetically modified mouse strain that has increased 
mitochondrial antioxidant capacity, CCl4 induced fibrosis was decreased, suggesting 
that 6N mice would have decreased hepatic fibrosis (Mitchell et al., 2009b). Even so, in 
a model of angiotensin II-induced left ventricular cardiac remodeling, 6N mice have 
increased collagen content compared to 6J mice (Cardin et al., 2014). The fibroblasts 
isolated from these mice also have increased Col1a1 transcript accumulation, and this 
supports the findings of our chronic CCl4 study (Cardin et al., 2014). As stated above, 
there have been several reported SNPs and it is possible that one of the SNPs alone or 
in combination with Nnt may be contributing to the differences observed in 6N vs 6J 
mice after chronic CCl4 exposure (Zurita et al., 2011). 6N mice heal faster than 6J mice 
after acute CCl4 exposure and while the 6N mice display increased fibrosis at this time 
point after chronic CCl4, it would be interesting to evaluate fibrosis resolution in these 
two sub-strains to see if 6N mice can also resolve fibrosis faster than 6J mice.  
Our study highlights the importance of identifying and choosing the correct 
control sub-strain when using genetically-modified mice in studies which utilize acute 
and chronic CCl4. Similar to the contradictory reports on Jnk2-/- mice in APAP-induced 
liver injury, comparing a genetically modified mouse to the wrong C57BL/6 sub-strain 
after CCl4 exposure may lead to data misinterpretations. This experimental caveat is 
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vitally important in this new age of experimental rigor, transparency and reproducibility 
required by the National Institute of Health (Collins and Tabak, 2014; Omary et al., 
2016). Also, as stated above, it is especially important when interpreting the data 
presented in this dissertation, as the genetically modified mice that were utilized are on 
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 Chronic liver disease and the complications that arise from it have become a 
major problem in the world (Abu-Wasel et al., 2013; Roberts et al., 2014; Kochanek et 
al., 2016). In 2014, liver disease was rated the 12th leading cause of death in the United 
States (Kochanek et al., 2016). In developed countries, like the United States, chronic 
liver disease is often caused by alcohol and drug abuse and/or over nutrition and 
obesity (Penny, 2013; Corey and Kaplan, 2014; Woolbright and Jaeschke, 2015). 
Patients are initially diagnosed with steatosis, but if injury becomes chronic the patient 
can progress to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) (Llovet et al., 
2003; Postic and Girard, 2008; Pellicoro et al., 2014). Some patients are able to reverse 
steatosis and fibrosis if the etiologic agent is removed and their liver can return to 
normal function (Bataller and Brenner, 2005; Pellicoro et al., 2014). Unfortunately, for 
the patients that progress past fibrosis to cirrhosis and HCC a liver transplant becomes 
the only treatment option for survival (Llovet et al., 2003; Rai, 2013). Liver transplants 
are invasive, costly, and require lifelong immunosuppressive drugs (Rai, 2013). An 
additional complication is the shortage of healthy livers available for transplant (Parikh 
et al., 2015). Basic science has provided a number of potential therapeutic targets, but 
none have translated to the clinic as viable treatment options for advanced liver disease 
(Cohen-Naftaly and Friedman, 2011; Mehal and To, 2016). Thus, increased research 
into the mechanisms of hepatic wound healing, and disease progression/regression are 
needed, which was an overarching goal of this dissertation. We hypothesized that the 
extracellular matrix (ECM) molecule hyaluronan (HA), HA binding proteins, and 
receptors (collectively referred to as the HA network) aid in hepatic wound healing after 
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both acute and chronic hepatotoxin induced liver injury, with a specific focus on HA itself 
and the HA receptor HA mediated motility receptor (HMMR).   
 
Role for Hyaluronan (HA) and HA mediated motility receptor (HMMR) in acute and 
chronic liver injury induced by CCl4 
 
Discussion 
 Hyaluronan (HA) is a non-sulfated glycosaminoglycan that is ubiquitously present 
in the ECM (Fraser et al., 1997; Jiang et al., 2011). High levels of HA are found in the 
vitreous humor of the eyes, the skin, and synovial fluid (Cowman et al., 2015). There, it 
acts as a space filler, ECM stabilizer, and shock absorber, respectively (Meyer and 
Palmer, 1934; Anderegg et al., 2014; Guidolin and Franceschi, 2014). HA is also 
present in high amounts in fetal tissue and contributes to fetal tissues’ ability to heal 
without a scar, also called regenerative healing (Longaker et al., 1991; Leung et al., 
2012). Following injury, HA is transiently increased in many adult tissues including the 
skin, lung, and intestine and plays a role in the wound healing process and disease 
progression in each of these tissues (Bai et al., 2005; Kessler et al., 2008; Mack et al., 
2012). This transient increase in HA contrasts with the high basal HA found in fetal 
tissue and is thought to contribute to the fibrotic healing observed in adult tissue (West 
et al., 1997).  
 Over 30 years ago, HA was identified as a potential biomarker for liver disease 
(Engstrom-Laurent et al., 1985). It is increased in the plasma of patients with liver 
disease and since its discovery has been closely correlated with disease severity (Lee 
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et al., 2010; Lee et al., 2013). Despite the established role for HA in disease 
progression in other tissues and its use as a biomarker for liver injury, there has been 
little research into a possible pathogenic role of HA in the progression of liver disease. 
We are the first to show, using genetically modified mice, that there is a potential link 
between HA, a HA receptor (HA mediated motility receptor, HMMR), and several 
aspects of the acute hepatic wound healing process, including inflammation and matrix 
remodeling. We propose HA aids in the regenerative wound healing that occurs after 
acute hepatic injury, resulting in no excess ECM, similar to healing observed in fetal 
tissue. We have also proposed a link between HA, HMMR, and chronic wound healing, 
specifically that these two molecules are required for matrix remodeling and ECM 
clearance.  
 Using mice deficient in one of the hyaluronan synthase genes (Has3-/-) and 
carbon tetrachloride (CCl4) to induce acute liver injury, we show an increase in not only 
injury and inflammation, but a subsequent increase in wound healing including 
regeneration and matrix remodeling (Chapter 3). Surprisingly, we also observed 
increased hepatic HA content in Has3-/- mice compared to wild-type mice, and this HA 
was found in the centrilobular regions of the liver where CCl4 caused necrosis. These 
differences, particularly the increased wound healing, are associated with an increase in 
both the gene expression and protein levels of HMMR. We therefore examined wound 
healing following acute CCl4 in Hmmr-/- mice and found a delay in inflammation and 
wound healing compared to wild-type mice (Chapter 4). Hmmr-/- mice also had delayed 
hepatic HA accumulation. Following chronic CCl4 we observed a similar reciprocal 
relationship. Has3-/- mice displayed increased pro-fibrotic markers but increased matrix 
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remodeling compared to wild-type mice. In contrast Hmmr-/- mice displayed decreased 
pro-fibrotic markers and decreased matrix remodeling compared to wild-type mice 
(Chapter 5). A summary of these finding can be found in Figure 7-1. 
 The observed increases in injury and inflammation in Has3-/- mice was 
unexpected and opposite of what is found in published literature. In a dextran sodium 
sulfate (DSS)-induced model of colitis, Has3-/- mice are protected from colon damage 
and had decreased inflammation (Kessler et al., 2015). Unlike the increase in hepatic 
HA content we observed, Has3-/- mice have decreased intestinal HA content following 
DSS-induced colitis (Kessler et al., 2015). Additionally, in the lung, Has3-/- mice have 
decreased injury, neutrophil recruitment, and macrophage inhibitory protein (MIP2) 
compared to wild-type mice after ventilator induced lung injury (Bai et al., 2005). This 
was associated with decreased low molecular weight (LMW) HA fragments in Has3-/- 
mice compared to wild-type mice (Bai et al., 2005). This, again, is in contrast our study, 
where we see increased inflammation and increased hepatic HA content in Has3-/- 
mice compared to wild-type mice after acute CCl4 exposure. This suggests a potential 
difference in cell type expression of HAS enzymes exists and that these differences 
contribute to differential responses to injury depending on the tissue type.  
 There are three possible ways that HA and inflammation are related during tissue 
injury and repair (discussed in detail below and outlined in Figure 7-2). The first way HA 
can contribute to inflammation is by directly stimulating pro-inflammatory mediators. 
During tissue injury, endogenous HA (considered high molecular weight, HMW-HA) is 
cleaved to LMW-HA fragments that induce inflammatory changes within the tissue. In 
alveolar macrophages, LMW-HA fragments induce pro-inflammatory chemokines  
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Figure 7-1: Summary of findings for acute and chronic CCl4 exposure in Has3-/- 
and Hmmr-/- mice. 
 
A. Mice were exposed to a single injection of CCl4 and parameters of hepatic injury and 
wound healing were evaluated. B. Mice were exposed to 2 injections of CCl4 per week 
for 5 weeks to induce fibrosis and parameters of fibrosis and matrix remodeling. Has3-/- 
mice were compared to C57BL/6J control mice and Hmmr-/- mice were compared to 
C57BL/6N control mice. ! represents genetically modified mouse response is 
increased compared to wild-type; " represents genetically modified mouse is 
decreased compared to wild-type; = represents genetically modified mouse has similar 
response compared to wild-type 
Acute CCl4 Has3-/- Hmmr-/- 
Injury !	 = 
Pro-inflammatory 
microenvironment !	 "	
Macrophage migration !	 "	
HSC activation markers !	 "	
Matrix metabolism !	 "	
Chronic CCl4 Has3-/- Hmmr-/- 
Pro-fibrotic transcripts !	 ! 
Fibrosis = = 






Figure 7-2: Hyaluronan, inflammation, and hepatic stellate cells influence one 
another. 
 
Pro-inflammatory signals like TNFα and IL1β can induce HA synthesis. Reciprocally 
LMW-HA fragments induce inflammation via TLR2 and TLR4. Additionally the 
HA:HMMR interaction aids in macrophage localization. HA is synthesized by activated 
HSC and subsequently increases mechanical stress further activating HSC in a feed 
forward loop. Lastly, HSC synthesized HA increased leukocyte binding and localization 
and conversely, pro-inflammatory signals activate HSC.  
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including CCL2 and CXCL10, which promote a pro-inflammatory microenvironment 
(Horton et al., 1998). In Has3-/- mice we observe an increase in hepatic HA content, 
which may be being cleaved to LMW-HA fragments and directly induces inflammation. 
We also observe an increased percentage of <100 kDa HA fragments in Has3-/- mice, 
which again could be contributing to the increased Ccl2 and Cxcl10 transcripts in   
Has3-/- mice. Conversely, Hmmr-/- mice have decreased hepatic HA, which would limit 
LMW-HA fragment formation and subsequent inflammation in Hmmr-/- mice compared 
to wild-type mice.  
 As stated above, HA itself could be inducing inflammation, but a second way HA 
and inflammation could be related is that inflammation could be inducing HA deposition 
as has been demonstrated previously. Interleukin (IL) 1β and TNFα induce HA 
synthesis in endothelial cells that then subsequently binds monocytes in vitro (Vigetti et 
al., 2010). IL1β also stimulates HA synthesis by fibroblasts, which then forms 
protrusions with CD44 and ICAM1 and becomes adhesive for monocytes in vitro (Meran 
et al., 2013). In both of these studies, increased Has2 expression was considered the 
cause of the increased HA synthesis. We also observe increased Has2 expression 
following acute CCl4 exposure, although Has1 is expressed to a higher degree in both 
wild-type and Has3-/- mice. However, it is possible that the differential inflammatory 
response we observe in Has3-/- and Hmmr-/- mice is contributing to the differential 
hepatic HA content. Thus more inflammation equals more HA deposition in Has3-/- 
mice compared to wild-type mice, and less inflammation equals less HA deposition in 
Hmmr-/- mice compared to wild-type mice.  
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 Finally, HA interacting with HMMR may be contributing to localization of recruited 
macrophages and, subsequently, inflammation. In addition to the increased 
inflammatory microenvironment we saw in Has3-/- mice, we saw an increase in hepatic 
HA and HMMR. We propose that recruited macrophages express HMMR on their 
surface and use HA to localize to the necrotic area and contribute to inflammation. 
Preliminary work in our lab shows a 20-fold increase in expression of Hmmr in non-
parenchymal cells (NPC) compared to hepatocytes isolated from the liver both 48 and 
72 hours after acute liver injury induced by CCl4, supporting the hypothesis that HMMR 
is expressed by macrophages following acute liver injury. HMMR is already linked to 
macrophage migration in other models of tissue injury, including excisional skin 
wounding and bleomycin induced lung injury. Specifically, using a HMMR mimetic that 
prevents the interaction between HA and HMMR inhibits macrophage migration into 
excisional skin wounds (Tolg et al., 2012). Similarly, a HMMR blocking antibody 
prevents macrophage migration into the lung during bleomycin induced lung injury 
(Zaman et al., 2005). When we evaluated inflammation in Hmmr-/- mice exposed to 
CCl4, we observed decreased inflammation compared to wild-type mice. This further 
supports the hypothesis that a HA:HMMR interaction is important for macrophage 
migration into the liver following acute liver injury. Still further work should be done (as 
described below) in order to determine more specifically macrophage localization and 
what contribution HA is playing in that localization. The localization of hepatic 
macrophages becomes important in not only the inflammatory phase of wound healing 
but also matrix remodeling and will be described in more detail below. 
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 Another aspect of liver wound healing we found affected by HA and HMMR was 
liver regeneration. There are two potential ways that regeneration could be affected. 
The first could be related to inflammation. Inflammation plays a vital role in liver 
regeneration. In fact, TNFα primes rat hepatocytes to enter the cell cycle and proliferate 
(Webber et al., 1998). Additionally, when inflammation is prevented by depleting Kupffer 
cells, effectively lowering Tnfa transcripts, ethanol induced DNA synthesis is inhibited 
(Owumi et al., 2014). Therefore, it is possible that the increased inflammation in Has3-/- 
is priming hepatocytes to enter the cell cycle earlier than their wild-type counterparts. 
This may be why we observe increased regeneration in Has3-/- mice compared to wild-
type mice. Conversely, the decreased inflammation observed in Hmmr-/- mice may be 
the reason that there is a delay in regeneration in Hmmr-/- mice compared to wild-type 
mice after acute CCl4 exposure. 
 While HA and HMMR may be playing a role in the increased inflammation and 
subsequent regeneration, it is possible that HMMR, potentially independent of HA, may 
be playing a direct role in regeneration. In addition to HMMR’s extracellular role in cell 
migration, intracellular HMMR plays a vital role in cell cycle regulation. After HMMR 
knockdown in HeLa cells, there is an increase in mitotic spindle abnormalities; these 
cells are still able to enter the cell cycle but are arrested at the G2/M phase transition 
(Chen et al., 2014). A portion of the HeLa cells will eventually complete mitosis, but it 
takes significantly more time to complete than the HeLa cells expressing HMMR (Chen 
et al., 2014). This parallels the delay in regeneration we see in Hmmr-/- mice 48 hours 
after CCl4 and the subsequent recovery to wild-type regeneration levels by 72 hours 
after CCl4. Because the liver is required for survival, it is likely that there are multiple 
202	
mechanisms that can compensate for and overcome HMMR deficiency. While we do 
observe increased Hmmr expression in NPC fractions compared to hepatocyte fractions 
after CCl4 induced liver injury, there is also increased expression of Hmmr in 
hepatocytes from 48 to 72 hours (Hmmr expression at basal levels in hepatocytes and 
nonparenchymal cells has not been evaluated). Similarly, the increased proliferation in 
Has3-/- mice compared to wild-type mice occurs at 48 and 72 hours, and at both time 
points HMMR is higher in Has3-/- mice compared to wild-type mice. This further 
supports a role for HMMR in hepatocyte proliferation. In vitro experiments could help 
elucidate a role for intracellular HMMR in hepatocyte proliferation (described below).  
 Matrix remodeling, including both synthesis and degradation can also contribute 
to/be affected by HA and the HA network (outlined in Figure 7.2). Matrix synthesis 
occurs in the liver after both acute and chronic liver injury and requires activation of 
hepatic stellate cells (HSC), which differentiate into myofibroblasts and synthesize ECM. 
As stated above, HA is increased after dermal tissue injuries in the skin, and as we 
have shown, HA deposition also occurs in the liver after injury. Previous studies show 
that HSC isolated from livers following partial hepatectomy synthesize HA (Vrochides et 
al., 1996). We have demonstrated here that HA is deposited around the central vein 
regions of the liver. This is the region damaged by CCl4 and is also where the activated 
HSC localize, supporting the role of HSC in the synthesis of HA after toxin induced liver 
injury. Similar to the transient increase of HA in the skin, HA is removed from the liver 
after wound healing, likely being degraded by hyaluronidases and subsequently taken 
up by liver sinusoidal endothelial cells (Csoka et al., 2001; Harris et al., 2007). Future 
work will help to elucidate how HA is removed following liver injury. 
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 In addition to fibroblasts being a main producer of HA, HA can also affect 
fibroblast phenotype. Animals deficient in both Has1 and Has3 (Has1/3-/-) have 
decreased HA deposition following excisional skin wounding as expected due to the 
lack of two HA synthase enzymes (Mack et al., 2012). Has1/3-/- mice also have faster 
myofibroblast differentiation and dermal wound closure compared to wild-type mice 
(Mack et al., 2012). This study has similarities and differences to the outcomes we 
observed in our study. While we do not see decreased hepatic HA content as was 
observed in the dermal injury study, we do see increased markers of HSC activation in 
Has3-/- mice after both acute and chronic CCl4 exposure. This study, as well as ours, 
points out that HA synthesis is likely a cell type- and tissue-specific response to injury.  
 Additional studies in the skin further support a role for HA in wound healing and 
fibroblast activation. When a HA-based filler is injected intradermally into photodamaged 
human skin, collagen production increases (Turlier et al., 2013). This is likely due to 
increased mechanical stress on the fibroblasts caused by the HA injection coupled to 
the large amounts of water organized around each HA molecule (Turlier et al., 2013). A 
similar mechanism influences HSC activation; increased stiffness increases HSC 
activation, both in vitro and in vivo after acute liver failure (Dechene et al., 2010; Olsen 
et al., 2011). It is therefore possible that the increased HA in Has3-/- mice is attracting 
fluid to the liver, causing increased mechanical stress sensed by HSC, and thereby 
increasing HSC activation markers. The reverse could be happening in Hmmr-/- mice, 
where decreased HSC activation markers are observed in the context of an acutely 
injured liver with profoundly reduced HA content.  
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 HMMR itself is linked to both fibroblast activation and migration (Tolg et al., 
2006). Similar to many parameters listed above, Hmmr-/- mice show a fibrotic response 
reciprocal to that observed in Has3-/- mice; i.e. Hmmr-/- mice have lower induction of 
pro-fibrotic genes after both acute and chronic CCl4 exposure compared to wild-type or 
Has3-/- mice. Hmmr-/- mice also have decreased hepatic HA deposition after acute 
CCl4 exposure. Tolg, et al. demonstrated Hmmr-/- fibroblasts are unable to migrate to 
the extent of wild-type mice in vitro and this leads to defective wound healing, in vivo 
(Tolg et al., 2006). Additionally, using a HMMR mimetic that prevents the HA:HMMR 
interaction, wound healing is delayed and  associated with decreased collagen content 
in the wound bed (Tolg et al., 2012). This published literature, along with the data 
presented in this dissertation, support a role for HMMR and HA in HSC localization.  
 The final step in wound healing after acute liver injury is matrix degradation. This 
is also important to fibrosis regression after chronic liver injury. Matrix degradation 
occurs through a coordinated action of matrix metalloproteinases (MMPs) and their 
inhibitors (TIMPs) (Hemmann et al., 2007; Duarte et al., 2015). Similar to many 
parameters outlined above, we observed a reciprocal pattern of matrix degradation 
between Has3-/- mice and Hmmr-/- mice after acute CCl4. Specifically, Has3-/- mice 
have increased matrix metabolism compared to wild-type mice and Hmmr-/- mice have 
decreased matrix metabolism compared to wild-type mice, which mirrors the HA 
deposition between the transgenic strains. After chronic CCl4, matrix remodeling was 
increased in Has3-/- mice and decreased in Hmmr-/- mice, paralleling the results of our 
acute CCl4 studies  
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 In the liver, MMPs are primarily produced by macrophages (Fallowfield et al., 
2007b; Duarte et al., 2015). CCR2, the receptor for CCL2, is expressed by 
macrophages, and is required for the recruitment of macrophages to the liver after injury 
(Mitchell et al., 2009a). Ccr2-/- mice have delayed fibrosis resolution following chronic 
CCl4 exposure and this is associated with delayed Mmp2 and Mmp13 transcript 
expression (Mitchell et al., 2009a). Similar results are found when macrophages are 
depleted using a Cd11b-DTR transgenic mouse model (Duffield et al., 2005). Since 
macrophages are vital for matrix metabolism in the liver following liver injury, the results 
we obtained (i.e. increased matrix metabolism and HA deposition in Has3-/- mice and 
decreased matrix metabolism and HA deposition in Hmmr-/- mice) further support a role 
for HA and HMMR in macrophage localization to areas which require matrix 
degradation. Additionally, HA itself induces both Mmp9 and Mmp13 transcripts in Lewis 
Lung Carcinoma cells and primary embryonic fibroblasts (Fieber et al., 2004). It is 
therefore possible that the increased HA in Has3-/- mice may be contributing directly to 
the increased matrix metabolism. Conversely, the reduced HA deposition in Hmmr-/- 
mice may be contributing to decreased matrix metabolism after acute CCl4.  
 Hepatic wound healing after acute liver injury is regenerative, similar to that 
observed in injured fetal tissue, and does not result in ECM accumulation 
(Constandinou et al., 2005; Leung et al., 2012). We have observed an increase in 
hepatic HA, which is associated with wound healing. However after chronic CCl4 we do 
not see the same extent of HA present in wild-type or Has3-/- mice as we do after acute 
liver injury. Chronic liver injury is analogous to adult tissue healing in the skin, which 
heals with a collagen-containing scar (Bayat et al., 2003; Pellicoro et al., 2014). It is 
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therefore tempting to speculate that the increased HA found following acute liver injury 
is contributing to the regenerative response, and because this HA accumulation is 
limited after chronic injury, perhaps this prevents regenerative repair. However, because 
we have only evaluated a single time point after chronic CCl4 we cannot conclusively 
say that there is not as much hepatic HA after chronic liver injury as we see after acute 
liver injury. Despite the limited HA found after chronic liver injury, we do see increased 
matrix metabolism in Has3-/- mice and decreased matrix metabolism in Hmmr-/- mice. 
This further supports our hypothesis that HA and HMMR are involved in not only acute 
hepatic wound healing, but fibrosis resolution.  
 
Conclusions 
 We provide the first evidence of a role for HA and HMMR in both hepatic wound 
healing after acute liver injury as well as in fibrosis resolution. Specifically, we propose 
that following acute liver injury, hepatocytes and Kupffer cells release pro-inflammatory 
cytokines that activate HSC to produce HA. We suspect that there is a feed-forward 
loop between HA, inflammation, and HSC activation driving wound healing after acute 
and chronic liver injury (outlined in Figure 7-2). This likely involves a critical HA:HMMR 
interaction aiding in macrophage migration. This increased pro-inflammatory 
environment then likely contributes to hepatocyte proliferation required to repair the liver 
after acute injury. However, it is currently unknown what, if any, role intracellular HMMR 
plays in hepatocyte proliferation. As HA accumulates, there is increased mechanical 
stress, in turn increasing HSC activation. This could again be another feed forward loop 
as activated HSC synthesize HA (outlined in Figure 7-2). Finally, in both acute and 
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chronic liver disease, HA and HMMR continue to contribute to macrophage localization 
which aids in matrix degradation. A working model as described above can be found in 
Figure 7-3.  
 
Future directions 
 We are the first to propose a role for the HA network in liver injury and repair 
after acute and chronic liver injury. However, future work, both in vitro and in vivo, is 
required to determine precise mechanisms by which this occurs. Has3-/- mice have 
increased HA synthesis, most likely from activated HSC. In order to determine if the 
Has3-/- HSC actually have increased HA synthetic capacity or if they are influenced by 
the increased inflammation observed in Has3-/- mice, HSC can be isolated from both 
Has3-/- and wild-type mice. The HSC can be plated on plastic, which will stimulate 
activation and HA content can be measured in the cell culture supernatant using the 
same HA ELISA-like assay used to measure HA content in the plasma. A similar 
experiment can be done with isolated Hmmr-/- HSC. This will allow us to separate pure 
HSC HA synthetic capacity from inflammation induced HA synthesis.  
 In order to determine what role HMMR is playing in migration and activation of 
macrophages and/or HSC, it would first be important to determine where HMMR is 
expressed. Although we have preliminary evidence that HMMR has higher expresion in 
non-parenchymal cells than in hepatocytes, it would be important to co-localize HMMR 
with known markers for hepatic macrophages (F4/80, CD11b, or CCR2), hepatocytes 
(Albumin), liver sinusoidal endothelial cells (CD31), and activated HSC (αSMA) or to 






Figure 7-3: Current working model describing a role for HA and HMMR in hepatic 
wound healing. 
 
1. Acute CCl4 exposure causes centrilobular necrosis leading to 2. the production of 
cytokines and chemokines. 3. These chemokines recruit macrophages to the liver; 
subsequently increasing the pro-inflammatory microenvironment. 4. At the same time, 
HSC become activated and begin synthesizing HA. 5. The chemokines recruite 
monocytes to the liver that then differentiate into macrophages. We propose these 
macrophages express HMMR and use both the chemokine gradient and the HA being 
synthesized by HSC to localize to the necrotic area and remove cellular debris. 6. What 
remains a question is what role if any intracellular HA and intracellular HMMR is playing 
in hepatocyte regeneration.  
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blotting, or flow cytometric analysis. While this will tell us what cells are expressing 
HMMR, using HMMR floxed mice to make cell type specific HMMR-deficient mice will 
allow us to determine how important HMMR is in each of these cell types and how it 
contributes to the wound healing process.  
 Because HMMR has critical functions in cell migration and proliferation, both of 
which contribute to hepatic wound healing, it will be important to separate the two 
aspects. To understand more mechanistically what role HMMR plays in migration, in 
vitro scratch wound assays or Boyden chambers could be used. For example, plating 
HSC or macrophages that are HMMR-deficient and monitoring their migration will tell us 
if HMMR is in fact playing a role in the migration of either of these hepatic cell types. 
Stimulating migration with HA, both HMW and LMW, in the presence or absence of 
peptides which prevent HA from binding HMMR, will help show if it is truly a HA:HMMR 
interaction aiding in the migration of these cell types. Additionally, in order to determine 
if HMMR plays a direct role in hepatocyte proliferation, cell cycle flow cytometry could 
be utilized to evaluate the cell cycle phases of both wild-type and Hmmr-/- hepatocytes 
after acute CCl4 exposure. This would aid in determining if Hmmr-/- hepatocytes 
become stalled at the G2/M phase transition. Additionally, in vitro Hmmr could be 
knocked down in primary hepatocytes or HepG2 cells and proliferation monitored, and 
should include an assessment of spindle defects that may occur. If HMMR is playing a 
role in hepatocyte proliferation, I would expect HMMR to localize to hepatocytes,  
Hmmr-/- hepatocytes to be stuck in G2/M phase, and that the knockdown of Hmmr 
would inhibit hepatocyte proliferation. If none of these occur, it is likely that the 
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differential regenerative response in Has3-/- and Hmmr-/- mice is due to the differences 
in inflammation. 
 Since we propose possible feed forward mechanisms are contributing to HA 
synthesis, inflammation, and HSC activation, a good next step would be to inhibit HA 
synthesis and monitor the effect that has on inflammation and HSC activation. 4-
methylumbeliferone (4-MU) is a pharmacologic HA synthesis inhibitor that works in two 
ways. First, it is conjugated to glucuronic acid, one of the two monosaccharide 
components of HA, by UDP-glucuronosyltransferase which then makes glucuronic acid 
unavailable for HAS enzymes to use for HA synthesis. This effectively depletes the 
substrate pool and prevents HA synthesis (Kakizaki et al., 2004; Nagy et al., 2015b). 
Second, 4-MU reduces Has enzyme expression (Kultti et al., 2009). Paul Bollyky has 
described the use of 4-MU incorporated into a chow diet at 5% (wt/wt) and shows it 
effectively inhibits HA synthesis in mouse models of diabetes (Nagy et al., 2015a; 
Kuipers et al., 2016). We have preliminary data showing we are also able to inhibit HA 
synthesis following acute CCl4 exposure by feeding mice the same 5% 4-MU diet for 2 
weeks prior to CCl4 exposure.  Importantly, 4-MU feeding does not alter peak liver 
injury, measured by ALT activity, allowing us to understand how HA affects wound 
healing parameters after liver injury. We hypothesize that while decreased HA may 
inhibit early inflammation, it may have a detrimental effect when it comes to wound 
healing, namely on cell proliferation and matrix remodeling. In other words, if HA is 
important for wound healing, then preventing HA should limit wound healing.  
A way to determine if the HA:HMMR interaction is required for hepatic wound 
healing would be to use mice that over-express HMMR in macrophages that cannot 
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bind HA and mice that over express a wild-type (HA-binding competent) HMMR. These 
mice were recently developed by our collaborator, Dr. Rashmin Savani and will be used 
in future collaborative studies. The three studies outlined above will allow us to 
determine the specific roles that HA, HMMR, or the HA:HMMR interaction play in 
inflammation and wound healing in the injured liver. If HA:HMMR is critical to the wound 
healing process, we would hypothesize that the mice expressing HMMR that can not 
bind HA will have delayed wound healing.  
 HA signaling largely depends on size. ELISA-like assays provide a quantitative 
value for total amount of HA in a sample, however they do not distinguish between 
different HA sizes. Isolation of HA from tissue can be accomplished through a series of 
ethanol precipitations and by digesting everything but glycosaminoglycans from the 
sample (Cowman et al., 2015). Once the HA has been isolated, simple agarose gel 
electrophoresis and staining with a cationic molecule called Stains All can be used to 
visualize HA (Cowman et al., 2011). Because HA is polydisperse, HA will appear as a 
smear in the gel and an average molecular mass can be determined when compared 
against HA standards of known molecular weights (Cowman et al., 2011). We have 
isolated HA from mouse intestine (as a positive control) with success, however isolating 
HA from liver tissue has been more difficult and is something we are working to 
optimize. As a second approach to learn something about HA molecular weight, we 
utilized molecular weight cut off columns in combination with the ELISA-like assay to 
determine amounts of HA over a broad range of sizes. Alternatively, using size 
exclusion chromatography or anion exchange columns in combination with an ELISA-
like assay would be a better way to monitor narrower size fractions (Cowman et al., 
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2015; Yuan et al., 2015). Any of these methods would help to better understand the size 
of both plasma HA and intrahepatic HA and help to better predict what roles HA is 
playing in wound healing based on the size. 
 Once HA is synthesized and extruded into the extracellular space it can interact 
with a number of HA binding proteins and receptors, and together this constitutes the 
HA network. For our initial studies, we focused on HA and a single HA receptor, HMMR, 
and largely ignored the rest of the HA network. Evaluating other HA receptors, like 
CD44 and TLR2/4, which play roles in cell migration and inflammation, respectively, will 
give us a better understanding of the HA signaling occurring in acute and chronic liver 
injury (Jiang et al., 2005; Decleves et al., 2006). Similarly, HA binding proteins such as 
tumor necrosis factor-stimulating gene 6 (TSG-6), which plays a role in HA matrix 
stabilization and aids in the transfer of heavy chain (HC) from inter-α-inhibitor (IαI) to 
HA, can be monitored (Baranova et al., 2011; Martin et al., 2016). The addition of HC to 
HA increases leukocyte recruitment and could play a role in hepatic wound healing 
(Lauer et al., 2013). By examining the expression and localization of other portions of 
the HA network we could gain a more comprehensive understanding of HA’s role in liver 
disease pathology. 
 Based on the increased injury and pro-fibrotic response we observed in Has3-/- 
mice after acute CCl4 exposure, we were surprised we did not see increased fibrosis 
after chronic CCl4. Similarly, we were also surprised that delayed inflammation and 
reduced pro-fibrotic signature in the liver after acute CCl4 in Hmmr-/- mice did not 
decrease fibrosis after chronic CCl4. The apparent disconnect in both transgenic mice 
can be attributed to differences in matrix degradation following chronic CCl4. 
213	
Specifically, matrix degradation is enhanced in Has3-/- mice, while matrix degradation is 
reduced in Hmmr-/- mice after chronic CCl4 exposure, relative to each knockout’s wild-
type control. A caveat to this interpretation of our data is that we only looked 72 hours 
after the last CCl4 injection. Based on the single time point, we would hypothesize that 
Has3-/- mice will have faster fibrosis resolution compared to wild-type mice and 
conversely, Hmmr-/- mice will have slower fibrosis resolution compared to wild-type 
mice after chronic CCl4 exposure. In order to test this hypothesis, several time points 
after the cessation of CCl4 should be monitored. By euthanizing mice 1, 3, 5, 7, and 14 
days after the last exposure, it will be possible to monitor the regression of the fibrotic 
scar. By looking at 1 day after the last CCl4 exposure it will also be possible to 
determine if Has3-/- mice do in fact have increased fibrosis and if Hmmr-/- mice do have 
decreased fibrosis as would be predicted based on the transcript accumulation of pro-
fibrogenic markers we observed.  
 Lastly, an important next step in both the acute and chronic CCl4 exposure would 
be better localization of both macrophages and fibroblasts in injured liver over the time 
course of repair/fibrosis since we are implicating the HA:HMMR interaction in both. We 
have experienced some problems using F4/80 immunoflourescence to monitor 
macrophage migration into the liver. Specifically, we see a high amount of variability, in 
both the intensity and staining patterns observed in a single tissue section. Use of 
CCR2 reporter mice (CCR2-RFP mice) would bypass this problem and provide an 
easier way to determine recruited macrophage localization (Saederup et al., 2010). Also 
because these macrophages express RFP, we can combine that with the HABP (GFP) 
staining already optimized in the lab to co-localize HA and the CCR2+ macrophages. 
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Using αSMA as a marker for HSC is an effective way to monitor HSC localization and 
could be done to localize HSC with and without HABP-costaining in Has3-/- and   
Hmmr-/- mice after acute and chronic CCl4 exposure. We would expect that using these 
different techniques we could confirm the hypothesis that HA and HMMR are important 
for macrophage localization to the necrotic area and fibrotic septae after acute and 
chronic CCl4 exposure respectively. 
 Overall, by delving into in vitro methods to try to tease apart the different feed 
forward loops that may be present in inflammation, HA, HSC activation, and 
regeneration, we can provide a better mechanistic understanding of the role of HA and 
HMMR in liver injury and wound healing after both acute and chronic hepatotoxin-
induced injury. Considering other aspects of the HA network, including additional 
receptors and binding proteins, will give a more comprehensive look at what role HA is 
playing in liver disease pathology. Additionally, by inhibiting HA synthesis in vivo we will 
be able to monitor how HA itself effects the wound healing process. In terms of chronic 
CCl4 and fibrosis regression, monitoring several time points in the healing process will 
give us a better understanding of how HA and HMMR contribute to fibrosis regression. 
Finally, utilizing better techniques to localize macrophages during the wound healing 
process, as well as using αSMA to localize HSC will help to determine if the HA:HMMR 
interaction does, as we propose, contribute to the localization of these cells during both 
acute and chronic wound healing. 
 
Differences in C57BL/6 sub-strain response to acute and chronic CCl4: 




 During the course of this dissertation, we discovered that the two genetically 
modified mice being utilized were on different C57BL/6 sub-strain backgrounds; Has3-/- 
mice are on a C57BL/6J (6J) background while Hmmr-/- mice are on a C57BL/6N (6N) 
background. We therefore sought to explore differences in hepatotoxicity and the wound 
healing response to acute and chronic CCl4 exposure between these two commonly 
used mouse sub-strains thinking this could provide better insight into understanding 
how HA and HMMR affect wound healing and fibrosis after acute and chronic liver 
injury. Differential hepatoxicity to APAP overdose has been described in these two sub-
strains (Bourdi et al., 2011; Duan et al., 2016). We hypothesized that, similar to APAP 
induced liver injury, 6N mice would have increased liver injury after acute CCl4 
exposure. We also hypothesized that due to 6N mice having increased injury, they 
would have a more robust wound healing response leading to fibrosis after chronic CCl4 
exposure.  
 We found that the 6N mice do in fact have increased injury, but this is not due to 
a difference in CCl4 bioactivation by CYP2E1 in vivo or in hepatocyte sensitivity to CCl4 
in vitro. Increased injury results in increased wound healing response as has been 
shown previously and is likely contributing to the many differences we observed 
between 6N and 6J mice in acute liver injury (Mehendale, 2005). Following acute liver 
injury induced by CCl4, we observed increased inflammation, regeneration, and matrix 
synthesis in 6N mice compared to 6J mice. The increased inflammatory 
microenvironment observed in 6N mice is likely influencing the increased regeneration, 
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as has been shown previously (Strey et al., 2003; Owumi et al., 2014). Pro-inflammatory 
cytokines can activate HSC, so it is also likely that the increased inflammation in 6N 
mice is also contributing to the earlier HSC activation we observed (Imamura et al., 
2005).  
 In accordance with the increased liver injury and wound healing we observed in 
6N mice compared to 6J mice after acute CCl4 exposure, we hypothesized that 6N mice 
would have increased fibrosis following chronic CCl4. We did, in fact, see increased pro-
fibrotic markers and ECM accumulation visualized by picrosirius red staining in 6N mice. 
We did not evaluate matrix remodeling in 6N and 6J mice after chronic CCl4 exposure 
because there was no difference in matrix remodeling between sub-strains after acute 
CCl4 exposure and because we observed increased fibrosis in 6N mice compared to 6J 
mice. However, future studies could explore matrix metabolism and fibrosis resolution 
between these sub-strains to gain additional mechanistic clarity into the ability of the 
liver to heal after chronic liver injury. Because matrix remodeling was not different 
between sub-strains after acute liver injury, we hypothesize that fibrosis in 6N mice 
would resolve at the same rate as that found in 6J mice, but that complete fibrosis 
resolution would take longer in 6N mice as they have more fibrosis to begin with. 
 Similar to observations in the acetaminophen overdose literature, the implications 
of our work are important for labs that utilize CCl4 to induce acute and chronic liver 
injury in genetically modified mice and purchase wild-type control mice instead of using 
littermate controls. Because differences in injury and wound healing were discovered 
between 6J and 6N mice following both acute and chronic CCl4 exposure, comparing 
the genetically modified mice used in this dissertation to the wrong sub-strain would 
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have led to data interpretation errors. For example, by graphing ALT activity of all four 
genotypes used in this dissertation, it is evident that we could have incorrectly 
interpreted the Has3-/- data; i.e. there is no difference in ALT activities between Has3-/- 
and 6N mice (incorrect sub-strain) but there is increased ALT activity when comparing 
Has3-/- and 6J mice (correct sub-strain) (Figure 7-4).  
 
Conclusions 
 By evaluating both hepatotoxicity and wound healing following acute CCl4 
exposure, as well as fibrosis following chronic CCl4 exposure, we were able to discern 
differential responses in 6N and 6J mice. Following acute CCl4 exposure, 6N mice have 
increased injury and subsequent wound healing compared to 6J mice and following 
chronic CCl4 exposure, 6N mice have increased fibrosis compared to 6J mice. These 
sub-strain differences highlight the importance of using the correct sub-strain control 
when trying to correctly identify the impact HAS3 and HMMR deficiency has on hepatic 
wound healing and fibrosis after acute and chronic liver injury, respectively. Additionally, 
the NIH is currently stressing the importance of reproducibility and transparency in study 
design and reporting (Collins and Tabak, 2014). We believe that these studies show 
that it is important to report not only what strain of mouse the studies were completed in, 
but also what sub-strain, particularly if CCl4 is being used to induce liver injury. 
 
Future Directions 
 In Chapter 6, we proposed a number of possible explanations for the increased 





                  
Figure 7-4: ALT activity 48 hours after CCl4 exposure in all four strains of mice 
used in this dissertation. 
 
Due to the observed differences in peak ALT levels between 6J and 6N mice, 
comparing the genetically modified mice to the wrong sub-strain would have led to 
interpretation error. This is evident in the significant difference between 6J mice and 
Has3-/- mice (correct control) and no significant (n/s) difference between 6N mice and 
Has3-/- mice (incorrect control). 
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idea of hormesis (Milisav et al., 2012). 6J mice have a mutation in nucleotide 
nicotinamide (Nnt), which reduces antioxidant capacity within the mitochondria (Ronchi 
et al., 2013). It is possible that over time, 6J mice have adapted to the constant 
reduction in antioxidant capacity and thus require higher stress to induce inflammation. 
We have shown that the two sub-strains have equivalent cell death in vitro, but it may 
be possible that the cell death is not sending the same signals; i.e. that 6N mice have 
increased pro-inflammatory signals, thus increasing the innate immune response and 
resulting in increased injury. It would be interesting to evaluate macrophage 
chemoattractant proteins (like CCL2) production in mice exposed to CCl4. If 6J mice 
have adapted to the lower antioxidant capacity, it is possible that the same amount of 
cell death will not trigger the same inflammatory response.  
 It is possible that the increase in wound healing response in 6N mice compared 
to 6J mice after acute CCl4 exposure is entirely based upon the increased injury. It is 
known that following any form of liver injury, tissue repair follows a dose response; i.e. 
the more injury, the more robust the repair up to a threshold when the repair can no 
longer compensate for the increased injury (Mehendale, 2005). If we could determine 
an equitoxic dose of CCl4 to administer in order to have the same amount of hepatic 
injury in both 6J and 6N mice, we could observe what effect this has on the wound 
healing response. If the sub-strains no longer have a differential response (for example 
regeneration does not start earlier in 6N mice than 6J mice), then the wound healing 
response is entirely dependent on the extent of liver injury. 
 We observed an increase in fibrosis in 6N mice compared to 6J mice after 
chronic CCl4 exposure. We did not, however, evaluate matrix remodeling in these mice. 
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Because there was no difference in matrix remodeling in 6N mice after acute CCl4 
exposure, we hypothesize that there would be no difference in matrix remodeling in 6N 
mice compared to 6J mice after chronic CCl4 exposure. This can be measured by in situ 
zymography to directly measure MMP activity, as was done in Chapters 3 - 6. Similar to 
what was described above, looking at a single time point after chronic CCl4 has 
limitations, therefore to evaluate fibrosis resolution several time points after cessation of 
CCl4 should be evaluated.  
 Lastly, we propose that HA and HMMR play a role in hepatic wound healing after 
both acute and chronic CCl4 exposure. Because these two sub-strains have differential 
responses in both settings, it would be interesting to evaluate hepatic HA and HMMR 
levels. We hypothesize that 6N mice would have increased HA early, contributing to the 
increased inflammation we observe. However, because there is no difference in matrix 
remodeling, perhaps 6J mice reach 6N hepatic HA levels quickly, or hepatic HA is 
degraded more rapidly in 6N mice, and thus drive increased inflammation. Lastly, 6N 
mice have earlier regeneration, which again may be due to increased inflammation, but 
it may also be because 6N have increased intracellular HMMR expression. Evaluating 
HA and HMMR in these two sub-strains could provide more evidence of a role for the 
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